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We shall not cease from exploration
And the end of all our exploring
Will be to arrive where we started
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ABSTRACT
Studies were undertaken to produce and characterize enriched
anti-tetanus antibodies with potential therapeutic use.
A sensitive enzyme immunoassay (ELIZA) was developed for the
quantitation of antitetanus antibodies. This technique was used to
measure antibody levels in the sera of immunized donors, in crude and
purified tetanus-IgG preparations and for screening human and mouse
monoclonal antibodies to tetanus toxoid. The assay was capable of
measuring antibody levels as low as 5 x 10"^ IU/ml. The antigen
coated-plates prepared for this study had a shelf life of at least one
year. By inclusion of a third step involving antibodies to mouse
Ig-isotypes, a sandwich enzyme immunoassay (SEI) was developed, which
enabled the determination of the Ig-isotype of antitetanus antibodies.
The isotype specificity of this assay was confirmed by studies on
Protein-A Sepharose fractions of mouse antiserum.
The homogeneity of commercial tetanus toxoid preparations was
studied using gel filtration. The Wellcome tetanus vaccine proved to
be extremely heterogeneous; the Connaught tetanus toxoid was purer and
had higher toxoid activity.
An immunoaffinity technique was developed to isolate antibodies
with specificity for tetanus toxin from human plasma and from
polyvalent tetanus-IgG (Cohn Fraction II). Studies were undertaken to
establish the optimum conditions for the preparation of the
immunoaffinity column; the factors which were found to influence the
performance of the columns are discussed. The optimized column was
stable in storage and could be used repeatedly to isolate tetanus
antibodies without loss of capacity. The specific antibody was
extracted from the crude material by passing it through the column
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containing the immobilized antigen. Desorption from the column was
carried out at acid pH. Immunological and biochemical properties of
the preparations are presented. The affinity purified preparations had
specific neutralizing activities up to 182 IU per mg of IgG
representing up to 108-fold purification.
Studies were carried out on the immune response of CBA and BALB/c
mice to two tetanus toxoid preparations to determine whether the
antitetanus response was isotype restricted, whether there were
differences in the immunogenicity of the two toxoids, and finally to
establish the ontogeny of the response. An interesting finding was the
presence of naturally occurring antibodies which bound to the tetanus
toxoids in both strains of mice; these were of the IgA and IgM
isotypes. Furthermore, the purer toxoid preparation elicited a more
rapid and pronounced response than the crude vaccine. After a primary
challenge, the antibody responses to tetanus toxoid were detected in
all IgG subclasses except that of IgG2b> and on boosting the
antibody response was mainly of IgG^ subclass. Both strains of mice
exhibited similar responses.
A number of murine monoclonal antibodies were produced. These
were found to be of IgG]^ isotype using the SEI assay. A stable human
cell line (designated ES-12) secreting monoclonal antibodies to tetanus
toxoid was obtained. The antibody produced by this cell line protected
mice against the effect of tetanus toxoid. In both in vivo and in
vitro assays, this monoclonal had an antitetanus antibody level of
2.5-3.0 IU/ml.
The potential use and limitation of both immunoaffinity purified
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A.l History of Immunoglobulin Use
History of immunoglobulin (Ig) use began in 1890 when von Behring
and Kitasato announced that the serum of rabbit and mice that had been
immunized against tetanus had the property of neutralizing the effect
of the toxic substance produced by the tetanus bacillus. This property
of the serum was so durable that it remained active when the serum from
an immunized animal was transferred to a non-immunized animal. This
progressed through the clinical use of animal antitoxins in the
prophylaxis and treatment of human disease. The diphtheria antitoxin
prepared by Ehrlich (1897) constituted the first biological standard.
The development of Ig-therapy has been one of the mainstreams of
the science of immunology over the last 40 years. In the early 1920's,
the characterization of the pneumococcal polysaccharides prompted
extensive studies (reviewed by Janeway,1970), which led to the
purification of antipneumococcal antibodies from animal sera for
therapeutic use. During the 1930's purified heterologous
anti-pneumococcal antibodies were widely used in the treatment of
pneumococcal infection. However these preparations which were
purified from horse and later rabbit antiserum by salt fractionation
had major drawbacks, for they elicited severe allergic reactions when
repeatedly administered. Some of the animal antisera available and
used for passive immunity are listed in Table 3. It should be noted
that the only antisera available in many countries to tetanus and
rabies are of equine origin. The application of most of the animal
preparations were abandoned once antibiotics became available.
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Although progress in antibiotic research has been impressive at the
biochemical and microbiological levels, the mortality from pneumococcal
pneumonia is still close to 10% despite the exquisite sensitivity of
this organism to Penicillin G. Adult or neonatal bacterial meningitis
generally due to encapsulated micro-organisms carries a mortality rate
close to 40%, and Gram negative sepsis has a mortality of 30% - 50%
even under optimal antibiotic management (Waldvogel, 1981). These and
other therapeutic limitations indicate that other treatment modalities
will continue to be necessary to prevent or treat the explosive growth
of micro-organisms during infection. This could be achieved by
devising methods which can increase the clearance of pathogenic
organisms or their toxic products. Active and passive immunization
have been the strategies most extensively used in this respect.
Human immune serum globulin is a valuable and frequently
prescribed biological used to provide passive immunity against
microbial agents, toxins, or cells. Immunoglobulin is mostly used for
the short term preparation of certain bacterial or viral diseases when
active immunization is unavailable (i.e. hepatitis A) or when active
immunization has not been given before exposure (i.e. tetanus and
rabies). It is also used on a continuous basis in replacement therapy
for persons with antibody immunodeficiency.
Two types of immunoglobulin preparations are available: standard
human immune serum globulin (HISG) for general use (Table 1) and
specific immunoglobulins with a known antibody content for specific
illnesses (Table 2).
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A. 2 Some Properties of Immunoglobulins
The immunoglobulins(reviewed by Fahey, 1970; Janeway, 1970;
Spiegelberg, 1974; Stiehm, 1979) are the proteins of the plasma and
tissue which have antibody acitivity. Although there are five classes
of immunoglobulins - IgG, IgM, IgA (secretory IgA), IgD and IgE, only
IgG is present in significant quantities in HISG.
IgG is a glycoprotein with a molecular weight of 150,000 daltons
distributed equally between the serum and the tissue. The IgG molecule
is Y-shaped with two combining sites, one at the end of each arm
(Fab). It is made up of two heavy (gamma) chains and two light (kappa
or lambda) chains held together by disulphide bonds and weak covalent
forces. Its structure is illustrated in Fig.l.
There are 4 subclasses of human IgG, IgG^, IgG2» IgG3 and
IgG4 comprising about 70%, 15%, 10% and 5% respectively of the total
IgG. All normal persons have IgG molecules of all subclasses. These
subclasses differ antigenically and exhibit differences in biological
activity.
IgG has a mean half-life of 25 days, the longest half life of any
plasma protein. The synthetic rate of IgG is 35 mg per kilogram of
body weight per day. IgG metabolism is regulated by the serum level of
IgG, so there is an increase in catabolic rate with high levels of IgG
and a decrease at low levels. Thus, the IgG half-life of patients with
agammaglobulinemia is prolonged to 35 - 40 days.
IgG is made primarily in plasma cells that have differentiated
from circulating B-lymphocytes. These are located in central lymphoid
tissues (lymph nodes, bone marrow, spleen and liver), and peripheral
lymphoid tissues (secretory glands, intestinal walls). IgG destruction
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occurs within granulocytes (after phagocytosis of IgG-coated bacteria
and particles) in the reticuloendothelial system. IgG readily crosses
the placenta during late pregnancy, providing passive immunity to the
newborn for about six months.
IgG which comprises about 20% of total plasma protein and 80% of
the serum immunoglobulin, is the chief component of the body's
serological defences. It contains most of the antibacterial,
antiviral, antiprotozoal and antitoxic activity of the serum. Many
cells (i.e. lymphocytes, macrophages, killer cells) have a receptor for
the nonantibody (Fc) portion of IgG, permitting attachment of IgG to
these cells. The presence of antibody on target cells (tumour cells,
heterologous erythrocytes, allogeneic lymphocytes) may permit
antibody-dependent cytotoxicity by some lymphocytes, neutrophils and
macrophages.
IgG can also activate the complement systems, promote opsonization
(i.e. the recognition of bacteria by the phagocyte receptors), and
participate in antibody-dependent cytolytic reactions. It should be
pointed out that certain IgG subclasses (i.e. IgG^ and IgG3) are
more cytotropic and more able to fix complement than others (Shakib
et al. 1980) .
A.3 Clinical Applications
Indications for the therapeutic use of immunoglobulins have been
extensively reviewed in the literature (Janeway, 1970; Stiehm, 1979;
Nydegger, 1981, McClelland et_ a^. 1984 and McClelland, 1984) and will
be briefly summarized here. Tables 1, 2 and 3 provide examples of
diseases in which immunoglobulins (HSIG, specific or heterologous) have
been used.
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The use of human Ig preparations for passive immunization began
with the studies of McKhann and co-workers (1935), who used ammonium
sulphate to isolate Ig fractions from placental extracts. The major
advance in this field came with Cohn and co-workers' method of cold
ethanol fractionation of Ig from human plasma (Cohn jit^ a_l. 1946).
These preparations have been widely used for the treatment or
prevention of infectious diseases, and were also given to patients with
congenital or acquired antibody deficiencies. However, it was soon
recognized that intravenous injection of these preparations frequently
gave rise to adverse reactions. Efforts to eliminate these adverse
reactions by further purification and screening tests in animals ended
in failure, and therefore it was accepted that these preparations
should be restricted to intramuscular administration (Janeway, 1970).
A.3-1 Indications of Human Serum Globulin (HSIG)
Many antibody immunodeficiencies are treated successfully with
repeated intramuscular injections of HISG (see table for references).
The widest use of HISG is in the prevention of hepatitis A. Its
efficacy in this respect has been repeatedly demonstrated since Stokes
and Neefe (1945) showed that it prevented an epidemic in a children's
summer camp. Indications for the use of HISG for prevention of
hepatitis B are limited to the rare situations where hyperimmune
anti-hepatitis B antibody preparations (HBIG) are not available (Seeff
et al_. 1979 , review); its use in the prevention of non-A non-B
hepatitis however seems promising.
Administration of immunoglobulin in measles is becoming limited by
the growing proportion of vaccinated children. Nevertheless, the
preparation can be useful for non-vaccinated children exposed to
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measles, and followed by vaccination. Rubella prevention by HISG is
controversial because of its unreliable efficacy, but high doses of
rubella specific antibody (RIG) was found to prevent the infection "
(Schiff, 1969). Finally, HISG has shown to offer incomplete and
short-term protection against the paralytic poliomyelitis syndrome
(reviewed by Stiehm, 1979). HISG was used extensively in the
prevention of poliomyelitis before the development of specific
vaccines.
A.3.2 Specific Antibody Preparations and their Use
These limited indications have prompted many researchers to
develop potent and specific antibody preparations against particular
viruses and bacteria. During the last decade HISG preparations have
been partly replaced in clinical use by specific Ig. Preparation of
the specific Ig is identical to that of HISG (Cohn fractionation
technique), except selected donors with high natural titres against
specific antigen or hyperimmunized donors are used, whereas HISG is
isolated from the plasma of non-selected donors.
It is beyond the scope of this introduction to discuss in detail
the various indications for hyperimmune serum globulins (for review,
see again Stiehm, 1979; McClelland et_ al_. 1984). A list of diseases
for which specific immunoglobulins are available can be seen in Table
2, and only a brief overview of the subject will be given.
Relative indications of HBIG for hepatitis B are presently limited
to subjects accidentally contaminated by HBg-Ag containing blood or
secretions, neonates from mothers positive for HBg-Ag, and spouses of
HBg-Ag carriers (Reesnik et^ aT. 1979 and Tabor, 1980).
Administration of zoster immune globulins, or when available of plasma
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from a patient recovering from herpes zoster, will prevent the
complications of varicella in exposed, susceptible, immuno-suppressed
patients (Zia et al. 1980 and 1983). Rabies immune globulins have
become accepted standard therapy in conjunction with vaccination in the
prevention of clinical disease after bites due to rabid animals (Mertz,
1982). Vaccinia immune globulin has been shown to be effective in
protecting household contacts in case of smallpox (Stiehm, 1979). The
apparent eradication of smallpox has prevented the various indications
for the time being. Use of immune globulin from vaccinated adults in
the treatment of pertussis (Whooping cough) has been reported, if given
early in the incubation period. However, given during the coughing stage
it has been ineffective. Mumps immune globulins which is indicated
for postpubertal males who do not want to risk sterility has not been
shown to be effective (Stiehm, 1979). Rh (D) immunoglobulin (RhIG) is
used to prevent sensitization of Rh (D)- negative individuals who have
received Rh (D)-positive blood as a result of delivering an
Rh(D)-positive infant or fetus, or as a result of a transfusion
accident (Diamond, 1970 and Smith et £1. 1972). Finally, the toxin-
neutralizing properties of animal antisera have been used for several
years in the prevention or early treatment of tetanus, diphtheria and
botulism (Table 3). Although highly effective at the preventive stage,
their clinical efficacy during disease has sometimes been disputed.
Tetanus and TIG will be discussed in detail later in this chapter.
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A.3.3 Clinical Use of Monoclonal Antibodies
The introduction of the hybridoraa technology by Kohler and
Milstein (1975) has revolutionized the diagnosis and possible treatment
of many human diseases. There is already availalbe a wide range of
monoclonal antibodies of both proven and potential diagnostic
importance while many therapeutically important reagents are under
development (Table 4). For review, see McClelland (1984), James et al.
(1984) and McMichael (1981). The production of monoclonal antibodies,
their advantages and the problems associated with them, are discussed in
Chapter 6.
A.4 Tetanus
A.4.1 History of Tetanus
Tetanus has long been recognized as a disease of man and animals.
Nicolaier (1885) suggested that the organism causing tetanus was not
distributed throughout the body but confined to the wound of entry. In
1854 Simpson had already observed that the symptoms of tetanus were
similar to those of strychnine poisoning. The work of Nicolaier was
extended by Kitasato in 1889 who isolated the tetanus bacillus. In the
next year von Behring and Kitasato (1890) demonstrated the presence of
the neurotoxin in culture filtrates of the organism. They also found
that the administration of many small doses of the toxin in animals
induced immunity against it. Demonstration of antitoxin in the serum
of animals so immunized, together with similar findings with the toxin
of Corynebacterium diphtheriae, laid the foundations for the humoral
theories of immunity as well as for the vaccine prophylaxis and serum
therapy of many diseases (Smith, 1975).
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A.4.2 Pathogenesis
Tetanus is usually the result of contamination of a wound with
Clostridium tetani (an anaerobic bacillus), the spores of which are
widely distributed in soil and in the intestinal tracts of man and
animals (reviewed by Willis, 1969; Smith, 1975). Spores of CI. tetani
have been isolated from a wide variety of other sources, including
street and hospital dust, animal hair, catgut and so on.
If washed spores alone are injected into an animal they fail to
germinate, are phagocytosed and do not give rise to tetanus. It has
been shown that the germination of spores of CI. tetani is dependent on
the reduced oxygen tension occurring in devitalized tissue and
non-viable material in the wound. Infection when it occurs remains
strictly localized in the wound and the tetanic condition is due to the
effects of a potent diffusible exotoxin (tetanospasmin/tetanus toxin)
on the nervous system. It has been estimated that 1 kg of tetanus
toxin would be sufficient to kill the population of the world
(Edmondson, 1980). Tetanus toxin is one of the most toxic substances
known; the estimated lethal dose for man is 60 ng (reviewed by van
Heyningen, 1971). It should be noted that, unlike diphtheria, the
natural disease of tetanus does not confer immunity (Vakil et al.
1964). This is because a lethal dose of tetanus toxin is too small an
amount of antigen to give rise to any immunity.
A.4.3 Tetanus Toxin - Mode of Action
Tetanus toxin is a simple protein. Its molecular structure and
characteristics together with its inactivated form (tetanus toxoid) is
described in detail in Chapter 3. However,comparatively little are
known about its action at the molecular level. This is in contrast
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with, for example, diphtheria and cholera toxins which are quite well
understood (Van Ueyningen, 1971; Van Heyningen, 1980; Bizzini, 1981) •
Tetanus toxin is produced by the invading bacteria at the site of
infections but its effects are widespread throughout the body, although
only the nervous system is directly affected. This implies immediately
that there must be some transport to the site of action. The mechanism
of this transport has been reviewed in detail (Bizzini, 1979, and Van
Heyningen, 1981).
Most human tetanus falls into one of two categories: "general"
tetanus, which is characterized by general convulsion all over the body
following on early spasticity, first in the jaw muscles (lockjaw) and
then moving towards the trunk and outer limbs, and "local" tetanus in
which the muscles of one specific infected limb become spastic.
Intramuscular injection of toxin into a limb produces local tetanus,
but intravenous injection produces general tetanus. It is now thought
that the toxin reaches its site of action by uptake into terminals at
the neuromuscular junction followed by axonal transport in the
motorneurones (Van Heyningen, 1980).
A.4.4 Portal of Entry
A.4.4.1 Accidental Tetanus
In countless situations the tetanus bacilli penetrate the human
body through a break in the skin (Veronesi, 1981). The presence of
foreign 'bodies' in wounds constitutes an important predisposing
factor. Other lesions favouring tetanus infection are burns, skin and
mucosal ulcerations, infected dental decay, bites or scratches by dogs
or other animals, perforation of the earlobe and nasal septum to insert
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rings or pieces of wood (Indian practices).
A.4.4.2 Neonatal Tetanus
Neonatal tetanus is usually a very severe disease with high
lethality. The portal of entry is the umbilical cord, which was
contaminated at its distal end by local application of tetanogenic
substances such as earth, tobacco, coffee powder, spider webs, etc. In
Africa some tribes use extracts of green bananas to dress the umbilical
stump. It has been reported that 10% of 319 cases of tetanus in
Bombay, India, occurred in infants born in hospital, suggesting that
the instruments used to cut the umbilical cord were not adequately
sterilized. In Brazil 91.6% of the mummified umbilical stumps examined
were positive for tetanus bacilli cultures (Athavale, 1965); the number
of cases was not mentioned.
A.4.4.3 Gynaecological and Obstetrical Tetanus
Most cases are a consequence of infection and necrosis of the
uterus during the post-delivery period or, more frequently, after
induced abortion due to septic manipulation. This form of tetanus is
frequently associated with gangrene of the uterus, severe sepsis and
high lethality (Veronesi, 1981).
A.4.4.4 Otogenic Tetanus
The usual portal of entry is the middle ear where an acute or
chronic infection is present. There have been reports on the
importance of otogenic tetanus among 25-30% of cases in India. This
high prevalence has been related to lack of hygiene and negligence in




There are cases in which the portal of entry could not be
determined precisely. Patel in India (1965) and Veronesi (1981) refer
to 17% and 15.9% (respectively) of their cases where the tetanus focus
could not be found (cryptogenic).
A.4.4.6 Other Portals of Entry
Tetanus may occur after surgery, after infection with inadequately
sterilized needles (especially among drug adicts), smallpox vaccine,
infected varicose ulcers, etc. (Veronesi, 1981). There has been a
report of an uncommon case of tetanus which occurred after allogeneic
bone marrow transplantation (Kendra, 1982).
Although tetanus is more likely to develop in untreated patients
with severe badly soiled wounds than in those with clean superficial
injuries, today it most commonly follows mild injuries (Willis, 1981).
This is due to the protective measures that are instituted routinely in
cases of severe wounding, but are so frequently omitted in cases of
minor trauma. A slight penetrating wound produced by a splinter of
wood or even a dirty abrasion is the type of lesion from which tetanus
commonly develops.
In general, although tetanus is not seen as an epidemic and
there is much under-reporting, a large number of cases are observed
annually on a world-wide basis.
A.4.5 World Distribution of Tetanus
In general terms it may be said that the incidence of tetanus and
the form that the disease is likely to take are related to the
social environment and habits of a population. For example, neonatal
13
tetanus and puerperal tetanus are common in underdeveloped communities
where standards of living, sanitation and hygiene are low. Even in
more advanced societies, where tetanus is relatively uncommon, the
incidence of the disease is related to such factors as military
commitments, agricultural activity and drug addiction on the one hand,
and by the standard and availability of wound treatment and the immune
status of the population on the other.
Tetanus is a killer disease; the world wide mortality rate has
been estimated at one million per annum (Bytchenko, 1975). The tetanus
incidence is 1 in 25,000 of the population (Jones, 1981), and not 1 in
3 million as previously reported (DHSS 1970-76). Some 8% of the deaths
in developing countries are due to tetanus in the new born
(Cvjetanovic, 1981).
There are differences in mortality due to tetanus between
countries at different stages of socio-economic development, with
different types of agricultural practices and quality of soil. Fig.2
illustrates the world distribution of tetanus neonatorum.
A.4 .5 • 1 Africa
For the period of 1971-1980 deaths from tetanus were reported
irregularly from hospitals of 46 African countries. In 1979 the
incidence of tetanus was known to WHO in only 27 countries. The
average number of reported deaths from hospitals varied from 3000-6000
per year. It has been estimated (Bytchenko, 1981) that the mortality
rates from tetanus neonatorum per 100,000 live births in 1973 were high
in Burundi (3370), Benin (2990), Kenya (1030), Malawi (1090), Senegal
(2970), Central African Republic (2960), Chad (2410), Gambia (1280),
14
Guinea (2780), Ethiopia (2720), Uganda (1120) and Zaire (1000). In
Nigeria, for example, the private clinics run either by midwives or
herbalists did not undertake immunization against preventable disease
(including tetanus), because vaccines are usually only supplied to
Government health institutions. Furthermore, some women believed that
native medicine could protect against tetanus (Odumosu, 1982).
A.4 .5 .2 Asia
Deaths from tetanus were reported from only 29 countries in Asia.
The available data show a marked decline in the annual incidence of
tetanus in Japan and Mongolia, and rather uncertain situation in other
countries. For 1973 the estimated mortality rate due to tetanus
neonatorum were Nepal (3305), Bangladesh (3200), Maldives (3060), India
(2754), Indonesia (1270), Pakistan (1148), Sri Lanka (448), Philippines
(325), Malaysia (237), Thailand (221) and Jordan (143).
Although further studies on tetanus are necessary to have more
accurate information on the true epidemiological situation, the data
(Bytchenko, 1981) collected from various sources give an impression
that the incidence of tetanus neonatorum in the majority of Asian
countries during the period 1971-1980 was gradually declining. This
trend could be explained on the basis of socio-economic changes which
have taken place for the last 20 years.
A.4.5.3 America
Although the incidence of tetanus has decreased dramatically with
the routine use of tetanus vaccine, nevertheless in 1980 alone, 95
tetanus cases were reported from 33 states (Mortality and Morbidity
Weekly Report, 1981). The risk of tetanus is not limited to major
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wounds; one third of patients who contract the disease in the United
States have either no obvious wound or a wound considered to be trivial
by the patient. The case-fatality rate of 45-55% has not changed since
1975 (Brand et al. 1983). The majority of deaths have occurred in
adults over 50 years of age, either because they have never been fully
immunized or because they have not received the necessary booster doses
of tetanus toxoid.
In the United States the incidence is highest in the southern
states such as Louisiana and Alabama, followed by Texas, Florida,
Tennessee, Georgia, Missouri, Kentucky, Arizona and Arkansas. The
incidence in New York City and in Washington D.C. is also high because
of the number of heroin addicts (Smith, 1975).
The mortality from tetanus neonatorum was reported as 12,000 for
Latin America; the case fatality rate ranging from 60-93% in
different countries.
A.4.5.4 Europe
The distribution of the rates reveals an increase from the north
to the south. The morbidity and mortality due to tetanus in
Scandinavian countries and in the north of the European part of the
USSR were always from 10 to 44 times lower than in the southern
European countries. Since 1921 the loss of human lives from tetanus in
Europe has exceeded the figure of 30,000 per 10 years. During the
Second World War the incidence of tetanus increased in many European
countries. After the war there was a steady decline of mortality rates
along with the improvement of the standard of living. Active
immunization of children and grown-ups speeded up this trend. For the
first time in its history, Europe lost less than 10,000 people from
tetanus during the 10-year period (1971-1980). High proportions of
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new-born children among tetanus patients were reported from Greece
(57%), Portugal (56%), Spain (41%), Yugoslavia (5%) and Italy (5%) (see
Bytchenko, 1981)- In France, tetanus accounts for 200-300 deaths per
annum. It affects mostly females, and mostly aged 40-50 years (Ajjan,
1981). In a country such as Switzerland where one could expect a high
percentage of vaccination against tetanus, a recent investigation
carried out by 111 general practitioners showed that only 42% of urban,
30% of suburban and 28% of rural female population were adequately
vaccinated (Eckermann, 1981).
In the United Kingdom, there were 19 notifications of tetanus in
England and Wales in 1969 and 18 in 1980, with an increasing proportion
of inpatients aged 45 and over, and a declining proportion under 15
(PHLS Public Health Laboratories Report, 1982). Limited information
was available about the circumstances relating to deaths, but minor
garden injuries were important in the elderly, and sports injuries in
the 14-44 age group.
Recent trends of tetanus indicate that no area in the world is
free from this major lethal infection. it seems that vaccination alone
cannot be relied on in controlling the disease and the case fatality
can be greatly reduced by modern methods of treatment.
A.4.6 Tetanus Prophylaxis
Different prophylactic procedures may be adopted according to the
age, previous immune status of the individual and the local incidence
of tetanus. The most important prophylactic procedures for the
prevention of the tetanus are as follows:
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A.4.6.1 Active Immunization
Active immunization is the prophylactic measure of choice as this
establishes basal immunity before exposure to the risk of tetanus.
Vaccination against tetanus forms an essential part of any routine
immunization program for children. It may be instituted at any age by
the administration (i.m.) of two doses of adsorbed tetanus toxoid at an
interval 4-6 weeks followed by a third dose 6-12 months later.
Thereafter reinforcing doses should be given every 5-10 years.
Additionally, an immune patient with a tetanus prone wound should
receive tetanus toxoid if the last booster was given more than 12
months previously (PHLS, Public Health Laboratory, 1982).
Since its development, in 1923, by Ramon, tetanus toxoid has been
submitted to various improvements with regard to the mode of
detoxification of the toxin (Gottlieb, 1967), purification,
concentration and improved antigenicity (discussed in Chapter 3). In
addition, tetanus toxoid, for a long time, has been combined
advantageously with other antigens, such as diphtheria-pertussis (DTP,
triple vaccine), typhoid and paratyphoid and more recently, with live
attenuated measles vaccine (Veronesi, 1981). Also,it has been shown in
animals and in man that active immunization against tetanus may be
achieved with just a single shot of special tetanus toxoid (Dastur,
1981) .
It is assumed that once an individual is immunized with tetanus
toxoid, the circulating antibody titre will never fall to zero but will
rather fall to some lower limit and remain at that level throughout the
lifetime of the individual (Gottlieb, 1967). More recently, it has
been questioned whether the protective blood level of antitoxin (0.01
I.U./ml) is a really safe level, since not infrequently, in some areas
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of the world, individuals with blood tetanus antibody ranging from 0.01
to 1.0 I.U./ml may get tetanus, usually of mild severity and low
fatality rate (Iran, Salimpour, 1978).
A long-term program of routine immunization of pregnant women with
two doses of tetanus toxoid is at present being recommended by the
WHO's Expanded Program on Immunization (1980) as an effective approach
to the control of neonatal tetanus. The last dose is administered 2-4
weeks before delivery. Active maternal immunity is passively
transferred to the fetus through the placenta. The newborn retains
these maternal passive antibodies for a period of about 1 or 2 months,
which is long enough to protect against eventual tetanus infection
originating in the umbilical cord. For infants born to women with
inadequate tetanus immunization, prophylactic treatment at birth with
homologous or heterologous antitetanic sera should be considered.
A.4.6.1.1 Adverse Reactions to Tetanus Toxoid
Allergic reactions to tetanus toxoid occur in about 1% of
individuals, mainly those who have been over-immunized (Willis, 1981).
Reactions are usually local (local redness, swelling, pain), but more
severe reactions such as fever, vomiting, anorexia, persistent crying
and seizure have been reported (Cody et al. 1981 and Hirtz et a_l. 1983)
in children age 0-7 years old following the immunization with DT or DTP
vaccine. In March, 1979, the U.S.A. Department of Health reported four
sudden deaths which had occurred since November 1978 in infants who had
been vaccinated during the 24 hour period prior to death (Bernier
et al. 1982).
The reactions are believed to be due to impurities of tetanus
toxoid and the adjuvant (AIP04) present in adsorbed tetanus toxoid
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(Collier, 1979). However, the majority of toxoid reactors are found to
have high blood levels of antitoxin (Levine et al. 1981). In order to
minimize these reactions, it is recommended that plain and not absorbed
vaccine be used when reinforcement of immunity to tetanus alone is
desired (Collier, 1979), and to avoid hyperimmunization.
Active immunization does not provide any protection in a
non-immune patient who requires immediate prophylaxis (Willis, 1981).
A.4.6.2 Passive Immunization
Generally speaking, administration of antitoxin to the
non-immunized is indicated for all people with a soiled wound.
Sufficient amounts of tetanus antitoxin should be inoculated as soon as
possible in an attempt to block the toxin from being fixed by the
central nervous system (CNS). It is much more difficult to neutralize
the toxin which has already been fixed by the nervous structures
(gangliosides)• As a consequence of this, passive immunization should
be given very shortly after injury, before any toxin can reach its
target cells in the CNS.
It has been shown experimentally that large doses (1000 IU/kg) of
antitetanus serum (ATS) may prevent tetanus in guinea-pigs if given not
later than 6 hours after the inoculation of a lethal dose of tetanus
toxin (Bytchenko ejt a_l. 1970).
A.4.6.2.1 Heterologous Passive Immunization
The use of heterologous ATS, usually equine or bovine, is based on
the property of the tetanus antitoxin to neutralize fully the tetanus toxin,
provided an adequate amount of ATS is added in vitro to the toxin.
However, when the ATS is challenged in vivo against the toxin, a
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greater amount of ATS is required to produce similar results (Veronesi,
1981). The most common dosage being used is 1500-3000 I.U. (i.m.).
The chief disadvantages of heterologous antitetanus serum are
allergic reactions (more on this later) which are likely to follow its
use, and the accelerated elimination of antiserum from sensitized
patients. The latter is of some importance, since in these patients
quite substantial doses of antitoxin provide inadequate protection.
Patients must be tested for sensitivity to heterologous antitoxin
before a full dose is administered. Intradermal testing is unreliable,
and the trial dose method is used. This involves subcutaneous
injection of 0.1 ml of the serum and the patient's general condition is
observed before a larger dose is given. If the patient is
hypersensitive further heterologous serum must not be given (Willis,
1981).
A.4.6.2.2 Tetanus Immunoglobulin of Human Origin (TIG)
The need for homologous instead of heterologous ATS became more
obvious when the harmful effects of heterologous ATS were followed by
the failure that such prophylaxis showed during World War II (Eckmann,
1963).
Homologous antitoxin provides better protection and has none of
the disadvantages of animal antiserum. Hypersensitivity reactions to
human immunoglobulin are rare (if injected i.m.), and there is no risk
of its accelerated elimination. A single dose of 250-500 I.U. provides
protection for about 4 weeks (Willis, 1981).
The usual prophylactic dose of human TIG is 250 units for tetanus
from wounds without adequate, prior, tetanus toxoid immunization or in
the event of immunological problems. In the event of severe,
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neglected or old (more than 24 hours) wounds, 500 units may be
administered (Furste et al. 1981). The available preparations are
formulated for intramuscular use only, since intravenous injection of
TIG has caused reactions (Janeway, 1970).
Passive immunization with fragments of tetanus antitoxin was
introduced in the hope of overcoming several disadvantages of ATS.
First of all it would activate complement less. Secondly, it was hoped
that the fragments would distribute better than IgG into tissue spaces
or even into cells because of their lower molecular weight. Thirdly,
it was hoped that fragments made from heterologous IgG would be less
immunogenic than the parent IgG, and that consequently their rate of
immune elimination and their ability to induce unwanted immune
reactions would be lower.
Two types of fragments, Fab (Bizzini, 1981) and F(ab)g (Erdman,
1981) were investigated. Fab is produced by papain digestion and
F(ab)2 is produced by pepsin digestion of the Ig molecules. Fab soon
turned out to be less suitable for therapeutic purposes. Its
neutralizing potency is low, and in animal experiments, the speed of
elimination was very high. Fab preparations have not been used for
tetanus prevention in man. Homologous F(ab)2 is marketed for passive
immunization in tetanus. Its neutralizing potency is higher in
comparison with Fab, but still lower (about 50%) in comparison with
IgG. Heterologous F (ab)g is as immunogenic as its parent IgG, and
is eliminated faster (Wellhbner, 1981).
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A.4.6.3 Active-Passive Immunization
Active-passive immunization is advised for those who have never
been vaccinated against tetanus and are in need of optimal protection
against this disease. First a dose of adsorbed tetanus toxoid is given
to the person at risk who would also receive tetanus antitoxin
(homologous or heterologous). The principle is that when passive
immunity is declining, active immunity appears and thus avoids the
unprotected period when tetanus toxin could cause tetanus.
Naturally to avoid interference between the toxoid and the antitoxin,
the products should be injected separately, using a different syringe
and injection site. The patient will have to return later for the rest
of the course of active immunization. The first dose of toxoid does
not provide any protection in non-immune patients who require immediate
prophylaxis (PHLS, Public Health Laboratory, 1982).
A.4.6.4 Antimicrobial Prophylaxis
Although the prophylactic administration of antibiotics to all
cases of open wounds is not recommended, it has been suggested that
antimicrobial prophylaxis, combined with surgical treatment of wounds,
should replace heterologous tetanus antitoxin (Veronesi, 1981). The
efficacy of antimicrobial prophylaxis is dependent not only on the
sensitivity of contaminating strains to the drug, but also on the
active concentration of the drug attainable at the site of
contamination. Most strains of CI. tetani are highly sensitive to
penicillin, metronidazole, tetracycline and erythromycin. In order to
be effective, however, prophylaxis must be commenced soon after injury,
within 6 hours, and continued for at least 5 days. Antimicrobial
agents are not active against tetanus spores and have no effect upon
preformed toxin (Willis, 1981).
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Although the value of antimicrobials as a replacement for antisera
remains unproven, chemoprophylaxis, used with care and discretion,
could play an important part in tetanus prevention, especially when
antitoxin is not available.
A.4.6.5 Surgical Prophylaxis
Prompt and adequate wound toilet and proper surgical debridement
of wounds are of paramount importance in the prevention of tetanus as
there is an increased risk that tetanus spores may germinate in a wound
if there is delay in cleansing. Surgery is essential for all wounds,
no matter how trivial. It may range from medical excision to simple
washing; the aim is to remove dirt, foreign bodies, necrotic tissue,
and blood clots, and to restore the blood supply to the part.
Antimicrobials may be administered systemically before surgery and
may be applied topically as part of the surgical toilet (PHLS, Public
Health Laboratory, 1981). Of course ATS when indicated will ensure
safer surgical prophylaxis.
Wound management including tetanus prophylaxis schedule employed
by Lothian Health Board is outlined in Table 5.
A.4.7 Treatment of Tetanus
The treatment of established tetanus has four aspects: (1)
prevention of absorption of further toxin by the administration of
antitoxin, and by surgery of the wound, (2) control of reflex spasms,
(3) prevention of intercurrent pulmonary or other infection, (4)
control of fluid and electrolyte balance, and maintenance of nutrition.
Many accounts of treatment have been published (see for example
Edmondson, 1980; Ray £t^ aJL. 1981; Willis 1981, Duguid et al, 1978 and
Sanders 1979).
24
As previously stressed tetanus is particularly widespread at the
present in the developing and underdeveloped countries. In these less
fortunate countries, hospitals are very modestly equipped. A
specialized unit serving 1 million inhabitants may have to admit up to
500 cases of tetanus per year (Ray £t^ al. 1981). Intensive care is
therefore completely inaccessible to the vast majority of patients who
develop tetanus throughout the world, thus justifying the need for
simplified and effective treatment of the disease by such means as
serum therapy.
A.4.7.1 Serum Therapy
In the treatment of established tetanus, antitoxin is of proven
value. Heterologous ATS has long been considered the principal element
in the curative treatment of the disease. It is often administered in
very large doses, e.g. up to 1 million units (Ray et jhL. 1981) by all
possible routes; in the neighbourhood of the wound, intramuscularly,
subcutaneously, intravenously, intrathecally and in association if
necessary.
The value of ATS has been questioned over the last 20 years,
mainly because of the risk of adverse reactions, particularly "serum
sickness" which although not very dangerous, is common (46% of cases).
In experimental studies, in which it was decided to omit serum therapy
completely, a significant increase in mortality was observed and caused
the trial to be discontinued (Patel et el. 1967).
As a precaution, even if most authors have abandoned massive serum
therapy, they still give moderate doses of ATS, such as 3,000 and
6,000 I.U. generally by the intramuscular route (Veronesi, (1981). A
preliminary intradermal test is advised to avoid anaphylactic
reactions. Comparison of the efficacy of different doses of tetanus
antitoxin has been carried out by Vakil et. al. (1963 and 1968) .
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An additional argument in favour of not abandoning serum therapy
was provided by Patel's demonstration (1967) of circulating toxin in
the blood, in 10% of cases, and in the cerebrospinal fluid (CSF) in 4%
at the outset of the disease.
Interest in passive immunotherapy has been rekindled as a result
of the introduction of human specific gamma-globulin, which has the
advantages of avoiding the risk of adverse reactions, if not injected
intravenously (Janeway, 1970), and with the return to favour of the
intrathecal route, recommended by Ildirim (1970).
A.4.7.2 Intrathecal Injection of Tetanus Antitoxin
As long ago as 1898, Roux and Borel injected tetanus antitoxin
(Behring's) into different parts of the central nervous System (CNS) of
guinea-pigs. From their results, they suggested a direct action of
tetanus toxin on the CNS.
Sherrington (1917) and Smith (1965) have also demonstrated a
beneficial effect of antitoxin injection directly into the CNS. After
intrathecal injection of ATS, animals have been saved at the stage when
neither intramuscular nor intravenous injections of antitoxin produced
any favourable response. However, at the later stage of tetanus
intrathecal antitoxin was not effective.
Although the intrathecal route was later abandoned because of
dangerous side-effects/interest has been rekindled by observations of
Ildirim (1975), first in the dog and then in the newborn infant. With
no intensive care, the mortality from neonatal tetanus has been reduced
from 90 to 17% by the intraspinal administration of 2500 I.U. of
tetanus antitoxin or of 250 I.U. of TIG, together with 10,000 I.U.
injected by the pre-umbilical, intramuscular or intravenous route.
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Encouraging results (with the exception of Vakil, 1981) have been
reported more recently by Gupta et^ (1980), Singh et a_l. (1980) and
Thomas et al. (1982). The latter has used a combination of ATS and'
steroid, first used by Sanders et al. (1977).
Intrathecal serum therapy which would appear to be a logical
course of action, is indeed almost certainly of some effectiveness, and
is being employed by an increasing number of physicians. The optimal
doses are 30 units per kg in adults, and 45 units per kg in children
(Ray et al. 1981). This route not only seems to be a more effective
route, it also requires much lower dose of antitoxin than that given
systemically (Smith, 1965). This finding is related to the barrier
which exists to the passage of antitoxin from the cirulation into the
brain. With the availability of more specific and purer TIG (human)
t
and removal of one major concern over safe^, it is beginning to look as
r
though there could be a role for the intrathecal route in the treatment
of tetanus.
A.5 Limitations of Conventional Methods
The most widely used immunoglobulin preparations have been those
prepared by modifications of the ethanol fractionation procedure of
Cohn. In the mid-1940's, Janeway and Berenberg documented that the
intravenous injection of immunoglobulin derived from Cohn fraction II
caused marked adverse reactions. The severity of these reactions
prompted the warning that the preparations were to be used
intramuscularly only. Efforts to eliminate the adverse reaction by
further purification of the immunoglobulin and attempts to develop an
adequate screening test in animals for detection of reactive
preparations all ended in failure (Janeway, 1970). After 40 years the
27
problems still remain; indeed even intramuscular administration of
these preparations has been found to cause reactions, ranging from pain
at the injection site to systemic effects (Finlayson, 1980). The
incidence is especially high (20%) in patients with antibody deficiency
receiving regular injections (Thompson, 1981).
Some of the reasons for these reactions have been (a) aggregated
IgG, (b) preservatives and (c) impurities present in the preparations.
The amount of aggregates vary from 0.1-3%. Functionally these
aggregates will activate complement, and spontaneous complement
activation by infused Ig-preparations may lead to severe reactions.
These aggregates are formed during the plasma fractionation process,
such as the cold ethanol or ammonium sulphate procedures (RSmer et al.
1981). Immunoglobulin preparations obtained by these methods have to
be further processed in order to obtain good intravenous tolerance in
high-risk individuals.
Some preparations use mercury based preservatives to maintain
sterility. This metal accumulates, and has been implicated as a cause
of diarrhoea in some patients. However, this is considered uncertain
(Thompson, 1981).
Impurities such as vasoactive enzyme prekallikrein activator (PKA)
and kallikrein or plasmin can be present in some preparations. When
preparations containing these enzymic contaminants are given
intravenously, reactions could include flushing, dyspnoea and
tightness in the chest (Alving, 1980). These preparations have been
tolerated better if diluted and slowly transfused (Welch crt al_. 1980).
In the case of an unexplained adverse reaction to an
immunoglobulin preparations, recipients have sometimes been
investigated for antibodies to IgG. In some cases, hypersensitivity
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reactions result from previous sensitization of the recipient to
special antigens, particularly IgA, or other immunogenic substances
present in the IgG preparation. Antibodies to IgA may be found in
individuals with a selective IgG deficiency, who have previously been
treated with immunoglobulins for recurrent infections or given blood or
plasma transfusion for other reasons. In such patients the
administration of blood and plasma is strictly contra-indicated
(Barandun et al. 1981).
In the past few years, several new immunoglobulin preparations for
intravenous application have been developed. The earliest
manufacturing approach was to isolate the immunoglobulin by a
conventional procedure, and then to modify the isolated protein.
Modifying agents included the enzymes pepsin (Schultz et cQ. 1962),
which had long been used in the processing of equine antitoxins, and
plasmin (Sgouris, 1967); both were used to remove the Fc-part of IgG.
Chemical modification of the IgG molecule was done by jg-propiolactone
(Stephan, 1975), by treatment with hydrochloric acid at pH4 (Barandun
et al. 1962), or by reductants for cleaving disulphide bridges (Masuho
et al. 1977) .
More recently, producers have attempted to modify the
fractionation procedure itself, so as to obtain immunoglobulins
suitable for intravenous use without enzymic or chemical treatment.
The methods developed include precipitation procedures, ion exchange
techniques, or combinations of both (Welsh et ad. 1980; Eibl, 1980 and
Hoppe et el. 1973).
The introduction of immunoglobulin preparations which can be given
in high intravenous doses has been accompanied by the observation of
side-effects, as described earlier. The various forms of intolerance
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were classified according to their aetiology as discussed in the most
recent workshop in immunotherapy (Barandun et^ a_l. 1981). Therefore
only intramuscular injections were once again recommended before safe
preparations for intravenous infusion were available (Hitzig, 1981).
Although intramuscular (i.m.) injections may be easier to apply, in all
other respects the intravenous (i.v.) application is superior, in
particular for the following three points: (a) because of the large
volumes often needed, i.m. injection is difficult and must be
distributed to several sites, (b) i.m. injection is painful for several
hours or days, (c) injected immunoglobulin is partly destroyed (40-60%)
by proteolytic enzymes (Hitzig, 1981). in this connection, it should be
noted that others have recently claimed that certain immunoglobulin
preparations can be safely given by the i.v route (Yap et al. 1983)
The above problems could be solved by developing techniques to
produce potent and specific antibody preparations against particular
viruses or bacteria(which is the subject of this thesis), these
preparations having the two virtues of not only high and reproducible
antibody titres against specific organism, but also containing no
impurities which are the main cause of adverse reactions. Therefore
low doses of a preparation containing high level of antibody directed
only against the relevant pathogen can be administered with safety.
The most attractive ways to obtain such preparations would be by
using the natural specificity of antigen-antibody reactions as in
affinity chromatography technique, or by establishing a cell line
capable of producing the monoclonal antibody of our choice suitable for
human use. Both approaches were used to produce specific anti-tetanus
antibody, and are explained in detail in Chapters 5 and 6 respectively.
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A.5.1 Limitations of Available Tetanus Antitoxin Preparations
Animal anti-tetanus serum (ATS as referred to earlier) is a
heterologous protein to man and is identified as a strong antigen by
the human immune system. The unwanted reactions are both numerous and
dangerous (Moynihan, 1955; Binns, 1961, Skudder et al. 1962 and Cox
et al. 1963). The incidence of unwanted reactions is between 5 and 10%
or even higher. The most dangerous reaction is anaphylactic shock
which may be evoked even by a small dose used in the intradermal skin
test (Buff, 1960). The first ATS injection may evoke the production of
anti-horse IgG antibodies. These antibodies form immune complexes with
ATS which lead to complement activation (as described earlier). A
third group of side-effects comprises serum disease (described for ATS
as early as 1938 by Lyall et al.). These result from the formation and
deposition on the vessel walls of immune complexes (composed of ATS and
precipitating IgG) with subsequent complement activation. Heterologous
ATS has been rendered less prone to produce hypersensitivity reactions
by new methods of purification that may remove most of the non-specific
immunoglobulin and other proteins responsible for such reactions (Robb,
1975 and Tardy et a^. 1978). In spite of these advances, anaphylactic
reactions may still occur in individuals receiving heterologous ATS
(Veronesi, 1981).
The need for homologous instead of heterologous ATS is obvious.
In this context, Rubbo (1967) said "There is a growing awareness that
this agent (ATS) is a potentially dangerous allergen and that a charge
of negligence could be brought against a doctor, not because it was
withheld but because it was used".
The use of human TIG has gradually increased, mainly in developed
areas where tetanus is already under control. In some highly developed
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countries, more deaths have been caused from anaphylactic shock due to
heterologous ATS than from tetanus itself (Ericksson et al. 1967).
The advantages of TIG (H) over heterologous ATS are (a) duration
of immunity is longer than that obtained with heterologous ATS, (b)
lower doses of homologous antitoxin (TIG (H)) are highly effective,
(c) dramatic reduction in side-effects. However, a few failures have
also been accredited to TIG (H) (see Tetanus Surveillance Report,
1974) since the preparation of TIG (H) is identical to that of human
serum globulin (Cohn fraction II) except that hyperimmunized donors are
used. This preparation still contains large amounts of other
non-specific antibodies and other impurities. As a result similar
side-effects to those produced by using other IgG preparations (Cohn
II fraction) are observed (see A.5.1). Furthermore, TIG (H), like
other IgG preparations, is restricted to intramuscular
administration.
A.6 Aims of the Current Project
When these studies commenced in 1979 the overall objective was to
develop novel procedures for producing an anti-tetanus antibody rich
preparation whichwould be used therapeutically. The present thesis
deals with investigations which had to be performed in the pursuance of
this objective; these studies are as follows.
In the initial phase sensitive ELISA assays had to be developed
which would permit the measurement of circulating anti-tetanus
antibodies in both man and mouse and in antibody preparations derived
from the plasma or serum thereof. Furthermore, in view of the fact
that I also planned to attempt to purify anti-tetanus antibodies by
immuno-affinity procedures, it was deemed necessary to develop assays
capable of measuring the affinity of such antibodies.
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While our prime interest was in the antibodies themselves, it was
felt in the light of the studies we propose to do that I ought to
investigate the heterogeneity of various tetanus-toxoid preparations.
This seemed particularly important in view of the apparent lack of
information in this area.
From the outset it was clear that the two most obvious ways to
obtain enriched anti-tetanus antibody preparations were affinity
chromatography of polyclonal antibody preparations or by the monoclonal
antibody technique. Both these approaches have been attempted in the
present study. However before attempting either approach, a certain
amount of additional background work was necessary.
In the case of the immuno—affinity studies where I was attempting
to enrich antibodies from polyclonal antibody preparations, a number of
studies had to be undertaken to establish the optimum conditions for
the preparation of immunoadsorbents and to evaluate various factors
which might influence their performance. Finally before attempting to
produce murine monoclonal antibodies to tetanus toxoid we felt it
advisable to investigate in detail the immune response of mice to
different tetanus toxoid preparations paying specific attention to the
isotype of the antibody elicited. The reason for performing all these
investigations is explained in greater detail in the thesis.
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FIG. A-l
ACTIVITIES ASSOCIATED WITH VARIOUS DOMAINS OF IgG
Binding to monocytes, K cells
















































Cunningham et al. 1981
McClelland et al. 1984
(review)
Stiehm, 1979 (review)
Hepatitis A Prevention Stokes et al. 1945
Suff et al. 1979
Hepatitis non-A non B Prevention Zuckerman, 1979 (review)
Measles Prevention Stokes et al. 1944
Stiehm, 1980





Hammon et al. (1954)
Stiehm, 1979 (review)
*HISG is prepared by alcohol fractionation of pooled human serum by the
Cohn procedure (Cohn fraction II). It is for intramuscular use only,





















































































































ANIMAL SERA AVAILABLE FOR PASSIVE IMMUNITY
Product Principle Use
Diphtheria antitoxin Prevention and treatment
Tetanus antitoxin (ATS) Prevention and treatment
(when TIG not available)
Rabies immune serum Prevention and treatment
(when RIG not available)
Botulism antiserum Treatment
Gas gangrene antiserum Treatment (efficacy doubtful)
Black Widow spider antivenin Treatment of spider bite
Crotalide antivenin Treatment of snake bite
Reference: Stiehm, 1979 (review)
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TABLE A-4
MONOCLONAL ANTIBODIES WITH POSSIBLE USE IN PASSIVE IMMUNITY*
Micro-organism Origin Reference
Clostridium tetani Human Gigiliotti et al. 1982
Boyd et al. 1982
Haemophilus influenza Human Hunter et al. 1982
Type B Rat Hason et al. 1982
Escherichia coli Mouse SUderstrom et al. 1983
Young, 1983
Group B Streptococci Mouse Harris et al. 1982
Thomas et al. 1982
Pseudomonas aruginosa Mouse McClelland, 1984
Herpes Virus Mouse McMichael et al. 1981
Protozoa (Malaria) Mouse McMichael et al. 1981
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B. GENERAL MATERIALS AND METHODS
B.l TOTAL PROTEIN ESTIMATION
Total protein concentrations were initially determined by the
Folin-phenol procedure of Lowry et_ aT. (1951). The protein standard
used was crystallised bovine serum albumin (Armour Pharmaceutical
Company, Phoenix, U.S.A.). A standard curve was constructed by
assaying 10-12 standards (in duplicate) ranging from 25 to lOOO^ig
protein per ml (Fig. 1 and Table 1). All estimations were performed in
duplicate.
In later studies the protein concentration of tetanus toxoid
preparations was determined by measuring the absorbance at 280 n.m. in
an SP-500 spectrophotometer (Pye Unicom, Cambridge, U.K.), using an
1 %
extinction coefficient (E ) for tetanus toxoid of 4.2. This
1 cm
extinction coefficient was determined by measuring the O.D. of a range
of tetanus toxoid preparations of known protein concentration
(determined by the above Folin-phenol technique (Fig. 2 and Table 2)).






= Protein concentration in mg/ml
4.2
B.2 PROTEIN CONCENTRATION PROCEDURES
Two different procedures were used to concentrate samples.
2.1 Ultrafiltration
A length of 8/32 "Visking" dialysis tubing (Gallenkamp, London,
U.K.) was soaked for 5 min in distilled water and threaded through a
rubber bung. A plastic filter funnel was then inserted into the
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dialysis tubing, and a firm seal made by inserting the end of the
filter funnel into the hole in the bung. The other end was tied off.
The sample to be concentrated was poured into the tubing and the bung
was inserted into the neck of a 250 ml Buchner flask with side arm.
The flask was evacuated and left at 4°C until the sample was
concentrated to the desired volume. The optical density of the
filtrate and the concentrate was measured at 280 n.m. to check for
leakage.
2.2 Minicon-B clinical sample concentrator
These were obtained from Amicon Ltd. (Woking, Surrey, U.K.). They
contained eight isolated sample chambers which held up to 5 ml of
sample and retain molecules with a M.W. greater than 27,000 M.W. The
inner surface of the chambers is a membrane of selective permeability,
backed by absorbent pads. Retained constituents are progressively
concentrated in the chambers as fluid is absorbed by the pads. Samples
can be concentrated 5-100 times as indicated by graduation lines.
B.3 IODINE LABELLING OF PROTEINS
Iodine, in particular ^25i was the isotope of choice for a
number of reasons. (i) It is a ^-emitting isotope which is preferable
to /3-emitters such as or l^C. xhe relative advantage of
radioiodine may be seen by a simple calculation that one atom
substituted into a molecule of insulin provides 200 times as many
radioactive disintegration per unit as would be produced if all 263
carbon atoms in the molecule were 600 atoms of would be
required to bring the same number of counts (Hunter, 1981). (ii)
has a longer half life (60 days) and higher isotopic abundance
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(80-95%) in commercially available preparations than 131j with its
shorter half life (8 days) and lower isotope abundance (15-20%).
(iii) 125i has a higher counting efficiency and is relatively less,
hazardous to work with than 131l because of its lower decay energy.
(iv) Although under some circumstances iodine may react with
sulphydryl groups, with histidine or with tryptophan, the chemistry of
radioiodination is predominantly the substitution of iodine into
tyrosine groups (Hughes, 1975). This is achieved by using a pH just on
the alkaline side of neutrality. The reaction consistsof substitution
of iodine, produced by oxidation of iodine into ionized tyrosine
(phenate) groups of the protein. Various oxidizing agents have been
used.
Two methods were used to radio-label proteins, both based on the
method of Greenwood et al^ (1962) utilising chloramine-T as oxidising
agent. The difference between the two methods was the nature of the
reducing agent used to neutralise the chloramine-T. In earlier studies
sodium metabisulphite was used to protect the protein from oxidation
damage but later this was replaced by cysteine-HCi (Brown et_ al_. (1982).
3.1 Iodination using Na2 S2 O5 as reducing agent
To 200-400 jig of protein in a glass bijou, the following reagents
were added in sequence
(a) 100 jil phosphate buffer (0.5 M pH 7.6)
(b) 10 jil (1 mCi) Na 125 j (Radiochemical Centre, Amersham, U.K.)
(c) 100 jil (400 jig) chloramine-T (60-90 seconds incubation with mixing
on a magnetic stirer)
(d) 100 jil (800 jig) Na2 S2 05
(e) 100 ji 1 (2 mg) sodium iodide
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The mixture was immediately applied to a G-25 or G-50 Sephadex
column (Pharmacia Fine Chemicals, Uppsala, Sweden). The column had
been equilibrated with phosphate buffered saline pH 7.2 (PBS) and
presaturated with excess bovine serum albumin (10-20 mg B.S.A. in 200
jii) to minimise adsorption of labelled protein to the Sephadex.
Bromophenol blue (1%) and phenol red (1%) with B.S.A. were first added
to estimate the void volume of the column and to ensure that the column
had been properly packed. Twelve 3.0 ml sample fractions were
collected, and 10 jrl aliquots of each counted on an Ultragamma counter
(1280 LKB, South Croydon, U.K.). To these aliquots was added lOO^il
foetal calf serum (FCS - Gibco Biocult, Paisley, U.K.) and an equal
volume of trichloroacetic acid (TCA 20%). The TCA-precipitated counts
were expressed as a percentage of the total count to measure the
that was protein bound. The total and TCA-precipitable counts
were then plotted against the fraction number (Fig.3). The counts in
each fraction were converted into jiCi terms using the formula
C VT 100 1
T X VC X 58 X 37,000 " XJLCl
where C = counts
VT = fraction volume in jxl
VC = volume counted injil
100 = the reciprocal of the counting efficiency of the gamma
58
counter and converts counts to disintegrations
37,000 = the number of disintegrations/second per^iCi.
T = counting time in seocnds.
The fraction(s) exhibiting highest radioactivity and TCA
precipitability were chosen and stored at -20°C until use.
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3.2 Iodination using cysteine-HCl as reducing agent
In later experiments, in order to minimise damage to the protein
resulting from oxidation, cysteine-HCl was substituted for
Na2S2C>5 and a lower concentration of choramine-T with a shorter
incubation period was chosen (Brown et aJ., 1982).
To 10-300^ig of protein the following were added in sequence:-
hate buffer pH 7.5 (0.25M)
Protein was separated from free iodine as described in
section 3.1.
3.3 Efficiency of radio-iodine labelling procedure
Labelling efficiency may vary depending on the protein being
labelled, its molecular size, the number of tyrosine group it contains,
its purity and concentration. In this study the Wellcome tetanus
toxoid labelled less efficiently than Connaught toxoid, IgG and BSA
(Table 3).
B.4 GEL FILTRATION
Gel filtration was performed on Sephadex (Pharmacia Fine
Chemicals, Uppsala, Sweden). G-25, G-50 and G-100 (Superfine grade)
were used for desalting, buffer exchange purposes and removal of
free label after iodination of proteins. G-200 Sephadex was used for
separation of protein mixtures (mainly tetanus-toxoid).
choramine-T (15 second incubation with mixing)
(d) 100ji 1 (62jxg) cysteine-HCl
(e) 855 jil (5 mg) KI
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4.1 Preparation of Sephadex gel
The dry powders were swollen in approximately 5 times their weight
of 0.06 M PBS pH 7.2 containing 0.02% NaNg at room temperature for
3 days for G-200 and 3 hours for the other types of Sephadex. After
swelling, the Sephadex was allowed to settle and the fines were removed
by decantation. The gel was suspended in PBS and this process was
repeated until the majority of fines had been removed.
4.2 Packing the gel bed
A column manufactured by Wright Scientific Limited (Stonehouse,
Surrey, U.K.), fitted with a sintered glass pad at one end, was partly
filled with buffer to check for leaks. The column was then clamped in
a vertical position, and the swollen Sephadex was poured down a glass
rod into the column. Before the Sephadex had fully settled, more
slurry was added and the process repeated until the column was
completely full. The column was then sealed and a variable speed
peristaltic pump (LKB 12000, Varioperpex) connected to the bottom of
the column. The flow rate was adjusted to that appropriate for the gel
type and column size used, and at least one column volume of the buffer
was pumped through. The efficiency of the G-200 columns was tested
before each experiment by performing a trial run with normal human
serum under the same conditions to be used with the experimental
samples. The elution profile of the major protein peaks were used to
calibrate the column.
B.5 PROTEIN-A SEPHAROSE CHROMATOGRAPHY
Protein-A is extracted from the cell wall of staphylococcus
aureus. It consists of a single polypeptide chain of molecular weight
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of around 41,000 daltons and contains binding sites that show a high
affinity for the Fc portion of immunoglobulin-G (IgG). Each
protein-A molecule is able to bind two molecules of IgG. Protein-A
interacts with IgG of many species and within a species this
interaction may be restricted to certain subclasses (isotypes) of IgG.
For example, in man, protein-A interacts more strongly with IgG of
subclasses 1,2 and 4 than with IgG3, and in mouse with all IgG
subclasses but not with IgM or IgA (Kronvall et_ al_. , 1970; Grey e_t
al., 1971).
Protein-A Sepharose (Pharmacia) was used to fractionate mouse IgG
subclasses. The procedure used (Ey et^ al_. , 1978) relies on the fact
that the binding of mouse Ig-isotypes to Protein-A Sepharose is pH
sensitive. Staphylococcal protein-A covalently linked to Sepharose
CL-4B (Protein-A Sepharose) was obtained from Pharmacia Fine Chemicals.
1.5 grams were swollen in 10 m M PBS pH 8.0 containing 0.05% NaN3 and
packed in a 20 ml column. Before use, the column was equilibrated with
0.1 M PBS pH 8.0. Mouse serum or ascitic fluid (1 ml + 1 ml PBS) was
applied to the column. The unbound immunoglobulins (M,A and E) and
other serum proteins were washed off using the equilibratingbuffer.
The various IgG subclasses were recovered by stepwise elution with
citrate buffer of decreasing pH. After each separation the Sephadex
column was washed thoroughly with phosphate buffer pH 8.0 and stored at
4°C. The column was used several times without any noticeable change
in its binding properties.
B.6 IMMUUO-AFFINITY CHROMATOGRAPHY
This is a form of adsorption chromatography in which the bed
material has immunologically specific affinity for the substance to be
48
isolated. The specific adsorptive properties of the bed material
(CNBr-activated Sepharose-4B) are obtained by covalently coupling a
relevant molecule (antigen or antibody) to the insoluble matrix. The
complementary antibody or antigen is isolated from the starting
material by passing it through the column, the specially adsorbed
material being recovered by changing the experimental conditions (see
Fig. 4).
6 .1 Coupling Procedure
CNBr-activated Sepharose-4B was obtained from Pharmacia and
prepared according to the manufacturer's instructions. Dry gel was
swollen and washed for 15 min on a sintered glass filter (Whatman,
Maidstone, U.K.) with 10-^ M HC1 solution (200 ml/g of gel). The
substance to be coupled (up to 10 mg protein/gm of gel) was first
dialyzed against 0.1 M borate buffer pH 8.0 containing IM NaCl and
0.02% NaN3, and then mixed with the gel. The mixture was rotated
end-over-end for 2-4 hours at room temperature or overnight at 4°C.
Unbound material was washed away with the coupling buffer and any
remaining active groups were blocked by treatment with 1 M ethanolamine
at pH 8.0 for 2 hours at room temperature. Three washing cycles were
used to remove non-covalently bound proteins, each cycle consisting of
a wash in 0.1 M acetate buffer pH 4.0 containing 1M NaCl followed by a
wash in borate buffer at pH 8.0. The gel was stored at 4°C in the
borate buffer containing a bacteriostatic agent (0.02% NaN3).
6.2 Immunoadsorption procedure and specific Ab recovery
The protein coupled gel was packed in a suitably sized syringe
barrel. The column was washed with at least one column volume of
borate buffer or PBS containing 0.02% NaN3. The solution to be
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absorbed was applied to the column- After the column was loaded, its
end was closed and the reactants allowed to remain in contact for at
least one hour. The unbound protein was eluted with PBS. Fractions of
3 mis were collected until the optical density (E nm ) of the
1 cm
effluent reached zero. The specific bound material was recovered by
running 0.2 M glycine-HCl pH 2.8 containing 0.5 M NaCl through the
column. Fractions of 1.5 ml were collected in tubes containing 0.5 ml
of 2 M tris-HCl buffer pH 7.8 in order to rapidly adjust the final pH
of the eluates to physiological levels. Elution was performed at room
temperature. The eluates were analysed for protein concentration and
specific activity. The protein containing fractions obtained with each
buffer were pooled, concentrated and kept frozen for further studies.
B.7 MANCINI RADIAL IMMUNODIFFUSION TECHNIQUE
Human IgG, IgA and IgM concentrations in fluids were estimated by
the Mancini radial immunodiffusion technique (Mancini £t^ aJ., 1965)
using Hyland commercial plates (L.C. Partigen plates, Hyland Lome,
Thetford, U.K.). In this procedure, the diffusion of antigen into agar
containing the specific antibody results in the formation of a circular
zone of precipitation at equivalence. The diameter of this zone is
directly related to the concentration of the diffusing antigen.
Before addition of samples the plate lids were lifted to allow
moisture in wells to dry (10-15 min at R.T.). Using a Hamilton syringe
4Jil of antigen was delivered to each well. Reference standards were
included in each batch of assays. The plates were incubated for a
minimum of 48 hours at R.T. The diameters (D) of precipitation rings
were measured using a magnifying eye-piece with a graduated scale. A
standard curve was obtained by plotting on two cycle semi-log paper the
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diameters against the protein concentration of the standards; the test
values were read off this curve. The results were expressed in mg/ml.
B.8 HAEMAGGLUTINATION ASSAY
The most important part of this assay was the bulk preparation of
tetanus toxoid-coated glutaraldehyde-fixed erythrocytes. This produced
a stock of coated cells which were stored at 4°C and retained
sensitivity throughout the 3| year period of the study. The method
used was based on the technique of Nelson et_ al. (1973).
8.1 Glutaraldehyde fixing of cells
One unit (450 mis) of human group "0" Rh-negative blood collected
in anticoagulant (citrate phosphate dextrose) was obtained from the
blood bank. The red cells were washed (x3) in physiological saline and
the packed cell volume (PCV) established after spinning at 1000 g for 5
min. A 2% (v/v) suspension was made in 1% glutaraldehyde in PBS pH 7.2
and incubated at 4°C for 30 min with rinsing every 10 min. The cells
were washed 3 times in saline followed by 3 times in distilled water to
get rid of haemolysed and non-fixed cells. After establishing the PCV
as before, 1 ml of tetanus toxoid at 300^ig/ml and 0.5 ml of 0.5% (w/v)
chromic choride was added to 1 ml packed cells. After mixing, this was
incubated at 25°C for 6 min, washed in saline (x3) and stored as a 20%
suspension in distilled water at 4°C until used.
8.2 Assay
An aliquot (25jil) of the samples under test was serially diluted
two-fold in 2% BSA saline (v/v) in microtitre "U" bottom plates (Flow
Laboratories, Irvine,Ayrshire). Two preparations of human anti-tetanus
IgG for clinical use, with known concentration of specific anti-tetanus
C ^ 0\.'
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antibody, were used as standards. These were human anti-tetanus IgG
(SNBTS Protein Fractionation Centre, Edinburgh, U.K.) and Humotet
(Wellcome, London, U.K.). Negative controls consisted of human serum
negative for anti-tetanus antibody activity (when available), or
diluting fluid. Standards, controls and samples were allowed to react
with 25ji1 0.6% suspension of tetanus-coated cells (in 2% B.S.A.-
saline) for two hours at room temperature. Negative samples were
characterised by a dot of cells in the bottom of the well. Samples
containing specific antibody caused the antigen-coated cells to
agglutinate. The last dilution of antiserum at which agglutination
was visible was taken as the antibody titre. This titre was converted
into international units by the following formula
I.U./ml = titres of test x known units of standard
B.9 HAEHAGGLUTINATION INHIBITION ASSAY (HIA)
Tetanus toxoid activity was measured by two stage HIA. The sample
(v/v), and mixed with an equal volume of standard anti-tetanus IgG at
0.125 I.U/ml of antibody activity. The plate was mixed by tapping
along each edge, then incubated at 37°C for 30 min. An equal volume of
0.6% tetanus-coated cells (section B.8.1) was added to all wells. The
plate was mixed and reincubated at 37°C for a further hour. In the
presence of tetanus toxoid the agglutination of the sensitized cells
was inhibited. This was characertised by a dot of cells in the bottom
of the well. The last dilution of tetanus toxoid at which the dot of
cells was visible was taken as the titre.
titre of standard
to be tested two-fold serially diluted in 2% BSA-saline
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B.10 SEPARATION AND STORAGE OF SERA AND PLASMA
10.1 Mouse antisera
CBA mice were injected i.p. with lO^ig of Wellcome tetanus toxoid.
BALB-c mice were injected i.p. with either 10 ^ig Wellcome or Connaught
tetanus toxoid. Identical booster injections were subsequently given
on days 28 and 56. Six mice from each treatment group were bled on day
0 and thereafter every fortnight until day 70. The serum of each
individual mouse was separated after centrifugation, and stored frozen
at -20°C.
10.2 Human plasma
Tetanus toxoid-boosted donors were plasmaphoresed. A sample of
each plasma was assayed for anti-tetanus antibody activity by ELISA (C.l)
and haemogglutination (HA). The high titre plasma were clotted with
commercial bovine thrombin (Parke Davis, U.S.A.; final concentration
of 10 units/ml) by mixing and allowing to stand at 37°C for 2 hr. The
clots were squeezed and the expelled sera were left stirring at 4°C
overnight during which time further clotting was occasionally observed.
The following day the anti-tetanus sera were divided into 25 ml
aliquots in glass McCartney bottles, and centrifuged at 200 g for 15
min. The clear supernatant was recovered and stored at -20°C in 0.1%
NaN3.
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Common laboratory reagents were obtained from BDH Chemicals Ltd.
(Poole, U.K.). This is a list of the specific materials where their
sources have not been mentioned in the text.
Tetanus vaccine (Well^-TT): Wellcome Foundation Ltd., Crewe, U.K.
Tetanus toxoid (Welly-TT): Wellcome Research Laboratories,
Beckenham, Kent, U.K.
Tetanus toxoid (Conn-TT) : Connaught Laboratories, Willowdale, Ontario,
Canada.
p-Nitrophenyl disodium phosphatase: Sigma Chemical Co. Ltd., Poole,
Dorset, U.K.
Radiochemicals (^-^1 anc[ 131];). Amersham International Pic,
Amersham, Bucks, U.K.
Ammonium Sulphate: May and Baker Ltd., Manchester, U.K.
RPMI 1640 ~ tissue culture medium: GIBCO Europe Ltd., Paisley, U.K.
Penicillin/Streptomycin: GIBCO Europe Ltd., Paisley, U.K.
Hypoxanthine: GIBCO Europe Ltd., Paisley, U.K.
Thymidine: GIBCO Europe Ltd., Paisley, U.K.
Aminopterin: Sigma Chemical Co. Ltd., Poole, Dorset, U.K.
Lignocaine Sigma Chemical Co., Ltd., Poole, Dorset, U.K.
Foetal Calf Serum (FCS): Flow Laboratories Ltd., Irvine, U.K.
Fungizone: Squibb & Sons Inc., Princeton, U.S.A.
Karomycin: Winthrop Laboratories, Surbiton-upon-Thames, U.K.
Leukopak (Nylon Wool): Fenwall Laboratories, Madison, Wisconsin,
U.S.A.
Tissue Culture flasks and Flat-bottomed plates: Corning Ltd., New
York, U.S.A.
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FIG. B-l: Standard calibration curve for determination of total
protein by Folin-phenol method
A standard curve is constructed by testing a range of protein
concentrations of BSA. This is then used to estimate the
total protein values of unknown samples.
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TABLE B-l
STANDARDISATION OF PROTEIN BY FOLIN-PHENOL METHOD
Standard
B.S.A. 0 .D. x O.D.2 ug /ml
1 0 0 25
2 0.01 0.01 50
3 0.09 0.1 100
4 0.26 0.27 200
5 0.38 0.38 300
6 0.55 0.55 400
7 0.65 0.65 500
8 0.76 0.76 600
9 0.84 0.86 700
10 1.0 1.0 800
Various dilutions of the protein standards tested in duplicate
show great similarity of the O.D. values. Using these values
a standard curve was constructed (see Fig.l) and used to
estimate the total protein values of unknown samples.
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TABLE B-2
A COMPARISON OF THE FOLIN-PHENOL PROCEDURE AND DIRECT UV
ABSORBENCE AT 280 n.m. FOR THE MEASUREMENT OF THE PROTEIN CONTENT
OF BATCHES OF TETANUS TOXOID
(a) (b)
O.D. 1cm
Tetanus-Toxoid Dilution (Folin) jig/ml E280n.m. Jig/ml
Neat 0.41 310 1.3 310
1:2 0.18 152 0.64 152
Batch: 1:4 0.045 72 0.32 76
(A50688) 1:8 0 - 0.17 41
1:16 0 0.09 21
Neat 0.42 316 1.4 333
1:2 0.19 158 0.67 160
Batch: 1:4 0.065 82 0.34 81
(A52111) 1:8 0 - 0.18 43
1:16 0 0.1 24
Neat 0.38 300 1.2 286
1:2 0.17 150 0.59 140
Batch: 1:4 0.03 62 0.31 74
(A51329) 1:8 0 - 0.17 41
1:16 0 0.09 21
Neat Not done 1.3 310
1:2 "
" 0.64 152





(a) The protein concentrations were measured by using the standard curve
(Fig.l) of Folin-phenol procedure.
(b) The values were obtained by direct U.V. measurement of protein
solutions using an extinction coefficient for tetanus toxoid of 42.









































































The values represent results of separate radio-iodine labellings.
The labelling efficiency varies depending on the protein being
labelled.
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FIG. B-3: Typical elution profile of radioiodinated tetanus
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DEVELOPMENT OF ASSAYS FOR MOUSE AND HUMAN
ANTI-TETANUS ANTIBODIES (ELISA)
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C.l DEVELOPMENT OF ASSAYS FOR MOUSE AND HUMAN ANTI-TETANUS ANTIBODIES
AND FOR ISOTYPE ANALYSIS
Introduction
Antibodies to tetanus-toxoid are a reliable indicator of host
protection, and the measurement of anti-tetanus antibodies is of value
in assessing the immune status of individuals at risk, for the
selection of potential donors, for the production of anti-tetanus
immunoglobulin, and in monitoring the efficiency of vaccination
programs. The advent of hybridoma technology has also necessitated the
development of sensitive assay procedures which can be applied to the
rapid screening of larger numbers of samples of limited volume or with
low concentration of antibody.
An Enzyme Linked Immunosorbent Assay (ELISA) had to be developed
to meet all the above mentioned purposes. It is a simple and sensitive
method for the quantitative determination of antibody to tetanus toxoid
permitting the detection of anti-tetanus antibody levels as low as 5 x
10"4 I.U./ml.
Prior to its development several techniques were available for
measuring anti-tetanus antibodies. The first and most widely used
method for detection of immunity to clinical tetanus was (and still
is) the toxin neutralization test, developed by von Behring and Kitasto
(1890). This test measures the ability of tetanus toxin antibodies to
protect mice from a standard inoculum of tetanus toxin. It is a time
consuming test, and it takes five days to analyse a serum sample. In
addition only antibodies of the IgG class seem to be capable of
neutralizing tetanus toxin in mice (Ourth et al^. , 1977; Winsnes et_
al., 1979). Nevertheless, it still remains a suitable in vivo test,
but it cannot satisfy routine screening need. Other techniques used
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include counter-immunoelectophoresis (Barr et al., 1975; Winsnes,
1979), an automated latex particle technique (De saint ££ , 1975)
and a direct haemoglutination procedure (Nelson et al., 1973). Results
from most of these techniques are expressed in the form^. or^ 6.0
I.U./ml (De saint _et_ a_l. , 1975).
More sensitive assays exist. These include the reversed RIA
technique which can detect levels greater or equal to 0.01 I.U./ml
(Bernath et al, 1974 and Dow et al, 1983). However like most RIA
assays they require long incubation periods. For example, the RIA
procedure using protein-A (Haberman et al, 1973) takes 4 days for an
assay and uses a large number of tubes rather than one microtitre plate
(96 wells). Another disadvantage of RIA as compared to ELISA is that
they generally require more purified reagents than ELISA technique
(Wang Ai Sha et al., 1982). In addition, there are the problems
associated with the handling of hazardous radioactive materials, and
requirement of expensive and special equipment such as gamma counter.
The ELISA to be described is a simple, safe, cheap, rapid and
sensitive assay. It takes 4 hours to perform and can detect
anti-tetanus antibody as low as 5 x 10~4 I.U./ml.
1.2 Development of ELISA for quantitation of total anti-tetanus
antibody (Human)
1.2.1 Introduction
The technique used was based on the ELISA procedure first
described by Engvall elt al. (1972). The steps involved in this assay
are summarised in Fig.la. In the initial step the wells of a
microtitre plate are coated with a dilute solution of antigen (in this
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case tetanus toxoid). The antibody preparation under test is then
added to the plate. This is followed, after incubation and washing by
an enzyme conjugated (in this study alkaline phosphatase) antibody
directed against the appropriate immunoglobulin. Finally, after a
further period of incubation and subsequent washing the substrate
(p-Nitrophenyl disodium phosphatase) is added. This reacts with
conjugated antibody liberating paranitrophenyl which exhibits a yellow
colour. The intensity of colour is then measured
spectrophotometrically in a Multiscan at 405 nm (Dynatech,
Massachusetts, U.S.A.), thus indicating the amount of specific antibody
in the sample.
This ELISA procedure was used routinely to assay antitetanus
antibody levels in serum samples of immunized donors, tetanus infected
patients, crude tetanus IgG preparations, purified tetanus antibody
isolated by means of affinity chromatography, and in screening human
monoclonal antibodies to tetanus toxoid.
1.2.2 Material and Method
1.2.2.1 The development of a satisfactory ELISA procedure
Different procedures for coating the antigen (tetanus toxoid) to
the plates, and for performing the assays were investigated in order to
establish the optimum procedure. This was subsequently modified for
semi-automated routine use. The concentrations of tetanus toxoid used
to coat microelisa plates were 500, 100^ug/ml, and thereafter two-fold
dilutions to 6.25 ^ig/ml. Each concentration of tetanus toxoid was
assayed against different concentrations of tetanus-IgG standard (range
0.5-0.0005 I.U./ml doubling dilution). These concentrations were the
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same in the 5 different procedures tried. The variables tested in the
procedures are listed in Table 1.
1.2.2.2 Choice of microtitre plate for ELISA
Microtitre plates from four different manufacturers were used,
these namely Costar, Dynatech, Optiken and Nunc (for details, see Table
2). The ELISA assay performed was procedure No.4 (Table 1).
1.2.2.3 Determination of optimal concentration of antigen
ELISA procedure (No.4) was carried out on plates coated with the
various dilutions of tetanus toxoid (range of 565-7.0^ig/ml). The
results (A^®5) obtained from titration of tetanus-IgG standard
tested on each dilution of tetanus toxoid were compared.
1.2.2.4 Investigation of the effect of excess washing on the test
results
The washing of the plates between the various steps of ELISA was
done using an automatic plate washer (Dynatech). One group of plates
were washed 4 times post conjugate and 2 times for other washes. In
the other plates the number of washes were doubled and' results were
compared.
1.2.2.5 Investigation of the effect of the incubation period with
substrate
After addition of substrate (1.0 mg/ml) to a duplicate set of
plates, the results (A^®^) were monitored after incubating (37°C),
one set of plates for 30 min and the other for 60 min.
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1.2.2.6 Determination of the optimum concentration of conjugate
The anti-tetanus standards were assayed by using 1:500, 1:800 and
1:1000 dilutions of the conjugate in PBS containing 0.05% Tween 20.
1.2.2.7 Investigation of the effect of storage and coating procedure
on results
A series of plates which were coated and stored under different
conditions were tested by assaying the three different anti-tetanus
standards, and serum samples from tetanus boosted donors. These were
as follows:-
Plate (a): coated with tetanus toxoid (50jig/ml) and stored at 4°C with
the fluid in the wells. The plates were tested every week for _5
weeks.
Plate (b): coated and incubated overnight with tetanus toxoid solution
in the wells, and used the next day.
Plate (c): coated with tetanus toxoid and incubated first at 37°C for 3
hrs, and then at 4°C overnight. Next day the plates were washed and
dried. One of these plates was compared to the above two plates and
the rest were sealed and stored at 4°C. These plates were used over a
period of 10 months.
1.2.2.8 Selection of the best anti-tetanus standard
For the purpose of applying the ELISA technique for routine
testing of sera of tetanus immunized donors, the assay had to be
standardized. This was done by comparing the 3 anti-tetanus standards
with known level of anti-tetanus antibody activity (I.U./ml). The
three standards were two-fold serially diluted and assayed in plates
68
coated in the three different ways (a,b, & c). The plasma samples were
tested at single dilution (1:10,000), and the results were read against
each of the anti-tetanus standard curves. The anti-tetanus antibody
level was expressed as I.U./ml.
1.2.2.9 Determination of non-specific binding in ELISA by using normal
human serum (NHS)
Human serum negative in anti-tetanus antibody was included in each
assay as a negative control. It was also used as a blank in the
multiscan microtitreplate reader.
To ensure there was no non-specific binding at higher NHS
concentration, tests were carried out using 10% as well as 1% NHS. A
series of two-fold dilutions and a few different concentrations of
anti-tetanus standard (NIBSAC) were read against both NHS
concentrations.
1.2.1.10 Heating of the plasma samples prior to ELISA
A series of plasma samples were preheated at 56°C for 30 min and
assayed in parallel with unheated samples. The samples were two-fold
serially diluted starting with 1:10 dilution.
1.2.3 Results and Discussion
1.2.3.1 The development of a satisfactory ELISA procedure
Five different procedures were tried in order to select a simple,
rapid and sensitive assay for detection of anti-tetanus antibody. Four
out of the 5 procedures tried gave satisfactory results, as illustrated
in Fig.lb.
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For further studies and as a routine assay, the procedure J3 was
chosen since it was the simplest, fastest and exhibited good
sensitivity. Although the Ag-coating and assay can be completed in the
same day, this procedure was further simplified for routine use by
coating hundreds of microtitre plates in advance. This involved an
initial incubation at 37°C for 3 hrs with tetanus toxoid followed by
further incubation at 4°C overnight. The next day the plates were
shaken dry, sealed and stored in batches of three at 4°C. Plates
prepared and stored in this manner had been found to be satisfactory
for at least one year after initial preparation, anti-tetanus antibody
titres as low as 5 x 10~^ I.U./ml still being detectable (see
Fig.2). The assay procedure using the stored tetanus toxoid coated
plates takes only 4 hours, whereas the most recent radioimmunoassay
techniques for tetanus antibody measurement takes 3-4 days to perform
(Dow et al., 1983) .
1.2.3.2 Choice of microtitre plate for ELISA
Microtitre plates can be purchased from a number of different
manufacturers. Unfortunately, however, the results of ELISA assays
appear to be dependent on the source of manufacture. To find the plate
which would give the most sensitive and reproducible results, ELISA
assays were performed on plates from a number of different
manufacturers (Fig.3 and Table 2). The best results were obtained on
plates made by "Costar" and "Dynatech", however as the "Dynatech"
plates were cheaper, they were chosen for further assays. Plates
manufactured by "Optiken" exhibited high anti-tetanus antibody titre,
but results were irreproducible. The reverse was true on plates made
by "Nunc" (Table 2).
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1.2.3.3 Determination of the optimal concentration of antigen
The assay appeared suitable over a wide range of antigen
concentrations, results of which are shown in Table 3 and Fig.4. A
use. Since a wide range of antigen concentrations can be used to coat
the plates with test sensitivity still maintained, it is not necessary
to detect the optimal concentration each time, as long as the same
tetanus toxoid is used. It is advisable that the optimal
concentration be checked if tetanus toxoid from other suppliers or any
other antigens are used.
1.2.3.4 Effect of excess washing on the test results
As observed in Table 4 and Fig.5, excess washing of the plates
does affect the test results. The absorbance at 405 n.m. (A^®^) of
anti-tetanus standard decreases slightly as the number of washes
increases, indicating that some protein can be detached from the wells
by excess washing.
1.2.3.5 Effect of time of incubation with substrate
By increasing the incubation time of the substrate at 37°C, the
intensity of the colour produced increased. As the results in Table 5
and Fig.6 indicate, there was a two-fold increase in optical density of
the anti-tetanus standard when the incubation period with the substrate
was doubled. This confirms that one hour incubation with substrate had
been a good choice, as it gives good sensitivity. But the shorter
incubation period should not have a dramatic effect on the overall
results if a standard is included in each assay. The calibration curve
thus obtained is used to evaluate the test results.
concentration tetanus toxoid was selected for routine
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1.2.3.6 Effect of different concentrations of conjugate on test
results
The optimal concentration of conjugate was determined using
different dilutions of the conjugate. The results in Table 6 and Fig.7
(a,b,c & d) confirm that the 1:500 dilution of conjugate is the best
concentration giving the most sensitive and most reproducible results,
the increasing linearly with the concentration of anti-tetanus
antibody standards.
1.2.3.7 Effect of the storage and coating procedure on results
In order to obtain an accurate and reproducible assay which can be
used on a routine basis, it was essential to find a reliable coating
and storage procedure for the plates. In this trial anti-tetanus
standards and serum samples were tested using plates which were coated
and stored under different conditions (see page 68). The sensitivity
of the test seemed to increase (Table 7, Fig.8 and Fig.9(a)), each week
using plates which were stored with tetanus toxoid solution in the well
(plate (a)). At the higher antibody concentrations, the results
increased greatly with storage to exceed the range which the multiscan
can measure (A^^ 2.0); this is shown in Table 7 (see results
of the 5th week). This could have been due to evaporation and thus
further concentration of tetanus toxoid solution in the wells and/or
further absorption of the antigen by the solid phase.
The results using plate (b), which was coated with the tetanus
toxoid solution in the wells but used immediately the next day were
better than in plate (a). Using these plates the antibody levels being
readable by multiscan up to 0.5 I.U./ml (Table 9) as compared to 0.01
in plate (a). However, routine assays using this coating procedure may
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not be practical for urgent samples because the plates must be coated
one day before the assay, and can not be stored for later use, since
the same problem abserved in plate (a) would arise.
Coating and storage as in plate (c) proved to be the best (that
was coating and incubating with tetanus toxoid solution in the wells
first at 37°C for 3 hrs and then overnight at 4°C. Next day after
washing and drying the plates, they were sealed properly and stored
until use). As it is shown in Fig.9(c), Tables 8 and 9, the results of
anti-tetanus standards in this plate were much better to that observed
above. The three standard curves were parallel and gave a wider linear
range (A^®^ = 0.08-1.2) than they did in plates (a) and (b).
A quantitative measurement of antibody levels in all of the 8
serum samples from tetanus-boosted donors was achieved by using only
one single serum dilution of 1:10,000 (Table 8). The antibody level
(I.U./ml) of the same sample read against three different standard
curves were the same, except when using plate (b).
In Fig.9(d) the standard (NIBSAC) curves from differently coated
plates are redrawn. This shows that plate (a) results are above the
acceptable/readable range of multiscan, and plates (b) and (c) results
are acceptable and reproducible, but since in assays using plate (b)
two days are needed, plate (c) proves to be the most suitable and
practical procedure for coating and especially storage, since they have
a long shelf life.
1.2.3.8 Selection of the best anti-tetanus standard
From Fig.9 (a,b and c) and Table 9, it is apparent that the
"NIBSAC" standard is the most suitable for the assay, followed by
"Humotet". A more linear standard curve was obtained with "NIBSAC",
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and its linear working range was wider than the other two standards
when assayed in three differently coated plates (Table 9). In
addition, as the "NIBSAC" standard is a pool of anti-tetanus plasma, it
would be best in routine testing of antiserum of tetanus immunized
donors. The "PFC" standard used in these tests appears to give
irreproducible results. This may be due to batch to batch variability
of the tetanus IgG concentration, this being in the range of 40-180
I.U./ml (according to PFC). All the batches are labelled 250 I.U./2.5
ml which makes this standard a rather unreliable one.
In Fig.10, the three standards have been two-fold serially
diluted. The "NIBSAC" standard curve approaches linearity between
doubling dilutions of 7 to 11. This demonstrates that fewer dilutions
of this standard can be used and maintain the same linear range, giving
the possibility of quantifying specific antibody concentration at a
single reading within that region (as in Table 8). However, it is
advisable to use other lower dilutions as well in order to detect lower
concentration of anti-tetanus antibody in sera of non-immunized donors.
In this conncection, it is interesting to note that antibody levels as
low as 5 x 10-^ I.U./ml can be detected using the ELISA assay which
has been developed (Fig. 9).
1.2.3.9 Determination of non-specific binding in ELISA using normal
human serum (NHS)
As a routine it is important to include in each assay a serum
negative in anti-tetanus antibody (NHS), as a negative control to look
for any non-specific reaction. NHS should give absolutely no colour
reaction when it is assayed under the same conditions as positive sera.
The multiscan ELISA-plate reader should be blanked using 1% NHS (rather
than BSA or substrate alone as some do), and then the test sample and
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standards read against it. In the test which was carried out using
higher NHS concentrations (10%) as well as 1%, there were no
differences between the two test results (Table 10 and Fig.11). Both
concentrations of NHS were negative by the ELISA, indicating that there
is no non-specific binding using this technique.
1.2.3.10 Effect of heating plasma sample prior to ELISA
An interesting finding has been reported by Vos et al_. (1978), who
used an ELISA technique to quantify antibody to LPS. They found that
at low serum dilutions(i.e. 1:10), the antibody level was lower than at
higher dilution (i.e. 1:100 or, antibody titre higher in more diluted
sample). This inhibition at higher concentrations was thought to be
caused by a heat-labile serum component, as heating of the serum at
56°C for 30 min prevented this phenomenon. Although I did not
encounter this problem to the same extent, a more linear dilution curve
was obtained by pre-heating the anti-tetanus plasma (Fig.12). The
results also showed an increase in reaction at higher concentrations of
heated sample.
1.2.4 Conclusions
1.2.4.1 The enzyme-linked immunosorbent assay developed to measure
anti-tetanus antibodies is rapid, sensitive and capable of
measuring anti-tetanus antibody level as low as 5 x 10-^
units/ml.
1.2.4.2 The use of microtitre plates instead of tubes is economical.
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1.2.4.3 A wide range of protein concentration can be coated to the
solid phase. Antigen-coated plates can be stored for routine
use for a long period of time (10 months so far).
1.2.4.4 There was no non-specific binding observed in this technique.
1.2.4.5 A wide range of standards can be used, but NIBSAC has proven
to be the most suitable standard.
1.2.4.6 It is ideal for screening large numbers of samples. The
specific antibody can be quantified at a single serum dilution
(1/10,000).
1.2.4.7 It is safe as compared to radioimmunoassay.
1.2.4.8 It can be used to measure all immunoglobulin classes and
subclasses .
1.2.4.9 It can be applied to measure any other antibody
quantitatively, as long as the relevant antigen can bind
readily to the polyvinyl solid phase.
1.3 Development of ELISA for quantitation of mouse anti-tetanus
antibody
1.3.1 Introduction
This assay was developed to quantitate anti-tetanus total antibody
level in sera of immunized mice. This was done to measure antibody
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responses of mice to various doses of tetanus toxoid, and prior to
fusion for production of mouse monoclonal antibodies to tetanus toxoid.
The assay was used extensively in screening large numbers of hybridoma
supernatants, and subsequently in measuring monoclonal antibody level
in mouse ascitic fluid.
The assay was slightly modified from the ELISA previously
described (Section C.l).
1.3.2 Materials and Methods
Materials and methods were similar to those used in the ELISA for
human anti-tetanus antibody (Section C.l), except for the conjugate .
The conjugate used in this assay was sheep alkaline phosphatase
conjugated antibody directed against mouse Ig (NEN, Southampton, U.K.).
In order to determine the optimal concentration different dilutions of
this conjugate were tested.
The antibody containing samples under test were examined at a
range of doubling dilutions, the initial dilution depending on the
sample being examined. The results after correction for background (1%
NMS) were expressed as log2 titres of antibody. The end point in
this assay was the dilution giving a reading at O.D405 of^ 0.1.
1.3.3 Results and Discussion
The ELISA assay for measurement of the total tetanus antibody of
mice to tetanus toxoid was identical to that developed to measure the
total tetanus antibody in human (Section C.l). The only difference was
that the conjugate chosen for this assay was directed against total
mouse Ig. Most commercially available AP-conjugated anti-Ig are not
just heavy chain specific but contain some light-chain activity as
well. Therefore assays performed with such reagents measure IgM and
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IgA antibodies as well as IgG.
The optimal concentration of this conjugate was determined using
pools of serum from both normal and immunized mice. The results are
shown in Table 11. A conjugate dilution of 1:500 was selected for






















































































































































































































2 3 4 5
Procedure No.
Results of the different ELISA procedures (see Table C.l-1)
used to establish the most sensitive method for measuring
anti-tetanus antibody levels (I.U./ml). Procedures 3 and 4
















































ELISA - titre of antitetanus - Ab measured in tetanus - toxoid






NUNC Immuno Plate I
for ELISA
1 : 12,800 1 : 12,800 1 : 12,800
COSTAR - Serocluster EIA
plate, Half-Area (A/2)
1 : 51,200 1 : 51,200 1 : 51,200
OPTIKEN DISH (nbl) 1 : 12,800 1 : 102,400 1 : 25,600
DYNATECH Microeliza 1 : 25,600 1 : 25,600 1 : 51,200
1. "Nunc" plate (Beveridge, U.K.) shows reproducibility of result,
but the Ab- titres were lower than observed with other plates.
2. "Costar" plate (Massachusetts, U.S.A.) demonstrates
reproducibility and sensitivity and is therefore the best plate
of the four plates to be used in this ELISA technique.
3. "Optiken" plate (Northumberland, U.K.) was highly irreproducible.
4. "Dynatech" plate (Sussex, U.K.) is relatively reproducible, and




COMPARISON OF 4 DIFFERENT MICROTITRE PLATES IN ELISA





^ Ick^ Ak-dilution >.
Although the best results were obtained using "Costar"
plate, "Dynatech" was chosen for routine use, since
these plates were cheaper and gave more reproducible results.
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TABLE C.l-3
Results of antitetanus standard assayed against different
concentrations of Tetanus Toxoid
I.U./ml (O.D.) with different concentrations
of Tetanus Toxoid
Antitetanus 565 113 56.5 28.5 14.125 7.06
IgG (P.F.C.) jig/ml jig /ml jig/ml jig/ml jig /ml jig/ml
0.5 1.834 1.77 1.589 1.498 1.491 0.889
0.25 1.122 1.558 1.252 1.291 1.27 0.936
0.125 1.086 1.311 1.372 1.597 1.171 0.933
0.06 0.835 1.062 0.967 1.109 0.79 1.069
0.03 0.401 0.705 0.703 0.651 0.757 0.532
0.016 0.289 0.536 0.463 0.488 0.445 0.224
0.008 0.208 0.345 0.256 0.302 0.26 0.162
0.004 0.084 0.237 0.142 0.153 0.061 0.064
0.002 0.014 0.169 0.069 0.069 0.057 0.016
0.001 0.0 0.129 0.033 0.037 0.015 0.0
0.0005 0.0 0.104 0.011 0.011 0.0 0.0
Note that within the range of antigen concentration of 28.5-113



























Effect of excess washing on ELISA
Tetanus IgG A405
(P.F.C.) Washed Washed








The absorbance at 405 n.m. of the standard
samples decreases as the number of washes
are Increased (see also Fig.5).
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FIG. C.l-5
EFFECT OF EXCESS WASHING ON THE TEST RESULTS
antiserum dilution (Ic^) ^
The drop in O.D. (A4Q5) values of the anti-tetanus
serum dilutions indicate that some protein can be




Effect of time of incubation














There is a twofold increase in
absorbence at 405 n.m. of the
test samples when the
incubation time with substrate
is doubled (see also Fig.6).
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FIG. C.l-6
EFFECT OF INCUBATION PERIOD WITH SUBSTRATE AT 37°C
< antiserum dilution (logg) >■
One hour incubation of ELISA plates was chosen for routine
use, since it gives good sensitivity. Shorter incubation
time can be used providing a standard is used in each assay,
and the test results are evaluated accordingly.
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TABLE C.1-6
EFFECT OF DIFFERENT CONCENTRATIONS OF CONJUGATE TESTED












1.0 2.0 1.748 1.157
Tetanus - 0.1 2.0 1.193 0.94
IgG 0.05 1.809 1.238 9.761
(P.F.C.) 0.01 1.084 0.462 0.453
0.005 0.633 0.421 0.206
(a) 0.001 0.047 0.0 0.0
0.0005 0.0 0.0 0.0
1.0 2.0 1.497 1.261
Tetanus - 0.1 1.838 0.981 0.966
IgG - 0.05 1.371 1.123 0.746
(Humotet) 0.01 0.646 0.240 0.322
0.005 0.310 0.151 0.221
(b) 0.001 0.0 0.0 0.0
0.0005 0.0 0.0 0.0
1.0 2.0 1.618 1.223
Antitetanus 0.1 1.818 0.95 0.937
serum 0.05 1.538 0.95 0.853
(NIBSAC) 0.01 0.764 0.324 0.333
0.005 0.346 0.255 0.253
(c) 0.001 0.0 0.0 0.0
0.0005 0.0 0.0 0.0
Conjugate dilution of 1:500 gave the highest sensitivity in all 3 different
anti-tetanus standards used (see also Fig.C.1-7, a,b,c & d).
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FIG. C.1-7
The optimal concentration of conjugate was determined
by testing different dilutions of conjugate against 3
different tetanus antibody standards as follows
(a) Tetanus IgG (P.F.C.)
(b) Tetanus IgG (Humotet)
(c) Tetanus antiserum (NIBSAC)
(d) All _3 standards tested using optimum
concentration of conjugate (1:500)
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FIG. C.l-7
EFFECT OF DIFFERENT CONCENTRATION OF CONJUGATE TESTED
WITH 3 DIFFERENT ANTITETANUS STANDARDS.
• - 1:500 dil
O - 1:800 dil













Antitetanus IgG I.U. x 10 /ml
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Antitetanus IgG I.U. x 10 /ml
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TABLE C.1-7
SHELF LIFE DETERMINATION OF PLATE COATED AND STORED AT 4°C
WITH TETANUS TOXOID SOLUTION IN THE WELLS
Tetanus IgG 0 •D. at further storage time
(P.F.C.)
I.U./ml
1st Week 2nd Week 3rd Week 5th Week
0.5 1.07 1.38 1.81 2.0
0.25 0.54 0.75 1.41 2.0
0.125 0.41 0.52 1.16 2.0
0.06 0.21 0.3 0.92 2.0
0.03 0.08 0.12 0.74 2.0
0.016 0.03 0.02 0.62 2.0
0.008 0.03 0.01 0.41 1.24
0.004 0.0 0.0 0.28 0.73
0.002 0.0 0.0 0.16 0.48
0.001 0.0 0.0 0.08 0.31
0.0005 0.0 0.0 0.0 0.12
0.00025 0.0 0.0 0.0 0.0
The O.D. has increased with every week of additional incubation.
In the 5th week the O.D. was above the readable range ( 2.0)
of the multiscan (see also Fig.8).
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FIG. C.l-8
SHELF LIFE DETERMINATION OF PLATE COATED AND STORED
AT 4°C WITH TETANUS TOXOID SOLUTION IN WELLS
The sensitivity of the test increased greatly with
storage of the Ag-coated plates, possibly due to
further concentration and absorption of the tetanus























































































































































EFFECT OF DIFFERENT STORAGE AND COATING PROCEDURES
■<: antitetanus - IgG I.U x 10~3/ml >■
Anti-tetanus standard (NIBSAC) was tested in
plates which were coated and stored under different
conditions. Plate (c) was chosen for long time
storage since the results given were within the
acceptable range (O.D.<2) and reproducible. Plates
coated and stored in this manner had been found to
have a shelf life of at least 1 year at 4°C
















































































































































































































































































































































COMPARISON OF DIFFERENT ANTITETANUS STANDARDS
^ antitetanus dilution (1092) >
It is apparent that the anti-tetanus serum standard
(NIBSAC) is the most suitable for the routine assay,
and its linear working range is higher than the other
two standards (see also Table 9).
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TABLE C.l-10
RESULTS OF ANTITETANUS STANDARD DILUTIONS (NIBSAC) READ AGAINST























Both concentrations of NHS were negative by ELISA. The multiscan
plate-reader was blanked using 1% and then 10% NHS, and antiserum
dilutions were read against each. Similar results were obtained




DETERMINATION OF NON-SPECIFIC BINDING BY READING
ANTITETANUS STANDARD AGAINST NORMAL HUMAN SERUM (NHS)
•4 antiserum dilution (log.,) ►
The multiscan ELISA-plate reader was blanked using
1% and 10% NHS, and then the test samples were
read against each concentration of NHS. There
were no differences between the two test results,




























































DETERMINATION OF OPTIMAL CONCENTRATION OF SHEEP ANTI-MOUSE Ig
(AP-CONJUGATED) AND OF NON-SPECIFIC BINDING
Conjugate Anti-tetanus ELISA-titre
dilution serum control of antibody
1:50 Pos. Control 1:1024,00
Neg. Control 1:100
1:100 Pos . Control 1:25,600
Neg. Control 1:50
1:500 Pos. Control 1:51,200
Neg. Control 0
Dilution of 1:500 for conjugate was selected for routine mouse assay,
since it shows optimum specificity with good sensitivity.
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C.1.4
DEVELOPMENT OF AN ASSAY TO MEASURE ANTI-TETANUS ANTIBODIES
OF DIFFERENT MOUSE Ig-ISOTYPES (SEI)
108
C.1.4 Development of an assay to measure anti-tetanus antibodies of
different mouse Ig-isotypes (SEI)
1.4.1 Introduction
Serum immunoglobulins (Ig) have been divided into different
classes on the basis of a variety of properties including the presence
of non cross-reacting antigenic determinants found on the Fc fragment.
These antigenic differences reflect amino acid differences in the
constant portion of the heavy chains. Five classes of Igs have been so
defined, some of which have been further divided into subclasses
according to more minor Fc differences (Spiegelberg, 1974). The
Ig-subclasses differ in their physical, chemical and biological
properties (Feinstein et al. 1964, Micuson, 1975). More recently the
term isotype has been used to cover both class and subclass differences
between various immunoglobulins (Ig).
In the mouse the major Ig-isotypes IgM, IgA, IgG^ and IgG2
were first identified by Fahey et a_l. (1964a). These workers
subsequently showed that the mouse IgG2 existed in two isotypic
forms, designated IgG2a and IgG2b (Fahey _et_ jQ. , 1964b). Later
IgG3 was discovered by Grey £t_ al_. (1971).
The ready availability of commercial antisera to the mouse Ig-
isotypes, and the lack of similar reagents to human isotypes at the
time this work was commenced, made the mouse a suitable model to study
the Ig-isotypic responses following tetanus injection.
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The mouse isotypes are similar in many regards to the human
(Stanworth et aT. , 1973). It was hoped that this study would provide
useful information with regard to projected investigations in human
with the ultimate aim of discovering the importance of particular human
Ig-isotype in the response to infection and in passive Ig therapy.
Other workers have measured total Ig-isotype levels in mice by
radial immuno-diffusion (Yount et al., 1970; Van der Giesen, 1975;
Shakib et al., 1975), immuno-diffusions (Stanislawski, 1976; Kronvall
et al., 1970), and radioimmunoassay (Morell et al., 1972; Radl et al.,
1975).
Specific isotype-associated antibody levels to tetanus toxoid can
be measured by immunodiffusion (Ourth et_ al. , 1977), immunofluorescence
methods (Van der Giessen, 1976) and by a modified RIA (Carrel et al. ,
1972). Such procedures with the exception of RIA are however
semiquantitative. RIA, although sensitive, requires use of rather
large quantities of anti-isotype reagents, with limited shelf life of
any of the iodinated reagents, long incubation periods, and has hazards
associated with the handling of radioisotypes (Ekins, 1980).
Enzyme immunoassays have certain advantages over conventional RIA
in that they are as sensitive, are more rapid and less expensive. A
Sandwich Enzyme Immunoassay (SEI) was therefore developed to quantify
the level of antibodies of a particular Ig-isotype in mice. This was
based on the ELISA technique described earlier (Section C.l).
1.4.2 Materials and Methods
Positive control: pooled anti-tetanus mouse serum obtained by boosting
preimmunized mice (ip) with 10^yug of tetanus toxoid. The mice were
bled seven days later. The sera were pooled, aliquoted and stored at
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-20°C. The same pool was used as a positive control for mouse
anti-tetanus antibody measurement in other studies.
Negative control: pooled normal mouse BALB/c serum (NMS).
Conjugate: Alkaline phosphatase (AP) conjugated goat anti-rabbit Ig,
at 1:2000 dilution (see list of antisera).
The above materials are those which differ from materials used in
the direct ELISA (Section C.l).
The procedure of SEI assay was essentially similar to the direct
ELISA as previously described (Section C.l), except that it
incorporated an additional step (Fig.l-Step 2). This involved addition
of what might be called bridging antibody (antibody specific to mouse
Ig-isotypes) to the Ag-Ab complex already fixed on the plate (See
Fig.l). The optimal concentration of the bridging antibody had to be
determined. The binding of the bridging antibody was detected by the
addition of AP-conjugated anti-rabbit Ig (H & L), followed by
substrate. Experimental antisera were initially diluted 1:10 or 1:100
followed by two-fold serial dilutions in V/V) 1% BSA in PBS. The
dilution of the experimental anti-tetanus serum was 1:200. This
constant dilution was initially used in order to optimize the
concentration of the bridging antibody.
The absorbance at 405 nm (corrected for background) was determined
in a Multiskan microtitre plate reader. The OD405 values were
plotted against log2 of the antibody titres.
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1-4.3 Results and Discussion
1-4.3.1 Determination of the optimal dilution of bridging antibodies
(antibody specific to Ig-isotype) for SEI
Initially antisera specific to each Ig-isotypes were tested
against constant concentration of primary antibody (pooled anti-tetanus
mouse serum) using tetanus toxoid coated plates. The dilution of each
bridging antibody providing a broad range in the linear portion and
giving OD405 = 1.0 was selected. Fig. 2 (A-F) illustrates SEI
plots for each isotype specific antibody, and a defined plateau in the
region of antigen saturation (Ag-Ab complex). The selected dilution
for each isotype specific antibody was divided by 3 in order to ensure
antibody would be in excess quantity, and to increase sensitivity.
These dilutions of the bridging antibody finally selected are listed in
Table 1 and were used in routine assay.
Prior to determining the optimum dilutions of anti-isotype
antibody preliminary experiments were performed with an antibody to
total mouse Ig. The initial experiment provided a basis for the
subsequent experiments with the more expensive isotype specific
reagents (Fig. 2(G)).
1.4.3.2 Determination of non-specific binding
As a negative control a pooled normal mouse serum (NMS) was always
assayed in parallel with the pooled antitetanus mouse serum. Fig. 2(G)
and Fig.3 indicate no non-specific binding by NMS but high
concentration of IgGq antibody was detected in the antitetanus serum.
The IgG^ antibody level decreases linearly with antiserum dilution,
and is still detectable in the sample at a dilution of 1:100,000
(Fig.3). The results were corrected for background using 1% BSA. Both
these positive and negative controls were included routinely in all
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assays for individual Ig-isotype measurement. During the course of the
study we found natural occurring antibodies to tetanus of the IgM and
IgA isotypes. These will be discussed later.
1.4.3.3 SEI assay using optimized dilution of Ig-isotype specific
antibody
The optimum dilution of each bridging antibody (see Table 1) was
incubated with various dilutions of antitetanus sample on tetanus
coated plates. After washing off the unbound antibody the conjugate
and substrate were added as before. Fig.4 illustrates the levels of
anti-tetanus antibody of each isotype in pooled mouse antisera used to
standardize the Sandwich Enzyme Immunoassay. It should be stressed
that every batch of isotype specific antibody should be titrated as
above prior to its use in a routine assay.
1.4.3.4 Comparison in the distribution of tetanus antibody isotypes
of Protein A-Sepharose fractions with SEI technique
Mouse anti-tetanus serum was fractionated on protein A-sepharose-4B
according to the method described in Section B.5, and by Ey et_ al.
(1978). The eluted fractions (Fig.5) of each peak were pooled and
concentrated . The amount of isotype specific antibody to tetanus was
measured by SEI (Fig.6). These results support the specificity of the
anti-isotype antisera used. There is however IgA carry over in
fraction 3 and 4 (Fig.6). This could be due to small amounts of
anti-IgGi and IgG2a activity in the IgA region or incomplete
resolution of these molecules by protein A affinity chromatography. It
should be noted that although separation of IgG3 isotype has not been
included in the protein A separation technique used (Ey et al., 1978).
Small amounts of this isotype were detected by the SEI assay.
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1.4.4 Conclusions
1.4.4.1 The SEI assay developed to measure anti-tetanus antibodies of
different classes and subclasses (isotypes), is rapid, sensitive and
specific.
1.4.4.2 Because the isotype specific antisera can be used at high
dilutions it is sparing on expensive reagents.
1.4.4.3 The specificity of the anti-isotype antisera used is
supported by the distribution of the antibodies by Protein A-Sepharose
fractions.
1.4.4.4 It is widely applicable. It can measure Ig-isotype levels in
any antiserum, as long as the relevant antigen can bind to the solid
phase. It should also be noted that antisera to Ig-isotypes of many
species are commercially available.
1.4.4.5 The SEI (and ELISA) assay should be readily adaptable to
automation and computerized data processing.
1.4.4.6 It should prove particularly useful in determining the
isotype of monoclonal antibodies.
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FIG. C.1.4-1
SANDWICH ENZYME IMMUNOASSAY (_S_E_I_)
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FIG. C.1.4-2 (G): PRELIMINARY EXPERIMENT FOR SEI
PERFORMED WITH ANTIBODY TO TOTAL MOUSE-Ig
•< Ab DILUTION >■
Twofold dilutions of (Rabbit) antimouse-Ig were tested
against fixed concentration (1:200) of mouse anti-tetanus
serum. Values were plotted after corrections for background
using both 1% NMS and 1% BSA as negative controls. This
Fig. also demonstrates the high specificity of the SEI assay.
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TABLE C.1.4-1









Dilutions of isotype specific antibody (2nd or bridging antibody)
required to saturate pooled anti-tetanus mouse serum (primary antibody)
at 1:200 dilution (15 jig) to give O.D. 405 of 1.0. The above are final
dilutions after dividing by 3 to ensure excess of antibody for routine
assay (SEI).
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FIG. C.1.4-3: DETERMINATION OF NON-SPECIFIC BINDING OF
SEI ASSAY
-* SERUM DILUTION +
Dilutions of both positive and negative sera for tetanus
antibody were tested against fixed dilution (1:4000) of
antimouse IgG^ . Results show no non-specific binding by


































































Ig-lsotype separation of antitetanus mouse serum (BALB/c)
on protein A sepharose
Each of the 10 eluted fractions were pooled and
concentrated. The Ig-isotypes of the
concentrated fractions were tested by SEI assay


















C ■ 2 CHAPTER 2
ATTEMPTS TO DEVELOP A TECHNIQUE FOR MEASURING THE ANTIGEN BINDING
CAPACITY AND THE AFFINITY OF ANTI-TETANUS ANTIBODY
125
C. 2 ATTEMPTS TO DEVELOP A TECHNIQUE FOR MEASURING THE ANITGEN BINDING
CAPACITY AND THE AFFINITY OF ANTI-TETANUS ANTIBODY
2.1 Introduction
Most antibody tests do not measure the initial interaction of
antigen and antibody but secondary phenomena such as agglutination,
complement fixation, etc. The ammonium sulphate test, first introduced
by Farr (1958) fulfills the need for a primary binding test, and also
enables determination of antibody affinity. It measures the capacity
of antisera to combine with soluble macromolecular antigens and detects
both precipitating and non-precipitating antibody. The Farr technique
relies on the fact that some antigens are not precipitated by
concentrations of annomium or sodium sulphate that precipitate
immunoglobulins. If such antigens are radioactively labelled and added
to an antiserum, any antigen combining with specific antibody will be
precipitated with half saturated ammonium sulphate while unbound
antigen will remain in the supernatants. The amount of radioactivity
precipated is an indication of the amount of antibody present. In
addition because this procedure allows simultaneous determination of
the amount of bound and free antigen, the affinity constant of the
antibody concentration can be measured by employing the Scatchard
equation (Scatchard, 1949):-
| = (ABt-B) Ka
where B and F are the concentrations of the bound and free antigen
respectively and Abt is the molar concentration of combining sites on
the antibody molecules at the dilution of antiserum employed. The
Scatchard plot is a graph of B/F against B, giving a straight line from
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which Ka can be determined by the slope, and Abt by the intercept on
the X axis.
A modified ammonium sulphate precipitation technique as described
by Alausa (1975) was used in the present studies with the aim of:-
(a) measuring the binding capacity and binding affinity of anti-tetanus
antibody in unfractionated sera from immunized donors, and hence to
select sera with the highest antibody affinity for isolation of
specific antibody against tetanus-toxoid by affinity chromatography.
(b) determining whether the antibody of high affinity is lost as a
consequence of this immunoaffinity purification technuique.
(c) ascertaining the binding affinity of anti-tetanus antibody during
the course of immunization.
2.2 Materials
2.2.1 Tetanus-toxoid (Wellcome, batch A50 688) was labelled with
125j ^ the chloramine-T method (Section B.3). The free iodine was
removed by Sephadex G-100 gel filtration (Alausa, 1975).
2.2.2 Antisera were obtained from the plasma of donors previously
immunized with 0.5 ml tetanus vaccine. Anti-tetanus IgG was obtained
from the Protein Fractionation Centre (Edinburgh), details of which are
recorded in table of antibodies (Section B.ll).
2.2.3 Normal human serum (NHS) was obtained from the Blood Transfusion
Service (Edinburgh). It was tested by ELISA and HA techniques and
found to be negative for anti-tetanus antibodies. This serum was used
as a protein carrier for radioiodinated antigen, as well as a negative
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serum control during the experiment.
2.2.4 Saturated ammonium sulphate (SAS): This was prepared and stored
at 4°C with some crystals in the flasks to prevent the solution from
becoming supersaturated. It was filtered before use and diluted 1:2
with PBS pH 7.2 to make a half saturated solution designated 50% SAS.
2.3 Methods
2.3.1 Measurement of antigen binding capacity (ABC)
This was carried out at 4°C. Serum dilutions greater than 1:10
were made in 1% NHS in PBS. The same diluent was used to dilute the
antigen.
A constant amount of antigen (0.106^ig of protein/0.5 ml) was
mixed with 0.5 ml of antiserum at different dilutions. The control
tubes were set up in duplicate and included (a) an Ag-control which
contained 0.5 ml 125j_iabeiiecj tetanus toxoid alone, and (b)
NHS-control which contained 0.5 ml of 1% NHS and 0.5 ml labelled
antigen. All the tubes were mixed and incubated overnight at 4°C.
One ml SAS was added to all the tubes except the Ag-controls, the
tubes were mixed immediately and then incubated at 4°C for 30 min
followed by centrifugation at 2000 rpm for 30 min at 4°C. The
supernatants were discarded and the precipitates washed by adding 3.0
ml of SAS/2. This was mixed well and centrifuged as above. The
supernatants were discarded and the precipitates were counted in a
gamma counter.
Calculations were performed as descirbed by Minden and Farr (1978) and
Alausa (1975). Steps involved were as follows:-
(a) % non-antibody bound Ag (%S) =
c.p.m. of Ag controls.p.m. of experimental
c.p.m. of Ag control—c.p.m. of NHS control
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(b) % P (% of Ag specifically bound to Ab) = 100 - %S.
(c) A graph of % P (linear axis) against the reciprocal of the
antiserum dilution (log scale) was plotted. From the plot, the
antiserum dilution which bound 33% of the antigen was determined
(ABC-33). The ABC-33 value for each antiserum was expressed as the^pig
labelled antigen bound per ml of undiluted serum. This was obtained by
multiplying the dilution of antiserum required to precipitate 33% of
the antigen by 0.33 times 0.212 (^ig/lml of antigen used in the assay).
2.3.2 Determination of the affinity constant (ka) of antitetanus-Ab
Equal volumes of an antiserum dilution which was found to bind 50%
of the labelled antigen (ABC-50) was incubated with 7-8 different
concentration of labelled antigen in duplicate and a Farr assay
performed as before. The controls were (a) Ag-control tubes containing
0.5 ml of each concentration of labelled antigen only, and (b)
NHS-control tubes containing 0.5 ml of 1% NHS and 0.5 ml of labelled
antigen at each concentration. The radioactivity in the precipitates
of each experimental tube (after correction for non-specific
precipitation using values obtained from NHS) represents bound antigen
(B). The difference between the total activity in the untreated
antigen control tubes for each concentration and the bound activity
represents the free antigen (F). A graph of (B/F) against (B) was
plotted after converting the concentration of bound labelled antigen to
moles/litre. In order to do this a molecular weight for tetanus toxoid
of 67000 was used (Alausa 1975). Although there was some debate about
the molecular weight of tetanus toxoid we decided for comparison sake
to use the molecular weight previously employed by Alausa (1975) in
determining affinity constant. The affinity constant (Ka) for each
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antiserum or tetanus IgG was determined from the gradient and is
expressed in litres/mole.
2.4 Results and Discussion
Preliminary experiments of Ag-binding capacity (Table 1) showed
that the assay worked. However later experiments indicated that the
assay was not very reproducible. Non-specific binding (high
background) appeared to be the main problem. Experiments were
therefore undertaken to investigate a number of factors that could have
been responsible for the variability.
2.4.1 The iodine—labelling of tetanus-toxoid
The labelling procedure may have altered the antigen. In Table 1
and Table 3, two different labelled tetanus-toxoid (Wellcome)
preparations were used. Table 1 shows less non-specific binding of
antigen by NHS than Table 3, with ABC-33 end point of 1:41 (Fig.l/Table
values were much higher using the second preparation (Table 3/Fig.3)
and the same anti-tetanus IgG. The ABC-33 was 1:360, and 25.2jag of
labelled antigen was bound per ml of undiluted antiserum.
The determination of affinity constant of anti-tetanus IgG is
illustrated in Table 2/Fig.2, but the results were not satisfactory.
Variability of B/F were observed in the lower range of the antigen
concentrations due to antibody being in excess (Table 2). Obviously
affinity constant can not be accurately calculated by plotting only two
points in the graph. This problem might have been overcome by
increasing the amount of antigen to antibody ratio, i.e. selecting
ABC-40 values, which determines the appropriate concentration of
1) and the ABC of the undiluted These
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antibody to be used in the assay, instead of ABC-60 which was selected
in this experiment. This was obtained from Fig.l.
2.4.2 The precipitation procedure
2.4.2.1 Different batches of Amm. Sulphate (SAS) gave different
results with respect to the amount of antigen precipitated. The
non-specific binding NHS (1:10 dilution) using SAS batch A (No. 07081,
M & B Lab. Chemicals, Manchester, U.K.) was only 20% as compared to
60% (Tables 4 and 5) using SAS batch B (No. 48870). Batch A (Table 4)
also showed that 91% of the antigen was bound to anti-tetanus IgG,which
is the highest percentage achieved in this trial.
There are certain factors that must be considered in preparation
of SAS (Minden & Farr, 1978). Its specific gravity must be between
1.2332-1.248. This was not measured in the above batches; therefore,
batch A was either a purer Amm. Sulphate, or happened to have the
required specific gravity. It has also been suggested (Minden and
Farr, 1978) that borate buffer should be used instead of PBS to make
the 50% SAS solution. This was tested in Table 6 (Borate buffer) as
compared to Table 7 (P.B.S. 7.2). It shows that the percentage of
bound-Ag is, if anything, slightly lower using borate buffer, although
no conclusion can be drawn as they were not directly compared in the
same assay.
2.4.2.2 Comparison of Amm. Sulphate with Sodium Sulphate
Table 7 shows that the tetanus-toxoid is not completely soluble in
50% Amm. Sulphate, therefore 16% Sodium Sulphate was used in parallel
with 50% Amm. Sulphate in attempts to decrease the non-specific
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background. As Table 7 shows, the 16% Sodium Sulphate had the effect
of reducing the amount of radioactivity (c.p.m.) non-specifically
bound. On the other hand Sodium Sulphate gave lower specific binding
values with higher antiserum dilutions. In neither case was 100% of
antigen bound.
The reagents were also compared for their ability to precipitate
antibody using "^^I-labelled anti-tetanus IgG". 87% was
precipitated by Amm. Sulphate and 90% by Sodium Sulphate (see Table
7).
2.4.2.3 NHS Control
The possibility existed that some of the "non-specific" binding of
antigen could be due to antibody in the NHS control, even though it was
negative in anti-tetanus antibody activity by haemagglutination assay.
In an attempt to reduce the non-specific binding by NHS which is used
as sample diluent as well as antibody-negative control, the NHS was
absorbed by affinity chromatography on a tetanus toxoid coupled
CNBr-activated sepharose-4B column (as described in Section B.6 & C.5).
the PBS eluates which were also negative for anti-tetanus activity by
the haemagglutination assay were used as a NHS control in the assay in
comparison with non-absorbed NHS (Table 7). There was no difference
between the absorbed and non-absorbed control sera.
2.4.3 Heterogeneity of tetanus-toxoid
One of the factors that may have been responsible for the
variability of the assay was thought to be the heterogeneity of the
Wellcome tetanus toxoid. A series of studies were carried out to
investigate the physiochemical characteristics of different tetanus
toxoid preparations, details of which are described in Section C.3.
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The results clearly indicated the heterogeneity of Wellcome tetanus
toxoid; it consisted of three main protein peaks by G-200 separation,
from which only 4.5S peak contained the toxoid activity. When
fractions were tested for antigen solubility, they were all 50% soluble
in 50% SAS. However this solubility was also observed with the pure
and homogeneous Connaught tetanus-toxoid, which indicates that the
non-specific binding observed in the antibody affinity assay was
probably not due to the heterogeneity of the Wellcome tetanus-toxoid.
Nevertheless, the pure tetanus toxoid labelled more efficiently with
1^1, giving a TCA precipitability of around 90% (results in
Section C.3) as compared to that of Wellcome toxoid (71% + 4.5).
Therefore the assay could have been repeated using the pure
tetanus-toxoid (not available at the time), or labelling (^^1) the
4.5S fraction of the Wellcome tetanus-toxoid which showed the highest
antigenic activity. However as discovered later (Tanavoli £t^ aJU 1978)
others have also observed that 50% SAS has resulted in excessive
non-specific precipitation in the Ag-Ab system used. As a result they
had to use a mixture of ethanol-ammonium acetate as the precipitating
reagent in their modified Farr assay.
In view of the difficulties experienced with the Farr assay,
further studies in this direction were abandoned.
2.5 Conclusions
The assay has proved to be irreproducible as discussed. It is
conceivable that the assay could be improved by taking into
consideration the following points, though this remains to be tested.
2.5.1 There are reasons to believe that the chloramine-T or the sodium
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metabisulphite used to reduce the excess chloramine-T may damage the
protein. The modified labelling technique described in Section B.3
might have proved more suitable.
2.5.2 It is possible that some of the solubility problems might have
been minimised by using a highly purified tetanus toxoid (Connaught) or
the 4.5S fraction of Wellcome toxoid.
2.5.3 Alternatively the non-specific precipitation of toxoid might
have been overcome by using in the assay the 50% SAS soluble fraction
of tetanus toxoid.
2.5.4 Cleaner separations of free and bound antigen might have been
achieved using a mixture of ethanol-ammonium acetate as the
precipitating reagent rather than 50% Ammonium Sulphate.
2.5.5 Excess antibody undoubtedly contributed to the variability in
Ab-affinity measurement (Ka). Therefore either higher concentrations
of the antigen, or higher dilution of the antiserum (less than ABC-60)
should have been used.
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TABLE C.2-1
DETERMINATION OF AG-BINDING CAPACITY OF HUMAN ANTITETANUS IgG
ABC-33 = 2.7 jig/ml (see Fig. 1)
Sample Dilution C-p-m• % Bound-Ag*
Ag-Control 0.212^ig/ml 4613 -
NHS 1/100 3 -
Antitetanus




» 1/200 484 17
•t 1/400 437 16
•• 1/800 412 16
■■ 1/1600 391 14
Preliminary experiment which showed that this assay is reproducible and
specific- No non-specific binding was observed with NHS.
* % Bound-Ag, considering the TCA precipitability of the




From the plot, the tetanus-antiserum dilution
which bound 33% of the tetanus toxoid
(ABC-33) = 2.7 M-g of labelled Ag per ml of
undiluted serum which was obtained by-
multiplying the dilution of antiserum (1:41)
required to precipitate 33% of the antigen
by 0.3 3 times 0.212 (|ig/ml of the antigen












































































































































































































DETERMINATION OF AG-BINDING CAPACITY OF HUMAN ANTITETANUS USING
SECOND BATCH OF LABELLED TETANUS-TOXOID. ABC-33 = 25.2jig/ml










Serum 1:40 11755 53
1:80 10738 26
1:160 11078 36
NHS 1:100 9655 -
AG-Control 0.212^ag/ml 15230 -
Same experiment as shown in Table 1, except a different batch of
Wellcome vaccine was used. Note that this antigen's binding capacity


























DETERMINATION OF Ag-BINDING CAPACITY USING SAS BATCH A












This batch of SAS shows (a) lower non-specific binding of Ag by NHS,




DETERMINATION OF Ag-BINDING CAPACITY USING SAS BATCH B
Sample Dilution C.p >m. % Bound-Ag
1:10 12780 60
NHS
1:100 5379 - —








This batch of SAS shows (a) higher non-specific binding of Ag by




DETERMINATION OF Ag-BINDING CAPACITY USING FRESH BATCH OF SAS,
AND BORATE BUFFER INSTEAD OF PBS-7.2 AS DILUTING FLUID





Serum 1:100 4660 21
1:200 4724 22
1:400 4513 17
NHS 1:100 3841 -
Ag-Control 0.212jig/ml 7760 -
The percentage of bound-Ag is slightly lower using borate buffer than
using P.B.S. (as in Table 7). It seems however that the nature of the
diluting fluid has no dramatic effect on the tesc results.
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TABLE C.2-7
COMPARISON OF AMM. SULPHATE V. SODIUM SULPHATE PRECIPITATION
FOR DETERMINATION OF AG-BINDING CAPACITY (ABC)
X Ppt.
Sample Dilution C.p.m. Bound-Ag Solution
1:10 5384 40
1:20 5057 34
Antitetanus 1:50 4867 30
Serum 1:100 4640 25
1:200 4031 12
1 iAOO 3938 10 50%"
NHS
(NH4)2SO4
Non-absorbed 1:100 3466 —
NHS
absorbed 1:100 4020 —
125I-labelled
tetanus IgG 1:20 618559 87
1:10 4197 40
1:20 3742 33
Antitetanus 1:50 2516 14








absorbed 1:100 1534 —




tetanus IgG 1:20 636725 90
(alone)
In this comparison study the non-specific binding of the NHS and of more
diluted samples were decreased using sodium sulphate as precipitating
agent. The results of absorbed-NHS did not differ from the non-absorbed.
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C.3 STUDIES ON TETANUS TOXOID PREPARATIONS USED IN THIS PROJECT
3.1 Introduction
Tetanus toxin is a powerful neurotoxin produced by Clostridium
tetani, an anaerobic organism, which is widely dispersed in nature, and
enters the body through the wound. Although the toxin has been under
investigation for many years, surprisingly little is known about' its
mode of action at the molecular level or about its chemical structure
and nature.
There has been disagreement in the past about the molecular weight
of the purified toxin. It is currently believed that the tetanus toxin
contains no lipid or carbohydrate moieties and is a simple protein of
approximately 150,000 daltons. It exists in two distinct forms:
"intracellular" (extract or unnicked) toxin which is a single chain,
150,000-dalton polypeptide, and "extracellular" (filtrate or nicked)
toxin. This is a protease-cleaved form composed of two
disulphide-linked polypeptide chains. These are referred to as the
"
Oi", "light" or "L"-chain (50,000 daltons) and the "j8", "heavy" or
"H"-chain (100,000 daltons) (Di Mari et el., 1982, Craven et al.,
1973). It turns out that the two chains must be tightly associated
together by non-covalent forces in the intact molecule, because even
under conditions when the covalent disulphide bonds are broken, it is
not easy to separate the two chains quantitatively. Several workers
have purified them by gel-permeation chromatography in the presence of
denaturing agents (Matsuda and Yoneda, 1975), but in all cases the
purification is incomplete: the H-chain which comes through the column
first is contaminated with L-chain, although the L-chain is
comparatively pure. The individual chains have little or no toxicity;
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what toxicity is found can be reasonably ascribed to contamination with
the other chain (van Heyningen, 1980).
The chief interest in the protein chemistry of tetanus toxin from
a practical point of view has been in the mechanism of production of
toxoid, which is defined as a protein so treated that it can elicit the
production of antibodies that neutralise the activity of toxin, but is
not itself toxic. Toxoiding is usually done by prolonged incubation of
the protein in formaldehyde solution (Loewenstein, 1909). It is well
documented that formaldehyde is a cross-linking reagent, forming intra
and interchain methylene cross linkage (Murphy, 1967; Bezzini et al,-
1974). The cross-linking reactions could explain the different values
reported for the size of the tetanus toxoid molecule (Largier et al. ,
1956; Raynaud et aJ., 1960 and Latham _et_ aT., 1965).
Of all the infectious diseases, immunization against tetanus has
proved one of the most effective (Haberman, 1978). The great success
of prophylaxis against the disease achieved by mass immunization with
tetanus toxoid, has meant that the preparation is produced commercially
in large amounts and variety all over the world. The tetanus toxoid
preparation used in most of our studies was a tetanus vaccine in simple
solution (Wellcome). This antigen was regularly used for
hyperimmunization of human volunteers for the production of tetanus
immunoglobulin used in passive protection against tetanus.
As a valuable adjust to our proposed affinity chromatography
studies we decided to investigate the heterogeniety of various
commercially prepared tetanus toxoid preparations. The products chosen
were (a) different batches of tetanus vaccine (Well^-TT), (b) a more
potent form of tetanus toxoid from the same manufacturer (Well2-TT),
and (c) a highly purified tetanus toxoid produced by Connaught
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Laboratories (Conn-TT). It should be stressed that the latter two
preparations were not licensed for human use.
The tetanus toxoids were investigated for their purity,
distribution and physico-chemical characteristics using the following
methods of analysis:-
(a) Gel filtration (trace labelled) using Sephadex G-200.
(b) Haemagglutination Inhibition Assay.
(c) Ammonium Sulphate and TCA precipitation.
3.2 Materials and Methods
3.2.1 Iodination of tetanus toxoids
All batches of Well^-n (A52111, A52109, A53255) except batch
A50688 were labelled with 125p by the Chloramine-T method using
cysteine-HCl as a reducing agent. The iodination procedure was as
described in Section B.3. This procedure was also used to iodine-label
Well2~TT and Conn-TT. The iodinated fractions were stored in 200 jil
aliquots at -20°C.
3.2.2 G-200 Sephadex gel filtration
Sephadex G-200 (which separates protein in the MW range between
5000-250,000) was used. All the experiments were performed at 4°C.
The gel was swollen and the column was packed as described in Section
B.4. The column (containing 0.05% NaN3) was stored at 4°C, and was
used repeatedly throughout the study. Before each run the column was
equilibrated with at least one column volume of PBS buffer.
The tetanus toxoid sample under test was dialyzed (against PBS
overnight at 4°C) and then concentrated to approximately 1.5 mg of
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protein per ml. A small amount of the same toxoid which has been
labelled was added as a marker. This gave approximately 10^ counts
per minute. The sample was loaded into the column and eluted at 3 ml
per hour. Fractions (200) of 1.5 ml were collected on an LKB automatic
fraction collector. The E * Cm of the fractions were monitored, and
280 nm
later measured by the Unicam SP-500 spectophotrometerto determine
protein concentratin. Aliquots (100each fraction were counted
in a gamma counter, and the counts (per 100 sec) and E1 cm
280 nm
values were plotted. The fractions composing each peak were pooled and
concentrated using a Minicon Concentrator. The total protein content
(as in Section B.l), radioactivity and antigenic activity (using HIA -
Section B. 9) of the concentrated fractions were determined. The TCA
precipitable (10% v/v) and ammonium sulphate precipitable (50%
saturation) counts were determined.
In one study by the gel filtration, characteristics of two
preparations were simultaneously compared by labelling one preparation
(Well^-TT) with ancj the 0ther (Well2~TT) with ^-^1.
The two samples were then mixed and subsequently fractionated on the
G-200 Sephadex column. The radioactivity of both iodines in the
fractions were measured in a dual channel system on gamma counter (LKB
1260 Multigamma II, Tarku, Finland), and results were compared.
It should be stressed that before each tetanus toxoid separation
run, the G-200 column was calibrated by running normal human serum (NHS
1.0 ml) as a standard. The elution profiles of the various tetanus




3.3.1 A comparison of different batches of Wellp-TT
Initially different batches of the same tetanus toxoid
preparation, namely Well^-TT were compared. The G-200 separation
profiles obtained are shown in Fig. 1, Fig.2 and Fig.3. All the batches
exhibited similar heterogeneity consisting of two main protein peaks
(19S, 4.5S) and a L.M.W. peak. When fractions of each peak were pooled
and concentrated only the 4.5S peak contained antigenic activity
demonstrable by the HIA test (Fig.4).
The radioiodine labelling capacity of this tetanus toxoid
(Well]^-TT) appeared reproducible from batch to batch, 68% +6.7 being
TCA precipitable. However this was lower than observed with the other
toxoid preparations. Total protein concentrations were also similar in
different batches (See Table 1).
3-3.2 A comparison of the two different tetanus toxoid preparations
from same source
A different preparation of tetanus toxoid (PX433) designated here
as Well2~TT was compared to Well^-TT preparation. Well2-TT gave
higher binding to 125j protein iodination (as indicated by TCA
precipitation), and higher tetanus toxoid activity was observed (see
Table 1).
On G-200 separation the elution profile observed (Fig.5) was
similar to that noted with the Wellp-TT (Figs. 1-3). In the study in
which the two tetanus toxoids were trace labelled with different
isotopes of iodine, similar elution profiles were obtained with both
preparations (Fig.6).
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3.3.3 A comparison of tetanus toxoid from two different sources
A purified and concentrated tetanus toxoid (Conn-TT) was compared
to Well-TT. The results are summarised in Table 1. The Conn-TT was
more concentrated (in mg of protein per ml), with greater tetanus
toxoid activity (HIA-titre), and appeared to label better than either
of the Wellcome tetanus toxoids. Furthermore on the basis of gel
filtration studies (see Figs. 7 & 8) it was obvious that the Conn-TT is
a purified product. It consisted (unlike Well-TT) of only one main
protein peak (4.5S) containing all of the tetanus toxoid antigenicity
(Fig. 4).
It should be noted however that with all preparations much of the
radioactivity associated with labelled products could not be
precipitated by 50 percent ammonium sulphate.
3 • 4 Discussion
Of the tetanus toxoids in this study, the Conn-TT preparation
proved to be the purest and have the highest tetanus toxoid activity.
The Well-TT preparations exhibited identical elutionprofiles from
batch to batch and preparation to preparation. All showed similar
degrees of heterogeneity. The peak containing most of the toxoid
activity was 4.5S in Well-TT and in Conn-TT. The latter was homogeneous
and gave rise to only one protein peak (4.5S). This finding agrees
with the findings of Pillemer et al_. (1948), and Largier (1956). These
investigators (who were the first to investigate the molecular state of
tetanus toxin) observed that the biological activity was associated
with a monomer of sedimentation coefficient of 4.5S. They also found
that the toxin, after being kept in a neutral isotonic solution at 4°C
for a few days, was partly converted to an atoxic dimer. The
"spontaneous toxoid" thus formed exhibited an apparent sedimentation
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coefficient of 7.OS.
More recent investigations have not confirmed the work of Pillemer
nor of Largier and their associates. In fact, toxin preparations
exhibiting similar toxic characteristics to Pillemer's monomer, were
found to have sedimentation coefficients ranged from 6.0 to 7.IS
(Dawson et^ al., 1968; Murphy et al., 1967 and Raynaud et al., 1960).
The cross-linking reaction between the toxin molecules or between toxin
and other proteins in impure preparations could influence the size,
distribution and purity of the toxin. During the toxoiding process, the
toxin molecules may undergo polymerization. This increases with
increasing concentration of formaldehyde and of protein (Murphy,
1967).
Chemical modification with reagents other than formaldehyde that
might be expected to lead to more specific and easily investigated
changes should be a more useful approach. In this connection it is
interesting to note that tetranitromethane has already been used
(Bizzini £t^ a^., 1973).
The preparation of pure toxoid may best be achieved by formalin
treatment of toxin that has undergone prior purification (Dawson et
al. , 1968), for this would reduce the chance of complexing with
irrelevant contaminants. It appears that the Conn-TT which proved the
purest in this study may have been purified prior to toxoiding.
In other experiments, such as protein iodination of the three
toxoids, the Conn-TT showed the highest binding to ^-^1. This was
indicated by TCA precipitation of the labelled proteins. However, much
of the radioactivity of all the preparations could not be precipitated
by half saturated ammonium sulphate. This is particularly relevant to
the Farr assay (used to measure the affinity of tetanus antibody)
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discussed earlier (Section C.2).
In the present section the physicochemical properties of different
toxoid preparations were compared. The reports of the comparative
studies such as coupling efficiency (to CNBr-activated sepharose),
immunogenicity, etc. are to be found elsewhere in this thesis (Sections
C.5 and C.4). It is apparent from these studies that the Conn-TT is
less heterogeneous than either of the Well-TT preparations. Whether or
not this pure preparation is more effective at eliciting anti-tetanus
antibodies in humans or produces fewer or weaker side reactions on
booster immunization remains to be established.
3.5 Conclusions
1. Both Wellcome tetanus toxoid (Well-TT) preparations are
heterogeneous.
2. The protein peak in G-200 separation containing most of the toxoid
activities is 4.5S in all of the three preparations.
3. Conn-TT differed from both types of Well-TT in the following
respects :-
(a) Conn-TT is more concentrated and has higher tetanus toxoid
activity.
(b) It is radiolabelled with iodine more efficiently.
(c) It is more pure, and it contains only one main peak (4.5S).
(d) Its cost is subsequently higher.
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TABLE C.3-1







(LF Unit/ml) 40 791 2500
HIA-titre
(TT activity) 1:128 1:8192 1:16384
Total Protein
(pg/ml) 312 + 11* 570 4600
I labelling





















* Average of 8 experiments on 4 different batches
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FIGS. C.3-1, 2 & 3
Radioactivity (o—o) and absorbance at 280 nm (•—• )
G-200 separated fractions of different batches
1 91
(labelled) of Wellcome vaccine (Well^-TT) is
measured. All the batches exhibited similar
heterogeneity, consisting of two main protein peaks


























FIG. C.3-4: TETANUS TOXOID ACTIVITIES OF CONCENTRATED





1 2 3 U
19S 7S 4-5S LMW
POOLED & CONCENTRATED PEAKS
When tetanus toxoid separated fractions of each peak
(Figs. 1,5 & 7) were pooled, concentrated and tested
(by Haemagglutination Inhibition Assay),the 4.5S peak
contained most of the toxoid activities.
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FIG. C.3-5
A different preparation of tetanus toxoid (Wel^-
exhibits very similar elution profile to that of











Comparison of the elution profiles of two different
tetanus toxoid preparations (Wellcome). The
products were labelled with different isotypes of
iodine, (Well^-TT • ®131x) ancj (Well2~TT o—o^25j) /
and were mixed before elution. They showed similar
patterns of heterogeneity, although Wel^-TT was
more concentrated. The radioactivities of the




























The tetanus toxoid preparation from a manufacturer
in Canada (Conn-TT) was not only more concentrated
with higher toxoid activity as compared to the other
preparations (see also Table 1 & Fig. 8), it consists
of only one main protein peak (o o 4.5S) as










The superimposed elution profiles (G-200) of two
tetanus toxoid preparations from different sources
illustrate the heterogeneity of Wellcome vaccine
(Well-TT • • ) and the homogeneity of Connaught
toxoid (Conn-TT o o) . The 4.5S peak contained
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C.4 THE RESPONSE OF MICE TO TETANUS TOXOID
4.1 Introduction
The response of two strains of mice to two tetanus toxoid
preparations was investigated partly because the study was of interest
in itself and partly because it could yield information that would help
our eventual aim of producing a suitable anti-tetanus antibody
preparation for clinical use.
At the time these studies were initiated, anti-human isotype
antisera for investigating the isotypes response in the human were not
available. Furthermore it was difficult to obtain preimmunization
samples in humans for investigating the primary response.
One point that we hoped to resolve was whether anti-tetanus
responses were subclass restricted. In humans,responses to diphtheria
and tetanus toxin have been variously reported as being predominantly
IgGp (Yount £t^ al., 1968), and involving all four subclasses (Carrel
et^ al. , 1972; van der Gissen et^ cFL. , 1976). Subclass restricted
responses to many antigens have been reported in mice (Torrigiani,
1972; Pelmutter et^ jhl. , 1978; der Balion et a_l, 1980), and humans
(Yount, 1968; Robby, 1970; Carrel £t^ al., 1972; van der Gissen et
al., 1976). Subclass restricted responses might be important in
dictating recovery from infection and the therapeutic effectiveness of
passively transferred antibody.
The study in mice was also performed to find out if different
tetanus toxoid preparatios varied in their immunogenicity and whether
there was any major genetically determined difference in the immune
response of two mouse strains. These were important preliminaries to
the production of monoclonal antibodies to tetanus toxoid.
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The anti-tetanus Ig-isotypes were assayed by a sandwich enzyme
immunoassay (See Section C.1.4) which could be readily adapted to the
human system, although unfortunately shortage of time prevented much
work being done on the human Ig-isotype resposes.
4.2 Mice and immunization schedule
The experiments were performed in 10-12 week old male CBA/Ca and
BALB/c mice. The CBA/ca mice were bred from breeding stock originally
obtained from the MRC Laboratory Animal Centre (Carshalton, England).
The original BALB/c breeders were supplied by Olac Ltd. (Bicester,
England). The mice were housed under conventional conditions and fed
on "libitum maintenance diet no.l" supplied by Special Diet Service
Ltd. (Wilham, England).
The mice were injected with one of two tetanus toxoid
preparations: Wellcome tetanus-toxoid (Well^-TT) and a purified form
of tetanus toxoid (Conn-TT) from Connaught Laboratories, described
previously (Section C.3). Mice were injected ip with 10jig protein in
phosphate buffered saline on days 0, 28 and 56. Six mice receiving
each treatment were bled out on days 14, 28, 42, 56 and 70. Sera from
uninjected mice served as preimmunization controls. Samples were
tested by ELISA (Section C.1.3), and by SEI assay (C.1.4).
4.3 Results
4.3.1 A comparison of the response of CBA/ca and BALB/c mice to
Well-TT
The responses of CBA/ca and BALB/c to Well-TT were almost
identical (see Fig. 1 and 3). Sera from unimmunized mice of both
strains contained antibodies to Well-TT but only of the IgM, IgA and to
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a lesser extent IgG3 isotypes. Up to 28 days after one injection of
Well-TT there was no discernible increase in the production of
anti-tetanus antibody of any isotype, with the sole exception of a
slight IgG2a response by CBA/ca mice. Following the first booster
injection anti-tetanus antibodies of the IgG^, IgG2a anc^
IgG2b appeared and with subsequent boosting some of these continued
to rise but IgG^ gave the highest titres. The isotypes that were
represented in the pre-existing antibodies showed less dramatic
increase after boosting and indeed the titres of IgM anti-tetanus
antibodies remained virtually unchanged. This agrees with the data of
Ersher £t^ a^. (1982) who also failed to find a very pronounced IgM
antibody response of mice to tetanus toxoid.
4.3.2 A comparison of the response of BALB/c mice to the different
tetanus toxoid preparations
The responses of BALB/c mice to Well-TT and Conn-TT are shown in
Figs. 2 and 3. Several differences were found. Pre-existing
antibodies of the IgG3 isotype to Conn-TT were not detected although
IgM and IgA antibodies were present. The response to Conn-TT was
prompter than that observed with Well-TT. IgG subclass responses to
Conn-TT (except IgG2b) were detected following primary challenge and
reached consistently higher levels.
4.3.3 Investigation of the cross-reactivity of antibodies evoked by
the different tetanus toxoids
In order to examine the possible cross-reactivity of Ig-isotype
antibodies elicited by the different toxoids, the reactivity of the
same sera from BALB/c mice that were tested in the preceding section
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and raised against both toxoids were assayed in plates coated with
either of the toxoid preparations. Similar levels of binding were
found irrespective of the antigen used to coat the plates (see Figs. 4
and 5). This indicates that the differences noted in Figs. 2 and 3 are
determined by the antigen used for immunization rather than the assay
procedure.
These results also confirm the reproducibility of the assay system used
in the present studies.
4.3.4 Further studies on the nature of the pre-existing antibodies to
tetanus
Additional experiments were performed to confirm the isotypes of
pre-existing anti-tetanus antibodies in BALB/c serum. Affinity
chromatography of the serum was done on protein A-Sepharose using the
elution conditions indicated in Fig.6 (see also Section B.5). The
fractions eluted with the various buffers were concentrated and
analysed for anti-tetanus isotype using the Sandwich Enzyme Immunoassay
procedure (Section C.1.4). The results (see Fig. 7a & b) confirmed
that the pre-existing anti-tetanus antibodies were predominantly of the
IgM and IgA isotypes.
4.4 Discussion
Subclass-rostricted responses to a variety of antigens have been
found in mice (Torrigiani, 1972; Pelmutter et al. , 1978; Der Balion,
1980) and man (Yount _et_ al., 1968; Robby, 1970, van der Gissen et al.,
1976). The reasons for selective expression are not clear. The
antigens do not bear any obvious similarities in chemical or physical
characteristics. Differences in antigen presentation may be involved
173
(Der Balion et al., 1980) as may regulating idiotypic networks (Geha,
1982). In man, the response to tetanus toxoid has been variously
reported as being predominantly IgG^ (Yount jjt^ al_., 1968; van der
Gissen, 1976) and unrestricted (Carrel et al., 1972). In this study
the responses of two strains of mice to the Well-TT preparation showed
no great restriction. The responses to Conn-TT were detected in all
IgG subclasses except IgG2b after primary challenge.
The presence of pre-existing IgM and IgA antibodies to tetanus
toxoid in mice of both strains is of interest. Since the majority of
people are immunized against tetanus, few studies are available on
pre-existing antibodies in man, although before the discovery of
tetanus toxoid Tenbrock and Bauer (1923) reported the detection of
antitoxin antibodies in the blood of one third of a group of
inhabitants of Peking,China, whose stool contained tetanus bacilli. A
more recent serological study in unvaccinated humans and animals in the
Galapagos Islands by Veronesi et al. (1983) found varying titres of
antibodies. No reports have been available on the Ig-isotype of
naturally occurring anti-tetanus antibodies. The fact that the same
titres of natural antibodies were detected against the purified tetanus
toxoid as against the cruder preparation makes it likely that the
antibodies were in fact against tetanus toxoid and not a contaminating
protein. These possibilities could readily be tested in mice.
The most probable explanation for the existence of naturally
occurring antibodies to tetanus toxoid in man and mice would be that
the organism stimulates a response after it is swallowed. Veronesi and
co-workers (1983) have even suggested that the oral route might provide
an effective vaccination route for humans against tetanus. This route
might preferentially stimulate IgM and IgA isotypes. Alternatively
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determinants might be shared between tetanus toxoid and other
macromolecules or intestinal organisms such as other Clostridium spp.
The finding that the responses of the mice to both tetanus toxoid
preparations were largely in the IgG isotypes agrees with the report of
Ershler et a^. (1982) who found that mice produced a poor primary
response to tetanus toxoid and on boosting the antibody was mainly
IgG^. It seems possible that the naturally existing IgM and IgA
antibodies may play a role in inhibiting the subsequent response of
these isotypes.
The lack of a primary response to Well-TT appeared to be due to
the crude nature of the preparations; it contains 60 times less toxoid
activity than Conn-TT at the same protein concentration. Tetanus
toxoid (here Conn-TT) appears in general to be highly immunogenic,
eliciting a primary response in mice with low doses (Willcox, 1975, and
this thesis). In spite of the crude nature of Well-TT no differences
were found in the ability of the two preparations to bind antibody
suggesting that responses to contaminating proteins are weak.
4.5 Conclusions
1. Conventionally housed CBA/ca and BALB/c mice were found to have
pre-existing antibodies to tetanus-toxoid.
2. These "naturally acquired" antibodies to tetanus toxoid were of the
IgM, IgA and to a lesser extent of the IgGg isotypes.
3. CBA/ca and BALB/c exhibited similar responses to Well-TT. A
significant rise in titre of any isotype not being detected until
after boosting.
4. Conn-TT in the dose used, elicited a more rapid and pronounced
response than Well-TT. Responses were detected in all IgG
subclasses except IgG2b after primary challenge.
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FIG. C.4-1
C.B.A. mice were injected with tetanus toxoid on days
0, 28 & 56 and sera were collected once every 2_ weeks.
The level of anti-tetanus Ig-isotypes was measured by
SEI assay. Note the presence of pre-existing
antibodies of IgM and IgA and to a lesser degree
IgG3 isotype. Antibody response to Well-TT is similar
to the BALB/c mice (Fig.3). There is poor IgG-
subclasses response after primary challenge with Well-TT,
with the exception of IgG2a. Following booster injection

















The Ig-isotype response of BALB/c mice to Conn-TT was
prompter than that observed with Well-TT (Fig.3). IgG
subclass responses was detected immediately following
primary challenge with Conn-TT (with the exception of
IgG2b)/ and reached consistently higher levels.
FIG. C.4-3
The pre-existing IgM and IgA antibodies were also seen
in mice injected with Well-TT. But unlike the response
to Conn-TT (Fig.2), IgG subclass responses to Well-TT































The cross-reactivity of Ig-isotype antibodies evoked by
Conn-TT were measured by testing the antisera in plates
coated with either of the toxoid preparations. Similar
levels of bindings were found irrespective of the antigen
coated to the plates (see also Fig.2).
FIG. C.4-5
The cross-reactivity of Ig-isotype antibodies were
measured by testing the antisera from Well-TT
immunized mice (BALB/c) in plates coated with either
of the toxoid preparations. Similar results are
observed as compared to Fig.3. These results
(Figs. 4 & 5) indicate that the differences noted in
Figs. 2 & 3 are determined by the antigen used for




























































































Ig - ISOTYPE SEPARATION OF NORMAL MOUSE SERUM (BALB/C)
ON PROTEIN - ASEPHAROSE
Each peak was pooled and concentrated. The Ig-isotypes of
the concentrated fractions were measured by SEI assay
(see Fig. 7 a & b)
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FIG. C.4-7a
The separated and concentrated Ig-isotype fractions
of NMS (Fig. 6) were tested by SEI on "Well-TT"
coated plates to investigate the nature of the pre¬
existing antibodies to tetanus. The results indicate
that the pre-existing antibodies were predominantly
of the IgM and IgA isotypes.
FIG. C.4-7b
Same concentrated fractions (Fig. 6) were tested on
"Conn-TT" coated plates and these results also
confirm that the pre-existing antibodies were
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C.5 IMMUNOAFFINITY PURIFICATION OF ANTI-TETANUS ANTIBODIES
5•1 Introduction
The use of human immunoglobulin preparations as a means of
transmitting passive immunity is well-established. This approach is
widely used in the prophylaxis of hepatitis A and B, varicella zoster,
measles,vaccinia, rubella and tetanus, and it is of particular value in
the management of patients whose own antibody producing ability is
impaired by therapy or disease.
Conventional high titre immunoglobulin preparations for clinical
use contain a very small proportion of specific antibody. They all
contain large amounts of IgG which is not directed specifically against
the relevant antigen. As a result, a large dose of protein must be
given to patients to administer a small dose of the specific antibody.
Large intramuscular injections are painful and the volume which can be
given remains strictly limited. A further limitation on the use of
these products is that intravenous administration often leads to
adverse hypersensitivity reactions. Some of these problems may be
overcome by the production of a purified immunoglobulin preparation of
high specific activity so that it is possible to give a large dose of
antibody in a small volume containing relatively little protein. Such
preparations are likely to be safe to administer by intramuscular,
intravenous and probably intrathecal routes.
Tetanus continues to be a major problem especially in the
developing countries of the world. Until very recently the mortality
rate reported from India and from other countries has been in the range
of 22-58% (Thomas et al. 1982). Special surveys conducted in some
developing countries have revealed that the disease was to be listed
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among the ten principal causes of deaths of the population. Up to 10%
of new-born babies were its primary victims (Bytchenko et al. 1981). A
recent report published on anti-tetanus prophylaxis (Brand ^ al. 1983)
indicates that one third of patients who contract the disease in the
United States have either no obvious wound or a wound considered to be
trivial by the patient. Men over 60 years of age and women over 40
are often not protected against tetanus, either because they have
never been fully immunized or because they have not received the
necessary booster doses of tetanus toxoid. The case-fatality rate of
45-55% in the United States has not changed since 1975. Their survey
of six hospital emergency rooms reveals incorrect treatment. Persons
most in need of adequate anti-tetanus prophylaxis were least likely to
receive it (one patient in four). There has been over-treatment with
tetanus toxoid, and under-treatment in conditions necessitating passive
immunization with tetanus immunoglobulin. Analysis demonstrated the
feasibility of improving the quality of care without adding to the cost
of care.
The importance of passive immunity using tetanus-IgG, and
increasing demand for a more purified and specific anti-tetanus
antibody, prompted the work described in this thesis. In the initial
stages, I concentrated on the isolation and characterization of this
antibody from both whole plasma and Cohn fractionated IgG. The
technique used was affinity chromatography which has a number of unique
advantages over conventional methods. Affinity chromatography exploits
the functional specificities of biological systems for the isolation of
proteins, polysaccharides, nucleic acids and other classes of naturally
occurring compounds. The unique specificity of biological
interactions, for example antigen-antibody,provides entirely new
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opportunities for achieving separations which are difficult or even
impossible using less specific techniques.
The preparation of immobilized proteins and other materials
requires an insoluble matrix to which the biopolymer can be attached
without the loss of its specific binding properties. CNBr-activated
Sepharose 4B, a bead-formed agarose gel displays nearly all the
characteristics of the ideal matrix. It shows very little non-specific
adsorption, has good physical, chemical and thermal stability and has
good flow properties. The open pore structure of Sepharose 4B which
allows it to be used for gel filtration of proteins up to 20 million
daltons, enables large molecules to be coupled in good yield. The
closed pore structure of cellulose and conventional polyacrylamide gels
is distinctly disadvantageous (Boegman et al. 1970; Steers et al.
1971).
This section of the thesis will cover studies on (a) the
preparation of immunoaffinity columns, (b) their application in
antibody isolation and (c) the characteristics of the antibodies
obtained by this procedure.
5•2 Optimization of binding
The basic procedure for preparing immuno-affinity columns is
described in detail in Section B.6. The amount of tetanus toxoid bound
to CNBr-Sepharose under various conditions was determined using
labelled tetanus toxoid as a tracer. In some of the
experiments the amount bound was also determined by measuring amount of
protein (both bound and free).
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The influence of the following factors on binding was determined:-
(a) Different antigen concentrationsand sample volumes.
(b) Different incubation periods and temperatures.
(c) Batches of CNBr-Seraphose of different ages.
(d) Different coupling buffers.
(e) Reproducibility of coupling procedure.
5.2.1 Antigen (TT) Concentration
5.2.1.1. Effect of sample volume: The details and results of these
experiments are recorded in Table 1. It is apparent that the smaller
the volume the better the binding (% coupled-TT is (a)^(b)^>(c)).
5.2.1.2. Effect of amount of antigen: As shown in Table 2, both
unconcentrated (lx) and 5x concentrated TT preparations coupled more
efficiently to sepharose than lOx concentration. This may be due to
CNBr-Sepharose capacity of binding being exceeded using lOx
concentrated tetanus toxoid.
5.2.2 Effect of incubation period and temperature
The % binding of tetanus toxoid to CNBr-Sepharose increased with
time at room temperature (R.T.), but plateaued at 4 hours. At 4°C the
coupling was more efficient than at R.T. up to 4 hours, but thereafter
dissociation appeared to have occurred (see Table 3).
5.2.3 Age of CNBr-activated Sepharose 4B
Tetanus toxoid was coupled to different batches of CNBr-Sepharose
with different date of expiry. As shown in Table 4 the coupling
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capacity of the older batches appears to have deteriorated.
5-2.4 Coupling buffer
The coupling efficiencies of tetanus toxoid from two different
manufacturers (Connaught and Wellcome) were compared using two
different working buffers. In this experiment both % counts and %
protein bound (TT) to CNBr-Sepharose was measured. As the results in
Table 5 demonstrate, higher % binding was achieved using borate as the
coupling buffer as compared to P.B.S. These results also showed that
Conn-TT binds better to CNBr-Sepharose than does Well-TT. Bindig, as
assessed by radioactive counting was irreproducible. This might be due
to free iodine, or loss of coupled gel in the filter during washes,
since this irreproducibility was not observed in % uncoupled TT.
5.2.5 Reproducibility of the coupling procedure
In order to determine the reproducibility of the coupling
technique, a series of immunoadsorbent columns were prepared by
coupling the XT to CNBr-activated Sepharose 4B under
precise conditions. Tables 6 and 7 show the results obtained with
these separate batches. The coupling procedure is reproducible
considering the many steps involved in the process. This
reproducibility is very apparent if one looks at the % uncoupled-TT
where the post coupling wash can easily be collected and measured (see
Table 6) .
5.3 Conclusions of optimum conditions for coupling tetanus toxoid to
CNBr-activated Sepharose 4B
According to results, binding is influenced by antigen
concentration, temperature, incubation period, age of the sepharose
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and the coupling buffer. Best results were obtained with:-
5.3.1 A higher concentration of TT in a smaller volume (minimum 1
mg/ml).
5.3.2 Incubation period of 4 hours at R.T. or overnight at 4°C.
5.3.3 Fresh batch of CNBr-activated Sepharose 4B.
5.3.4 Using 0.1 M borate buffer pH 8.0 as coupling buffer.
5.4 Immunoaffinity purification of human anti-tetanus antibodies
5.4.1 Materials and methods
The basic technique for coupling and preparation of the
immunoadsorbent column has been described in details in Section B.6.
In summary 3.5 mg of tetanus toxoid (Wellcome) was coupled to 2.5 g of
CNBr-activated Sepharose 4B. Following equilibration the antibody
containing plasma (20 mis) or Cohn-fractionated tetanus IgG (2.5 mis
containing 250 I.U. antitetanus) was applied to the immunoadsorbent
column. The unbound protein was then eluted with PBS 7.2. Fractions
of 3 ml were collected using an automatic fraction collector until the
optical density of the effluent reached zero. The specifically bound
antibody was recovered by elution in 0.2M glycine-HQ pH 2.8.
Fractions of 1.5 ml were collected in 0.5 ml of 2M Tris-HCl pH 7.8 to
neutralize the eluate and minimise denaturation. The O.D.s of all
fractions were measured in a Unicam SP500 spectrophotometer at 280 nm,
and values were represented as E ^ Cm
280 nm
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The distribution of anti-tetanus antibody activity (antibody
titre) in the effluent was determined by passive haemagglutination
assay (as in Section B.8), and ELISA (Section C.1.2), and expressed.in
IU/ml.
The eluates of each run were divided into four fractions and
concentrated by ultrafiltration through 8/32 Visking dialysis tubing
(as in Section B.2).
After determination of antibody activity by HA and ELISA, the
total protein content (mg/ml) of the concentrated fractions was
measured by the Folin-phenol procedure (Section B.l).
The concentration of IgG, IgA and IgM antibodies were determined
by radial immunodiffusion (Section B.7) and expressed in mg/ml of the
protein.
The specific activity and the % recovery of the specific antibody
or IgG were calculated as follows:-
Specific activity = Ab-titre of fraction
IgG concentration of fraction
% Recovery =
IgG concentration (or I.U.) of fraction x volume ,si ^ 00
IgG concentration (or I.U.) of original plasma (IgG) x volume
5.4.2 Results
Table 8 is merely a key to tube pooling of the effluents of each
run. Results of two runs which are illustrated in Fig.l and Fig.2,
show that the affinity chromatography technique can be used to
concentrate anti-tetanus antibody from human plasma (Fig.l) and human
IgG concentrates (Fig.2). There is a higher concentration of
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anti-tetanus antibody in glycine-HCl eluates compared to PBS eluates of
the unbound proteins.
Table 9 is a summary of the results obtained on concentrated
fractions. The specific activity is much higher in fraction B
(specifically bound protein) as compared to fraction A (unbound
protein). The bulk of the IgG and antibody activity (I.U.) were
recovered in fraction B. In run 2 performed on anti-tetanus IgG,
fraction B contained up to 96% of total anti-tetanus antibody activity
in approximately 1% of the original protein. This fraction contained
antibody of the IgG class only, with specific neutralizing activity of
151 I.U. per mg of IgG, representing 108-fold purification.
5.5 Discussion
Immunoadsorption is a useful method when low concentrations of
antibody are to be isolated from plasma or from crude immunoglobulin
fractions for prophylactic and therapeutic uses.
The coupling of the antigen was routinely performed at 4°C, and
the elution at room temperature. The chemical stability of the
immunoadsorbent column was excellent. Regular usage and washings with
acidic buffer are possible without loss of capacity or specific
properties, as long as the column is equilibrated with neutral buffer
before storage at 4°C, between runs. Studies using 125x-labelled
tetanus toxoid indicates that loss of antigen from immunoadsorbent
column following coupling is minimal. It was observed that the column
capacity did not decrease with repeated use. The same column was used
in all the four runs described without any variation in the results
obtained.
The immunoaffinity chromatography can be used to recover the human
specific tetanus antibodies in a highly purified and concentrated state
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on an industrial scale. It can be carried out in a closed system and
very rapidly.
Good results were obtained using this technique in order to
concentrate anti-tetanus antibody from human plasma and human IgG
concentrates. The specific activity obtained was about 80-182 I.U. per
mg of protein (=52-108 fold purification), and 1% of the total IgG of
the starting material contained up to 96% of the specific antibody
activity. This indicates that the starting material contained large
amounts of IgG which were not directed against the relevant antigen
(tetanus toxoid).
Using this technique, monospecific antibody obtained could also be
quickly isolated from human plasma with low antibody titre or from
crude IgG preparations. Using such concentrated antibody preparations
it would be possible to administer large dose of specific antibody with
safety which is of considerable clinical importance.
The same technique could undoubtedly be applied to recover from
donor blood antibodies against viral antigens such as: Hepatitis
surface antigen, Cytomegalovirus, Herpes Zoster, Herpes Simplex, or
bacterial antigens such as Pneumococcal polysaccharide.
5.4.2 Conclusions of immunoaffinity purification
Good results were obtained using the immunoaffinity technique
described to purify human anti-tetanus antibodies. The following
conclusions are drawn.
5.4.3.1 Antibody of higher specific activity is obtained using this
technique.
5.4.3.2 Can be used to enrich low titre antibodies in plasma.
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5.4.3.3 The immunoaffinity columns can be re-used, which is important
as regard to costs.
5.4.3.4 Unbound protein can be processed further.
5.4.3.5 The procedure is rapid and reproducible. It enables rapid
preparation of highly specific antibody preparation of clinical value.
5.4.3.6 The technique is widely applicable.
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TABLE C.5-1
SAME AMOUNT OF TT IN DIFFERENT VOLUME
Volumes (mis)
(TT 6.5 mg)
% Coupled in duplicate (4°C 0/N)
A B
(a) 3 25 37
(b) 6 16 28
(c) 12 11 11
It is apparent that the smaller the volume the better the binding of




SAME VOLUME BUT DIFFERENT AMOUNT OF TT
Concentration of TT % Coupled
(in 4.0 mis) (at 4°C 0/N)
Conc. (10x) = 12.0 mg 40
Conc. (5x) = 4.0 mg 62
Unconc. (lx) = 1.2 mg 60
Both lx and 5x concentrated tetanus toxoid coupled more
efficiently to Sepharose than lOx conc. This may be due to CNBr-
Sepharose capacity of binding being exceeded using lOx conc.
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TABLE C.5-3
EFFECT OF INCUBATION PERIOD AND TEMPERATURE
Incubation time
(TT conc. 2.5 mg/4 ml)
% Coupled TT
R.T. 4°C
1 hr 10 23
2 hrs 15 22
4 hrs 21 24
0/N 21 17
The % binding of tetanus toxoid to CNBr-Sepharose increased
with time at R.T., but plateaued at 4 hrs. At 4°C the
coupling was more efficient than at R.T. up to 4 hrs.
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TABLE C.5-4
EFFECT OF AGE OF CNBr-SEPHAROSE ON COUPLING CAPACITY
Expiry date of % Coupled TT
CNBr-Sepharose (2.5 mg at 4°C 0/N)
1 year (prior to) 39
1 month (post) 28
Is year (post) 22
3 years (post) 16
The coupling capacity of the older batches of CNBr-Sepharose
appears to have deteriorated.
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TABLE C.5.5
COMPARISON OF THE COUPLING EFFICIENCY OF TT
USING DIFFERENT WORKING BUFFERS
TT % Uncoupled TT % Coupled TT
Buffers
(in duplicate) Counts Protein Counts Protein
Well-TT 19 25 17 75
0.1M Well-TT 19 25 27 75
Borate +
1M NaCl
pH 8 -0 Conn-TT 5 3 26 97
Conn-TT 4 3 37 97
Well-TT 43 61 8 39
Stock Well-TT 44 60 15 40
Solution
PBS
pH 7 .2 Conn-TT 16 16 24 84
Conn-TT 18 17 5 83
Higher % binding was achieved using borate as the coupling buffer as
compared to PBS- These results also show that Conn-TT binds better to
CNBr-Sepharose than does Well-TT.
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TABLE C.5-6


















The reproducibility of coupling procedure is apparent if one
considers the many steps involved in the process. This
reproducibility is particularly shown in the % uncoupled-TT,
where the post coupling wash can easily be collected and
measured (see also Table 7).
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TABLE C. 5-7
DETERMINATION OF THE REPRODUCIBILITY OF COUPLING PROCEDURE
USING TWO DIFFERENT TT
TT Samples % Uncoupled TT % Coupled TT
(3.5 mg/4ml) Counts Protein Counts Protein
Well-TT
1 16 19 55 81
2 18 20 54 80
3 17 19 53 81
4 22 24 49 76
5 22 28 47 72
Conn-TT
1 8 6 57 94
2 6 5 49 95
3 8 5 67 95
4 9 6 58 94
5 9 6 59 94
These results confirm the reproducibility of the coupling technique,
especially if binding is assessed by the protein measurement. By
counting the radioactivity of the antigen, the % coupled-TT is much




KEY TO TUBE POOLING
Washing
Run Fraction Buffer Tubes
Fr. A PBS pH 7.2 1-20
Fr. B Glycine-Hcl
Serum pH 2.8 21 - 30
1 Fr. C




Fr. A PBS pH 7.2 1-17
Fr. B Glycine-Hcl
Serum pH 2.8 27 - 36
2 Fr. C
" 37 - 44
Fr. D 45 - 56
Fr. A PBS pH 7.2 1-14
Anti-tetanus Fr. B Glycine-HCl
IgG pH 2.8 37 - 47
1 Fr. C
ft 48 - 52
Fr. D 53 - 60
Fr. A PBS pH 7.2 1-16
Anti-tetanus Fr. B Glycine-HCl
IgG pH 2.8 17 - 28
2 Fr. C
•• 29 - 38
Fr. D 39 - 50
The eluates of each immunopurification run (see Figs. 1 & 2) were




IMMUNO AFFINTY OF ANTI TETANUS ANTIBODIES ON A TETANUS - TOXOID -
Cn Br_ SEPHAROSE COLUMN (STARTING MATERIAL ANTITETANUS SERUM)
Elution volume (ml)
Anti-tetanus antibodies were isolated from the plasma of
immunized donor. The specific antibody activities were
assessed by HA and by ELISA (d—a) . There is a
higher concentration of tetanus antibody in glycine-HCl
eluates in much smaller amount of protein (• • ) compared
to PBS eluates (the unbound protein).
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FIG. C.5-2
IMMUNO AFFINTY OF ANTI TETANUS ANTIBODIES ON A TETANUS -










Higher concentration of tetanus antibodies in smaller
amount of protein was obtained by immunopurification
of Cohn-fract.ion II (TIG) . This is shown by the






















































































































































































































































































































































































STUDIES ON MONOCLONAL ANTI-TETANUS ANTIBODIES
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C.6 STUDIES ON MONOCLONAL ANTI-TETANUS ANTIBODIES
C.6.1 Introduction
The generation of cell lines capable of permanent production of
specific antibody directed against a predefined immunogen was first
reported by Kohler and Milstein in 1975. This method was based on
fusion between myeloma cells and spleen cells from suitably immunized
animals. Antibody-producing lymphoid cells have a very short life when
cultured under in vitro conditions, but individual myeloma cell lines
can be grown permanently in culture. When both types of cells are
fused, hybrids can be derived which retain the essential properties of
(a) permanent growth and (b) production and secretion of antibody with
a pre-defined specificity. Since the hybrid cells can be cloned, it is
possible to direct the heterogeneous response of an animal (Fig.la).
The procedure therefore permits the derivation of monoclonal antibodies
(McAb) directed against very well defined antigenic determinants,
regardless of the complexity of the immunogen.
This discovery launched a new era in immunological research, and
it allows a new strategic approach to a wide variety of problems.
Hybridoma production represents a powerful tool for uniform,
large-scale production of homogeneous antibody against a variety of
antigens. Such reference reagents can be made in virtually unlimited
amounts for indefinite periods of time. Since the hybridoma
technology, in essence, clones out of the spleen individual
antibody-forming cells, animals can be immunized with impure antigens
and pure antibodies can be obtained. In principle, hybridoma can be
developed which will produce a desired antibody of any given class,
subclass, allotype, or even against a given antigenic determinant or
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epitope. Monoclonal antibodies of these types have numerous potential
investigational uses. This may conveniently be considered under the
broad headings of diagnosis, treatment and prophylaxis. It would
already be impracticable to list all of the monoclonal antibodies of
clinical interest. They are already very widely used in clinical
chemistry, clinical immunology, bacteriology, pathology and haematology
(reviewed by McMichael et al. 1982 and James ^et_ jhL. 1984). In
particular, they are now used for the routine typing of blood cells,
analysis of lymphocyte subsets (James et^ aJ. 1984), the quantitation
of a variety of drugs (Habor, 1982), hormones and serum components
(NIAID study, 1981), the identification of microbial organisms
(Mitchison et^ al. 1982 and Cohn, 1982) and in imaging and therapy of
tumours where an antibody-drug conjugate (magic bullet) may be used
(Greaves et^ al. 1982 and Thorpe et al • 1982).
Mouse monoclonal antibodies have already proved to be
extraordinarly powerful new reagents in laboratory investigations.
These tailor made reagents have improved the specificity, sensitivity
and reliability of a number of in^ vitro diagnostic procedures such as
radioimmunoassays, immunohistological and other immunoassays.
Monoclonal antibodies have already provided probes for studying the
structural-functional interrelationships of individual domains of the
immunoglobulin molecule, in determining subtle conformational changes,
and in studying V-region structure and genetics (NIAID study, 1981).
They have also advanced the applicability of immuno-affinity
purification techniques for isolation of biologically important
macromolecules from recombinant and other sources, or the removal of
undesirable contaminants (reviewed by James et al. 1984).
During recent years, monoclonal antibodies have played an
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important role in monitoring therapeutically important substances and
as therapeutic agents. They have made possible the identification of
functionally different subpopulations of lymphocyte. The relative
proportions of T cell-subsets seem to be an important determinant of
immune status (James et ad. 1984), and the antibodies can be used in
the pre-treatment of homograft recipients (Kaplan ad. 1982).
Monoclonal antibodies are likely to have their greatest role in
the study and treatment of viral illnesses, for which presently
available antibiotics are known to be ineffective. These include:
influenza, parainfluenza (Gigliotti et ad. 1982), herpes (Ewing et al.
1979), measles, retrovirus, rabies and RNA tumour viruses (NIAD study,
1981). Using monoclonal antibodies, it has been possible to identify
substrains of many of these viruses, indistinguishable with polyclonal
antibodies.
Monoclonal antibodies may also be therapeutically useful in the
management of infectious diseases caused by bacterial, fungal and
parasitic agents. In addition to their direct neutralizing or
inactivating effects on such agents, monoclonal antibodies of
appropriate specificity can be conjugated to antibodies and then
targeted to achieve significantly higher local antibiotic
concentrations, while reducing antibiotic levels in unaffected tissues
(Kaplan et^ ad. 1982).
We have attempted to produce continuous cell lines (human and
murine) secreting monoclonal antibodies against tetanus toxoid.
Tetanus toxoid was chosen as a model antigen because of its direct
relevance to the other studies in this thesis on polyvalent
anti-tetanus antibodies, and because of the obvious therapeutic
potential of monoclonal anti-tetanus antibodies. Two types of
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monoclonal antibodies were produced, initially of murine and later of
human origin. The human monoclonal antibody was produced mainly by
Epstein-Barr virus (EBV) transformation of antibody-producing
lymphocytes derived from tetanus immunized donors. These lymphocytes
were also fused with mouse myeloma cells to produce mouse-human, and
with human lymphoblastoid cells to produce human-human hybridomas
secreting human monoclonal antibody against tetanus-
The choice of assay used during the screening stages, to detect
and clone the hybrid secreting the desired antibody, is of the utmost
importance and should be given the greatest attention. There are many
ways of detecting the presence of antibodies, but not all assays are
directly applicable to monoclonal antibodies. First the concentration
of antibody in the culture supernatant is usually much lower than that
of hyperimmune serum, which makes the sensitivity and the specificity
of the assay of great importance, and second because of the vast
numbers of samples to be tested, and the urgency of knowing the
results, so that the chosen hybrids can be quickly cloned, rapidity,
simplicity and cost become very important. Taking these factors into
consideration, I developed the ELISA and SEI techniques (described in
Section C.l) to monitor the level and specificity of the antibody, and
to determine the Ig-isotype of the monoclonal antibodies produced
against tetanus. These techniques were used to (1) measure the
anti-tetanus antibody levels of TT-immunized mouse and human, (2)
monitor both murine and human fusion products and cloned cell lines,
(3) assess the level of anti-tetanus antibody in ascitic fluid,(4)
characterize the Ig-isotype of the monoclonal antibodies by determining
the distribution of antibody (i.e. the isotype) in protein A-Sepharose
fractionated ascites. In this Section the results obtained from these
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studies will be discussed.
6.2 Production of hybridoma in mouse system
The cell lines making antibody against tetanus toxoid were
produced according to the general methods of Kohler et jil (1975) and
Galfre j^t aJ. (1977).
Twelve week old BALB/c mice were immunized with 10 jig tetanus
toxoid (Well-TT or Conn-TT) intraperitoneally (i.p.) in complete
Freund's adjuvant. They were boosted (i.p.) with the same amount of
the antigen in Freund's complete adjuvant on various days thereafter
(see Table 1). The spleens were removed and splenic lymphocytes were
suspended at a concentration of 5 x 10^ cells per ml in complete
medium RPMI 1640 buffered with 20 mM Hepes, and supplemented with 2 mM
glutamine, 1 mM sodium pyruvate, 50 units/ml penicillin, 50^ig/ml
streptomycin, 10% foetal calf serum (FCS) and 5 x 10-^M
2-mercaptoethanol. The spleen cells were fused with a non-secreting
mouse myeloma cell line NS-1 abbreviated from P3-NSl/l-Ag 4-1 (Kbhler
et al, 1976). One week before the fusion, the myeloma cells were grown
into 75 cm^ flasks and were fed with the complete medium daily.
The method used for this fusion was as described by Oi et al.
(1980), which was modified after Fazekas et al. (1980). In two of the
fusions the T-cells were removed by running the spleen cells through a
nylon-wool column (leukopack), and using the non-adherent cells for
fusion. The fusion ratio in all experiments was two myeloma cells to
one spleen cell. The fused cells were plated out in 96-Well culture
plates, 2.0 x 10^ cells being added to each well, which contained a
feeder layer of 2 x 10^ mouse thymocytes. Polyethylene glycol 4000
(BDH Chemicals) at 38% (W/V) concentration was used as the fusing
agent. The fused cells were grown in RPMI 1640 medium (as described
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but without mercaptoethanol), containing 10~^M hypoxanthine, 4 x
10_^M aminopterine, and 1.6 x 10~^M thymidine (HAT)
(Littlefield, 1964). After seven days, aliquots of the supernatants
were removed and tested for tetanus antibody activity by the ELISA
procedure described in Section C.1.3.
Positive cultures were expanded and then cloned by limiting
dilutions (Mishell et a_l. 1980) into 96-Well plates in presence of 5 x
105 mouse thymocytes feeder cells per well. Clones were selected on
the basis of both their antibody secreting capacity and their growth
characteristics. As the clone cells multiplied, they were transferred
from the 96-well culture plate to a 24-well plate, at which stage
aminopterin was omitted from the medium (HT) and then into 25 cra^
flasks with ordinary medium (without HT).
Antibody-secreting clones were also grown up in ascites form as
follows: cells were harvested from cultures, resuspended in Dulbecco's
Minimal Essential medium, and 2 x 10^ cells in 0.2 ml were injected
i.p to a number of BALB/c mice which had been injected i.p. with 0.5 ml
Pristane (tetramethylpentadecane) ten and three days previously
(Potter, 1972). Ascites developed in about seven days. The fluid was
withdrawn from the abdominal cavity over a period of several days, and
tested for antibody activity by the ELISA procedure.
The immunoglobulin isotypes of the monoclonal antibodies were
analyzed by fractionaticn of the ascitic fluids on Protein-A Sepharose
column according to the procedures decribed in Section B.5. The
results of this procedure were subsequently confirmed by SEI assay
(Section C.1.4) employing isotype specific antisera.
A summary of the steps involved in the production of mouse
hybridoma producing monoclonal antibody is outlined in Figure la.
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6.3 RESULTS (mouse cell lines)
6.3.1 The production of mouse hybridoma secreting monoclonal antibody
to tetanus toxoid
Over 3000 cultures were set up giving rise to large number of
hybrids. Although some fusions resulted in high numbers of hybrids (see
Table 1), the incidence of specific antibody-secreting hybrids was
low. Table 1 (fusion 5 & 6) also shows that depletion of T-cells from
spleen cells before fusion had little or no effect on the number of
specific antibody-secreting hybrids.
6.3.2 The production of anti-tetanus antibodies by growth of cell
lines in ascites form
From fusion 1 (Table 1), two cell lines designated Fl.l and F1.6
continued to grow and produce monoclonal antibody to tetanus.
In an attempt to obtain anti-tetanus antibodies preparations of
high titre, some of the antibody-secreting cell lines (10^ cells)
were grown in ascites form. Studies in a large number of mice revealed
that the yield of antibodies by this procedure was extremely variable
even in mice challenged with the same cell line. However on occasions
ascites of relatively high titre were obtained. Furthermore in these
and other mice, the levels of anti-tetanus antibody appeared to
increase in the later tappings (Tables 2,3, and 4). The antibody
activity in ascitic fluid of mice injected with uncloned cell lines
(Fl.l and F1.6) was much lower (Tables 2 and 3) than in those injected
with cloned cell lines. (Tables 4 and 5). When sequential tapping was
performed, more concentrated antibody was obtained, and in most cases
the Ab-titre increased linearly with subsequent tapping (Fig. 2 and
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Table 4).
In a study carried out in the Department of Biochemistry (Van
Heyningen), ascitic fluid with high titre of antibody (from cell line
Fl.1.2) were found to bind to both chains of tetanus toxin.
6.3.3 Purification and Ig-isotype characterization of the mouse
monoclonal antibodies against tetanus
Although some of the ascites fluids obtained contained more than 40
times the antibody activity (Table 4) observed when the same cells were
grown in culture, these preparations also contained large amounts of
irrelevant protein of mouse origin. In order to isolate the monoclonal
antibody, and identify its Ig-isotype, the ascites fluid was therefore
fractionated on a protein A-Sepharose column. The results of two such
fractionations are shown in Figs. 3 and 5. Almost all of the tetanus
antibody activity was observed in the IgG]^ peak (Figs. 3 and 5).
Further analysis on these fractions with isotype specific antisera
using SEI assay confirmed that the antitetanus antibody was mainly of
the IgGq class (Figs. 4 and 6). These studies also illustrate the
effectiveness with which the various Ig-isotypes can be separated on
protein A-Sepharose (see earlier studies on immune mouse sera, Section
C.4).
6.4 Production of human monoclonal antibody to tetanus
Whole blood from immunized volunteers was collected in EDTA. The
volunteers had been immunized seven days or three months previously
with 150^ig in 0.5 ml of tetanus toxoid (Well-TT). The peripheral
blood mononuclear cells were isolated by Ficoll-Hypaque gradient
centrifugation (Bbyum, 1968). The remaining procedures are outlined in
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Fig.lb.
Two methods were used to prepare tetanus antibody-secreting cell
lines of human origin; hybridization and viral transformation.
Hybridization partners were murine plasmacytoma NS-1 (Kfcihler et al.
1976) and two clones (HMY 2.3 and HMY 2.9) derived from the human
lymphoblastoid line LICR-LON-HMY 2 (Edwards et al. 1982). Lymphocytes
were fused at a ratio of 2:1 using 35% (w/v) polyethylene glycol 1500
in serum-free medium for eight minutes.
In the viral transformation procedure antigen-specific lymphocytes
were enriched by incubating the tetanus antibody-producing B cells on
TT-coated plastic flask. The adherent B cells were subsequently
recovered by adding lidocaine (4 mg/ml w/v) and were vigorously
pipetted. The transforming B95-8 substrain of EBV from a marmoset cell
line was used to immortalize the isolated B cells (Miller et al. 1973).
EBV is a herpes virus that infects the primate B cell. Lymphocytes
(10^/ml) were incubated for 2 hours in supernatant from the
EBV-producing cell line. The lymphoblastoid cell line so produced were
treated in the same way as the hybrids.
After fusion or transformation, the cells were maintained in HAT
medium as described in the mouse system. However on this occasion this
medium was supplemented with 20% FCS, 1 mM oxaloacetate, and the
antibiotics used were 10^ig/ml Kanamycin 2.5^ig/ml Fungizone. The
cells were cultured initially at a density of 2 x 10"* cells/0.2 ml in
flat-bottomed 96 well-microtitre plate, and in some of the experiments
in 24 well-plates containing a feeder layer of 5 x 10^ mouse
peritoneal macrophages.
For in vitro antigen boosting, mononuclear cells were incubated at
2 x 10^/ml for 72 hours at 37°C in complete medium containing 5 ng/ml
219
TT and 5 x lCP^M 2-mercaptoethanol, but omitting the HAT components.
Antibody-secreting cell lines were cloned by limiting dilution in
U-bottomed microtitre plates in complete medium containing 30%
thymocyte culture medium (TCM) prepared from BALB/c and CBA mouse
thymocytes (Reading, 1982).
Culture supernatants were screened for anti-tetanus antibody
activity by the ELISA procedure (as described in Section C.1.2)
The mouse toxin neutralization assay was performed by Dr. F.
Sheffield at the National Institute for Biological Standards and
Control (Holly Hill, London). The in vivo protection of anti-tetanus
antibody secreted by one of the human cell lines, designated ES-12 was
investigated in a standard 4-days mouse protection assay (British
Pharmacopoeia, 1980). Culture supernatant from ES-12 had been tested
without prior concentration or purification; culture medium from a
non-secreting cell line acted as a negative control.
6.4.1 Human Ab-response to TT-booster immunization
Healthy adult human volunteers were each given one intramuscular
injection of Well-TT (0.5 ml). Blood samples were collected on 5,7,14
and 26 days, and at 6 months after the injection. The levels of
anti-tetanus antibody in the samples were measured by both the ELISA
and HA procedures.
6.5 RESULTS (human cell lines)
6.5.1 Comparison of fusion partners
Fusion of human lymphocytes with the human lymphoblastoid HMY 2
line yielded more cultures than fusion with mouse myeloma NS-1 cell
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line, under identical conditions (Table 7). HMY 2.3 appeared to fuse
more successfully than HMY 2.9 line. That is, they gave rise to more
hybrids. All cultures except those from HF2 fusion ceased to grow. In
this fusion, where 480 wells had been seeded, only 55 wells showed cell
growth, and three of these secreted tetanus-specific antibody. One of
these cultures designated ES-12 has continued to grow and secrete
anti-tetanus antibody.
6.5.2 In vitro boosting with antigen
Pre-incubation of lymphocytes with TT before fusion or virus
infection did not seem to increase either the number of wells with
growth or the proportion secreting specific antibody (Table 7).
The immortalized ES-12 cell line which secreted TT-specific
antibody was derived from a donor who had been boosted in vivo three
months earlier and without further iri vitro antigen stimulation before
fusion.
6.5.3 Preliminary characterization of tetanus antibody secreted by
the ES-12 cell line
As shown in Table 7, only one heterohybridoma (using NS-1 as
fusion partner) secreted antibody to tetanus as detected by ELISA.
Although the antibody level was initially high, it declined rapidly and
was undetectable 30 days after the fusion. Immediate cloning of the
positive culture showed no antibody activity in the supernatants (ELISA
results not listed). The cell line ES-12 was one of the five
human-human cell lines producing high levels of antibody activity. In
both the mouse (in vivo) protection assay and in vitro assay (ELISA),
ES-12 had a titre of 2.5-3.0 I.U./ml as compared to reference human
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standards (listed in table of antisera, and discussed in Section
C.1.2). This cell line which continued to grow and secrete antibody
to TT up to 9 months has been characterized further (Boyd et al. 1984
and James et al. 1984). Their results indicate that ES-12 cell line
expresses only the HLA phenotype of the donor and secretes an IgG3
kappa antibody. Its model chromosome number is 44, suggesting that it
is a virus-transformed lymphoblastoid cell line and not a hybrid.
In an attempt to stabilize the cell line, ES-12 has been
hybridized with an HAT sensitive lymphoblastoid cell line KR4 (Boyd
et al. 1984). The new hybrid (HF25) has a model chromosome number of
86, it grows at a faster rate than the parent cell ES-12, but the level
of IgG it secretes, and especially its anti-tetanus activity,is reduced
(Boyd et^ a_l. 1984).
The antibody secreted by ES-12 cell line was shown to bind to both
chains (H & L) of tetanus toxin in a study which has been carried out
in the Biochemistry Department of Edinburgh University (Van Heyningen
et al, personal communication).
6.5.4 Human response to TT-booster immunization
The results given in Table 8 indicate that the anti-tetanus
antibody levels before booster immunization were between 0.06 - 1.0
I.U./ml. The antibody levels then increased gradually up to day 14
after the booster immunization, and individuals achieved a significant
antibody rise (16 - 32 I.U./ml) by this time. This high level of
antibody was maintained in the donor's serum up to 6 months. The
lymphocytes of donor 1 were collected 3 months after the boost, and
these were used to produce the human monoclonal antibody to tetanus.
At this time the donor had produced a 267-fold increase in the serum
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concentration of specific antibody (Table 8, donor 1).
The results in Table 8 also demonstrate that the ELISA technique
is more sensitive than HA. Negative controls using unimmunized human
serum failed to give positive results.
6.6 Discussion
We believe that we have established continuous mouse and human
cell lines capable of producing monoclonal antibodies to tetanus
toxoid.
A large amount of mouse monoclonal antibody to tetanus was generated
by growing the hybridoma as an ascitic tumour in BALB/c mice.
Sequential tapping of ascitic fluid was performed to obtain more
concentrated antibody, and in most instances the Ab-titre increased
with the subsequent tapping. There are clearly advantages in using
late tappings for the preparation of monoclonal antibodies. It has
been shown by other workers as well (Hunter et aJ. 1982) that Ab-titres
vary from cell line to cell line and from mouse to mouse. As
experienced in the Department of Surgery, it is best to grow ascites
tumour in as many mice as possible and test the sequential bleed.
Another advantage of serial tapping (K.James et aJ., unpublished) is
that frequently much stronger and purer immunoglobulin of the specific
isotype has been observed at the later taps.
The level of antibody activity of one of the two cell lines was
low, and on occasions dropped to zero. It is apparent that the hybrid
has either lost the relevant gene or has been overgrown by
non-antitetanus-secreting hybrids. In such an instance it is vital to
go back and regrow the original hybrid and redone. Decrease or loss
of secreted antibody has been reported by others (Zurawski et d^. 1978)
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and has been attributed to multiclonality. Cloning results in
monoclones of identical cells. Should single cells subsequently lose
one or more chromosomes, but remain viable and continue to divide, the
original monoclonal culture will become biclonal (or even multiclonal).
The new cell line with fewer chromosomes is different from the first,
and that is one of the common reasons for loss of production from an
originally high-producing clone. In those mice where ascites tumour
did not grow, it is also possible that the numbers of cells injected
were less than 10?. With fewer cells, the mouse may be able to
defend itself against the tumour.
The ELISA assay proved to be highly sensitive, and allowed a rapid
and reliable screening system of the hybrid cultures in both mouse and
human systems. The dominant Ig-isotype produced by the two continuous
mouse cell lines is IgG^, which is the isotype found in the majority
of mouse monoclonal antibody (Lutz et £l. 1983). Recently IgGq was
found to be the predominant subclass of In vivo and Tn vitro produced
anti-tetanus toxoid antibodies (Stevens et al. 1983).
Monoclonal antibodies to TT have been produced in murine (Butler,
1983) and human system (Chiorozzi, 1982; Gigliotti, 1982; Kozbar,
1982). However if they are to be considered for therapeutic use, it is
important that they have protective activity _in vivo. We were able to
obtain a number of clones producing human anti-tetanus antibody. One
of these,designatedES-12,has continued to grow and secrete specific
antibody. Its culture supernatant without further concentration or
purification has been shown to be protective against tetanus toxin in
mice. In both in vivo protection and in vitro assay, the culture
supernatant has a titre of 2.5 - 3.0 I.U./ml. This ES-12 cell line was
obtained from fusion of immune lymphocytes with HAT-sensitive human
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lymphoblastoid cell line (HMY 2.3). One of the problems involved in
using lymphoblastoid cell line as a fusion partner in hybridization is
that spontaneous EBV transformed cells can arise in culture. Most of
the initial characterization of the ES-12 line was to determine whether
it was a hybridoma or not (Boyd, Farzad et al. in press, and Boyd
et a^. 1984). On the basis of karyotype analysis and tissue typing
studies, it would appear that the ES-12 cell line has arisen as the
result of spontaneous transformation in culture of an EBV positive
antibody secreting plasma cell. Studies on ES-12 cell line have been
continued after the termination of my study (Boyd et al. 1984). In
order to preserve the antibody secretion, ES-12 has been hybridized
with KR4 lymphoblastoid cell line. Although the new hybrid has grown
at a faster rate than the parent cell line ES-12, the amount of IgG
produced and its anti-tetanus antibody activity has reduced. The ES-12
secrete IgG, kappa and like mouse McAb it binds to both chains of
tetanus toxin (as tested by Simon van Heyningen) which agrees with
other studies (Gigliotti, 1982).
The frequency of the human-mouse hybrids was very low, and they
tended to be less stable than their human-human counterparts.
Nevertheless, other groups have successfully produced mouse-human
hybrids secreting anti-tetanus antibody (Gigliotti et al. 1982). The
frequency of EBV-transformation of B-lymphocyte was relatively high,
and high percentage of wells with growth showed anti-tetanus activity.
The necessity for removing T-cells from the lymphocyte population to be
fused is unclear, as conflicting reports have appeared in this area
(Butler et aJ. 1983 and Gigliotti et jil• 1982). In our own experience,
T-cell depletion did not increase the efficiency of mouse fusion, but
was essential for successful EBV transformation.
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While preselection of antigen-specific lymphocytes can increase
the proportion of antibody-secreting EBV-transformants (Kozbor et al.,
1981), it is not yet certain whether this approach is necessary in the
formation of hybridomas. Although initially there was a vigorous
growth of EBV-transformed cell lines, which produced high levels of
specific antibodies, they ceased to grow after a short time, and also
proved difficult to clone, possibly due to loss of chromosomes. In
contrast to other studies (Butler et al• 1983), in vitro boosting with
TT prior to fusion did not seem to increase the TT-specific cultures by
either the cell hybridization or EBV-transformation procedure.
The complexity of the interaction between variables can lead to
contradictory results between laboratories. For example, it is
conceivable that the beneficial effect of feeder cells is much greater
if the foetal calf .serum and media are suboptimal (Hurrell, 1982).
Since there is no entirely satisfactory test to predict the suitability
of the FCS, it is not easy to prove that the need for feeder cells, for
example, are related to the FCS batch. Experiments to study all these
variables are tedious and relatively uninteresting at a time when most
investigators are anxious to produce some useful antibodies,
irrespective of the efficiency of the process.
While the advent of monoclonal antibody technology offers many
advantages, it must be stressed that it also suffers from a number of
limitations. These include: (1) the excessive amount of work and time
involved in generating and stabilizing monoclonal antibodies, (2) the
difficulty in obtaining monoclonal antibodies against antigens that are
poorly immunogenic, (3) their exquisite specificity can limit their use
as therapeutic agents, rendering them less attractive at fixing
complement, opsonizing bacteria, and clearing toxin than their
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polyvalent counterparts and (4) the potential presence of EBV or
oncogenic virus in antibody preparations.
However, with the recent advances in this technology and with the
help of fast developing improvements in the cloning of specific antibody
genes, the future for human monoclonal antibodies holds great promise.
6.7 Conclusions
Mouse and human cell lines secreting anti-tetanus antibody were
produced.
6.7.1 The mouse monoclonals were grown in both tissue culture and
ascites form. By performing sequential taps of ascites-bearing mice,
anti-tetanus antibody preparations of high titre were obtained.
6.7.2 The antibody produced by both in vitro culture and in ascites
was of the IgG^ isotype.
6.7.3 A relatively stable human cell line (designated ES-12) secreting
anti-tetanus antibody was obtained by fusing PBL from a TT-immunized
volunteer with a human lymphoblastoid cell line.
6.7.4 Subsequent karyotypic and cell surface phenotype analysis
revealed that ES-12 cell line was a spontaneous transformant of an
EBV-positive cell.
6.7.5 The antibody produced by ES-12 was of the IgG3> kappa isotype
and protected mice from challenge with tetanus toxin.
6.7.6 Both the mouse and human antibody preparations appeared to react
with the ci and jtJ chain of tetanus toxin.
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FIG. C .6-la



















Seed in microtitre plate (96 wells)
in HAT medium
(a) Cloning positive cultures in 96
well plate
(b) Freeze part of the positive culture
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1 Wellcome 0,30 33 240 13 12
2 Connaught 0,30 33 300 5 0
3 Wellcome 0,28,56,
67
70 300 86 0.4
4 Connaught 0,28,56,
67
70 300 75 0
5* Wellcome 0,28,56,
67
70 170 80 0.5
6* Connaught 0,28,56,
67
70 160 54 0
7 Wellcome 0,14 17 480 23 0
8 Connaught 0,14 17 480 0 0
9 Wellcome 0,28,42 45 300 13 0







* T - cell depleted spleen used in fusion.
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TABLE C.6-2
ANTI-TETANUS Ab LEVELS OF MOUSE ASCITES FLUID DETECTED BY ELISA
FROM FUSION 1 (F1.6)-(UNCLONED CELL LINE)
Days mouse tapped

















Control anti-tetanus serum 1:25600
Negative Normal mouse serum 0
Control
N.B.: Ab-titre of the original hybrid before inoculation was 1:256
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TABLE C.6-3
ANTI-TETANUS Ab LEVELS OF MOUSE ASCITES FLUID DETECTED BY ELISA
FROM FUSION 1 (F1.l)-(UNCLONED CELL LINE)
Days mouse tapped

















Control anti-tetanus serum 1:25600
Negative Normal mouse serum 0
Control
N.B.: Ab-titre of the original hybrid before inoculation was 1:256.
Mouse No.l showed a 10 fold increase in the Ab-titre.
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TABLE C.6-4
ANTI-TETANUS LEVELS OF MOUSE ASCITES FLUID DETECTED BY ELISA
FROM FUSION 1 (FI.1.2)-( CLONED CELL LINE)
Days mouse tapped

















The above Ascites fluid containing high titre of monoclonal antibodies
were given to Dr.S. Van Heyningen (Biochemistry Department) for use in
their studies of molecular structures of tetanus toxin.
The antibody titre of the hybrids supernatants prior to injection was
1:256. The antibody activity increased on subsequent tapping, and the




ANTI-TETANUS Ab LEVELS OF MOUSE ASCITES FLUID DETECTED BY ELISA
FROM FUSION 1 (Fl.1.3) — ClONED (2x) CELL LINE
Days mouse tapped
















N.B. The Ab-titre of the original hybrids prior to inoculation was
1:160. The antibody was concentrated in ascitic form in various
degree, ranging from 0-32 fold of the original.
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FIG. C.6-2
When sequential tapping of ascitic fluid was performed,
more concentrated antibody was obtained, and in most























FIGS. C.6-3 and C.6-5
Profile of Protein-A Sepharose fractionated mouse
ascitic fluid for isolation of the monoclonal
antibody to tetanus. Almost all of the tetanus
antibody activity (by ELISA o - - o) was
observed in the IgG^ peak.
FIGS. C.6-4 and C.6-6
Further analysis of the separated fractions
(of Figs. 3 & 5) with isotype specific antisera
using SEI assay confirmed that the monoclonal



































































































































































































HV1 in vivo (a) 960 wells
20 pots
0 0





HV2 in vivo 480 wells
(cloned)
330 wells 8





HV6 - 480 wells
(cloned)
140 wells 4





N.B. (a) Lymphocyte donors were boosted 7 days earlier
(b) Three months since the last boost
All cultures ceased to grow further
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TABLE C.6-7
THE PRODUCTION OF HUMAN MONOCLONAL ANTIBODY TO TETANUS TOXOID USING MOUSE
















HF1 NS-1 -* 120 wells 2 0
HF4 NS-1 in vitro 120 wells
18 pots
0 0







H MY 2.3 -* 480 wells 55 3
HF6 H MY 2.3 in vitro 238 wells
21 pots
43 1
HF3 H MY 2.9 _* 240 16 1
HF7 H MY 2.9 in vitro 240 3 0
N.B. ^Lymphocyte donors were boosted three months earlier.
All cultures except HF2 ceased to grow. The cell line derived from




LEVELS OF ANTITETANUS ANTIBODY IN DONOR'S SERUM TAKEN AT
DIFFERENT INTERVALS
Date of Sample Haemagglutination ELISA
Donor Collection Ab Titre I.U. Ab Titre I.U.
Pre Boost 1:4 0.06 1:4 0.06
Day 5 1:4 0.06 1:8 0.13
1 Day 7 1:8 0.13 1:256 4.0
Day 14 1:512 8.0 1:1024 16.0
Day 26 1:256 4.0 1:1024 16.0
6th month 2.0 16.0
Pre Boost 1:8 0.13 1:16 0.25
Day 5 1:8 0.13 1:16 0.25
2 Day 7 1:16 0.25 1:64 1.0
Day 14 1:128 2.0 1:1024 16.0
Day 26 1:128 2.0 1:1024 16.0
6th month 2.0 16.0
Pre Boost 1:64 1.0 1:64 1.0
Day 5 1:128 2.0 1:256 4.0
3 Day 7 1:128 2.0 1:2048 32.0
Day 14 1:1024 16.0 1:2048 32.0
Day 26 1:1024 16.0 1:2048 32.0
6th month 8.0 32.0
Tetanus IgG Batch No.18 1:16000 250 1:32000 250
(PFC)
Tetanus IgG Batch No.17 1:8000 1:16000
(PFC)
Negative Normal human 0 0 0 0
Control serum
N.B. Ab-response varied among individuals but the peak of response was day





The main purpose of the work presented in this thesis was to
devise alternative techniques for isolation of antibodies to tetanus
toxin, and possibly to other biologically active agents.
In the initial phase, to ensure the proper selection of donors for
the production of tetanus-antibodies, a sensitive and simple assay
which would permit the measurement of circulating anti-tetanus
antibodies in man and mouse, and in the specific antibody preparations
derived from the plasma or hybridoma cell lines was required. The
ELISA assay was chosen to be developed in preference to equally
sensitive radioimmunoassay (RIA) for a number of reasons. These
include: its greater rapidity, lower cost, longer shelf life of
reagents as well as safety reasons. The most valuable findings were
that microtitre plates coated with tetanus toxoid were found to have a
shelf life of more than one year with no reduced sensitivity. The
assay was found to be extremely sensitive, capable of measuring an
anti-tetanus antibody level as low as 5 x 10""^ I.U./ml. The lowest
tetanus antibody levels measured by other techniques are: 6 I.U./ml by
radial immunodiffusion (Eldridge et^ al., 1975 and Cook £^^1- 1976), 5
I.U./ml by counterimmunoelectrophoresis (Entwistle et^ a^. 1973),
0.004 - 0.016 I.U./ml by RIA (Dow et al. 1983, Habermann, 1977 and
Bernath, 1974).
All in vitro methods for measurement of tetanus antibody are
generally less specific than in_ vivo neutralization tests, and the main
problem has been to show that there is a good correlation between the
two tests. In a comparative study testing our human monoclonal
antibody to tetanus, both the mouse protection assay and the ELISA
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showed similar antibody titre (2.5 - 3.0 I.U./ml). The neutralizations
method is however expensive, time-consuming and requires a large number
of suitable animals. A further limitation is that the method also
requires a relatively large volume of sample, especially when the
antibody concentrations are low. The sensitivity of the toxin
neutralization test in mice was recently reported to be only 0.01
I.U./ml, the minimum level thought sufficient for protection.
In the initial studies the ELISA was compared with
haemagglutination assay (HA) in which toxoid-coated human red blood
cells were used in preference to the sheep, turkey, goose and duck red
cells used by others (Konstantinova, 1981 and Pitzurra, 1981).
Although this HA test was faster than ELISA and was of adequate
sensitivity, it was less reproducible and amenable to automation and
standardization than the ELISA method. Furthermore, the HA test will
measure the tetanus-IgG only in the absence of IgM antibodies
(Crawford et^ al_. 1980). This ELISA technique is now being used
routinely by the Blood Transfusion Service (S.E. Scotland and
Edinburgh) for measuring the anti-tetanus antibody levels in the plasma
of donors, and by the Department of Surgery (University of Edinburgh)
for screening the monoclonal antibodies to tetanus.
The experiment using the ammonium sulphate precipitation technique
to measure the binding capacity and binding affinity of anti-tetanus
antibody proved to be irreproducible. A number of experiments were
undertaken to investigate factors that could have been responsible for
this. While these investigations failed to resolve the problem, it is
possible that an alternative labelling technique (see B.3) or
precipitation reagent (Tanavala et^ aJL. 1978), and the use of highly




The studies on tetanus toxoid preparations revealed that Wellcome
tetanus vaccine is extremely heterogeneous. The protein peak containing
most of the toxoid activities is 4.5 S. This observation is in
agreement with Pillemer et al^ (1948) and Largier (1956), but in
contrast with Raynaud et al. (1960) and Murphy et al. (1967). The
highly pure tetanus toxoid (Conn-TT) is homogeneous and consists of only
one main protein peak (4.5 S) containing all of the toxoid
antigenicity.
It seems that formaldehyde treatment of tetanus toxin in order to
prepare toxoid leads to significant polymerization (Bizzini et al. 1974
and Murphy, 1967). This could explain the different values reported
for the size of tetanus toxoid molecules. The allergy reactions
following active immunization for tetanus are believed to be due to
impurities present in the preparation, and to the polymerization
resulting from formaldehyde treatment (Wellho'ner, 1981). It appeared
that the Conn-TT which proved to be the purest of toxoid preparations
may have been purified prior to toxoiding. This tetanus toxoid also
radiolabelled with iodine more efficiently. Whether or not this pure
preparation is more effective at eliciting anti-tetanus antibodies in
human as it does in murine, or produces fewer or weaker side reactions,
remains to be established.
The method initially adopted to extract antibodies with
specificity to tetanus toxin from human plasma, and from standard
commercial immunoglobulins (Cohn Fraction II), was affinity
chromatography. The technique utilizes the unique specificity of
antigen-antibody interaction. This approach is especially useful when
isolating specific antibodies present rarely or at low concentration.
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A number of studies had to be undertaken to establish the optimum
conditions for the preparation of immunoadsorbent columns. Various
factors with respect to antigen (tetanus toxoid) concentration,
temperature, incubation time, coupling buffer, and age of the
sepharose were evaluated, and were found to influence the binding (see
Chapter 5). The column so prepared had an excellent chemical
stability and proved economical. The same column was used repeatedly
to isolate anti-tetanus antibody without loss of capacity or specific
properties. It could be concluded that the antigenic sites of the
column were not either blocked, inactivated or eluted as a result of
successive cycles.
All the elutions were carried out at room temperature, and
antibody elution was performed at acid pH without loss of biological
activity. The purification factor achieved was as high as 108-fold,
which is at least four times higher than obtained by the
Cohn-fractionation technique (Krijnen et^ al. 1970 and Levine et al.
1967). The specific neutralizing activity of the final product was
80-180 I.U. per mg or protein depending on the specific activity of the
starting material. This is at least twice as high as found by Tardy
et al. (1978), who used porous silica beads for the purification of
tetanus-antibody•
One of the main differences between this technique and the
classical column methods is its extreme rapidity, a factor which helps
minimize denaturation. Using this technique, almost all of the
specific antibody can quickly be isolated in not more than 1% of the
starting immunoglobulin. This permits the production of a purified
antibody preparation of high specific activity, so that it is possible
to give a large dose of antibody in a small volume containing
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relatively little protein. Such preparations are likely to be safe to
administer by intramuscular, intravenous and intrathecal routes.
This immunoaffinity technique is widely applicable. There are
good reasons to believe that this approach could be used (as it was
intended) successfully for isolation of other antibodies of potential
clinical value, including anti-Hepatitis B surface antigen,
anti-Varicella-Zoster, anti-Cytomegalovirus and anti-Pneumococcal
polysaccharide.
The immune response studies undertaken in mice resulted in some
interesting findings. The analysis of the Ig-isotypes were done by SEI
assay developed for this study. The responses of the mice to both
toxoid preparations are largely in the IgG isotype. This finding was
later confirmed by Ershler et aJ. (1982) who found that mice produced a
poor primary response to tetanus toxoid and,on boosting the antibody
was mainly IgG. However, in the present studies, antibody responses
were detected in all IgG subclasses except IgG2b immediately after
primary challenge with pure tetanus toxoid (Conn-TT). This toxoid
preparation not only elicited rapid, but also a more pronounced
response than the crude Wellcome vaccine.
An interesting finding was the presence of "naturally acquired"
antibodies in conventionally housed CBA/Ca and BALB/c mice. Similar
findings have recently been reported in non-vaccinated humans and
animals in the Galapagos Islands (Veronesi et al. 1983), and in India
(Wellhb'ner, 1981). No reports have been available on the Ig-isotypes
of these antibodies. According to the results presented here (Chapter
4) the pre-existing antibodies to tetanus are of the IgA, IgM and to a
lesser extent of the IgG3 isotypes. The fact that the natural
antibodies were found against both crude and pure toxoids indicates
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that the antibodies were against the tetanus toxoid and not a
contaminating protein. Both strains of mice exhibited similar
responses.
It is possible that spores of CI. tetani are swallowed by
man and mice, and have stimulated a response. It has recently been
suggested that the oral route might provide an effective vaccination
route for humans against tetanus (Veronesi et^ jkL. 1983). This route
might preferentially stimulate IgA and IgM antibodies. Alternatively,
determinants might be shared between tetanus toxoid and other
macromolecules or intestinal organisms such as other Clostridia. It
would be of great interest to verify whether a single dose of tetanus
toxoid would boost these low titres of "natural antibodies" to a
protective level in humans. This is significant where the present
three doses scheme given at spaced intervals does not receive the
cooperation of a large proportion of the population. Recently in
Denmark in those who had received only primary vaccination an
exponential fall off in immunity was seen, and 25-30 years after
primary vaccination, 28% had serum antitoxin concentrations below
(^0.01) the level of protection (Simonsen et a_l. 1984).
The studies undertaken on the immune response of mouse to tetanus
toxoids were also important preliminaries to our eventual aim of
producing a suitable anti-tetanus antibody of specific Ig-isotype for
clinical use, either by immunization of blood donors or by the
monoclonal procedure.
The ^n vitro production of McAb which had become popular during my
course of study, seemed to be another attractive approach to our aim of
the production of "specific" tetanus antibody. McAb which have been
called "the smart bombs of biology" (cited by Brown, 1982), normally
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bind to a single epitope on a single antigen. The major advantage of
this technology is that it enables the production of a continuous
supply of pure antibody of precisely defined specificity and isotype.
Production of McAb to tetanus toxoid in both mouse and human was
successful. The mouse hybrids were grown up in both tissue culture and
ascites form. By performing sequential taps of ascites-bearing mice,
anti-tetanus antibody preparations of high titre were obtained. The
mouse monoclonals were of the IgG^ isotype by both Protein-A
Sepharose fractionation and the SEI techniques. IgG^ was just
recently found to be the predominant subclass of in vivo and in vitro
produced mouse anti-tetanus antibodies (Lutz et al. 1983). The level
of antibody activity of one of the mouse cell lines was low, and
eventually dropped to zero. It is apparent that the hybrid has either
lost the relevant gene or has been overgrown by non-antitetanus
secreting hybrids. Decrease or loss of secreted antibody has been
reported by others (Zurawski et^ al^. 1978).
A relatively stable human cell line (designated ES-12) secreting
anti-tetanus antibody was obtained following the fusion of peripheral
blood lymphocytes from an immunized volunteer with a human
lymphoblastoid cell line (HMY 2.3). Subsequent karyotype analysis
revealed that this was a spontaneous transformant rather than a true
hybrid. The antibody produced by ES-12 protected mice from challenge
with tetanus toxin.
The frequency of the human-mouse hybrids were very low, and they
tended to be less stable than their human counterparts. Although
initially there was a vigorous growth of EBV-transformed cell lines
which produced high levels of specific antibodies, they ceased to grow
after 9 months in culture and proved difficult to clone, possibly due
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to loss of chromosomes (Zurawski e£ al. 1978).
These monoclonal antibodies, produced by both mouse and human
(ES-12) cell line, have been shown by ixnnunoblotting technique to bind to
particular peptides in the digests derived from both chains of tetanus
toxin (Van Heyningen, personal communication). This observation is of
importance with respect to the evolution of the tetanus toxin molecule
suggesting it arose by gene duplication. Studies of tetanus toxin
compositions would support such a view, as there is a sequence homology
between the heavy and light chain (Cornish-Bowden, 1983 and Taylor
al. 1983).
Of additional interest are recent reports suggesting that at least
two antigenic determinants of tetanus toxin molecule should be blocked
by antibodies for efficient neutralization, and this is believed to
require at least two monoclonal antibodies directed against different
epitopes (Mizuguchi et^ al^. 1982). Moreover, a recent report shows
that monoclonal antibodies to tetanus have appeared to be less suitable
than polyclonal sera for protection in animals (Ahnert-Hilger al.
1983). Such reservations are not fully supported by those in our own
laboratories.
The tetanus monoclonal antibodies are attractive tools which would
allow one to extend and specify the structure-function relationship of
different molecules of toxin. From the therapeutic viewpoint it seems
that the use of antibodies directed against the whole toxin molecule is
to be preferred for the time being to that of antibodies directed to
particular parts of toxin molecule (Bizzini, 1981).
While the advantages of monoclonal antibodies are considerable,
some caution is merited, particularly relevant to clinical usage.
These include the high cost of production, the immunogenicity
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of monoclonal antibodies of murine origin, human antibodies could
stimulate anti-idiotype antibody responses and finally there is the
possible hazard of transfering oncogenic material. Nevertheless, with
the technology in this field and in the field of gene cloning evolving
so rapidly, the future for human monoclonals holds great promise,
especially with the recent concern over the safety of blood production
in regard to the newly found blood transmissible disease AIDS.
It would be of great interest to compare the biological
effectiveness of the human tetanus antibodies produced by hybrids with
the immunoaffinity purified preparations, which have wider biological
flexibility both in molecular classes and in specificity.
In view of the comments expressed in many articles on tetanus-
serotherapy (Lancet editorials, 1974, 1980 and October 27th, 1984),
further study in this area is clearly wanted. However, in spite of the
recent advances in antibody production and purification it remains to
be shown that these novel products will be of any greater clinical
value than those currently in existance. Nevertheless, it is my firm
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